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Cancer invasion and metastasis are the leading causes of cancer-related deaths. 
Aquaporin-1 is a dual water and ion channel that is upregulated in many aggressive 
cancers including colon, breast, and brain cancer; aquaporin-1 enhances cell 
migration, invasion and metastasis in these cancer types. Other aquaporins with 
water channel function are not able to substitute for aquaporin-1 in facilitating cell 
migration. There is a gap in knowledge regarding the properties of aquaporin-1 that 
permit its migration-enhancing effect, but both the ion and water channel activities 
appear to be involved. Thus, it was hypothesised that aquaporin-1 water and ion 
channels exhibit a coordinated role in aquaporin-1-facilitated cancer cell motility. 
The aims of this thesis were to test whether pharmacological block of the aquaporin-
1 water and ion channel would impede cell migration and invasion in aquaporin-1-
expressing cancer cell lines, and to see if the efficacy of aquaporin-1 inhibitors 
depended on membrane localisation of the channel. Proposed aquaporin-1 blocker 
AqB050, AQP1 water channel blocker bacopaside II, and an aquaporin-1 ion 
channel blocker AqB011 were used. The circular wound closure assay is an 
innovative alternative approach for measuring cell migration and was introduced 
and utilised in this thesis. Cell viability and proliferation was quantified using an 
alamarBlue assay. Cell invasion was measured with the transwell assay. 
Glioblastoma, colorectal adenocarcinoma, and mammary gland tumour cell lines 
were used. Results showed that combined pharmacological inhibition of aquaporin-
1 water and ion conductance amplified the block of cancer cell migration as 
compared to block by each inhibitor alone, suggesting a cooperative role of 
aquaporin-1 water and ion channels in cell migration. Cancer cells that express 
aquaporin-1 on the membrane were more sensitive to block by aquaporin-1 
inhibitors; this could be an important screening tool for identifying cancer subtypes 
likely to respond to AQP1 inhibitors. AqB011 and AqB050 inhibited glioblastoma, 
breast and colon cancer invasiveness. A newly generated mixture of compounds 
(AqB051) containing the proposed AQP1 blocker AqB050 and related derivatives 
was found to strongly block cancer transwell invasion. The potent biologically 
active agent (not AqB050) was then narrowed to one fraction (fraction E) from 
AqB051. AqB051 and fraction E significantly inhibited invasiveness in all 
glioblastoma cell lines. Work in this thesis paves the way for improving methods 
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utilized for measuring cell migration, investigating the role of AQP1 ion 
conductance and subcellular localisation in cancer migration and growth, 
investigating a novel and potent inhibitor for glioblastoma invasion, and testing the 
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Chapter 1: Mechanisms of Aquaporin-Facilitated Cancer Invasion 
and Metastasis 
Michael L De Ieso1 and Andrea J Yool1 
1Department of Physiology, Adelaide Medical School, University of Adelaide, 
Adelaide, SA, Australia 
 
Chapter 1 is an introductory chapter, setting the premise of this thesis. It 
incorporates a published review paper: Mechanisms of Aquaporin-Facilitated 




Cancer is a leading cause of death worldwide, and its incidence is rising with 
numbers expected to increase 70% in the next two decades. The fact that current 
mainline treatments for cancer patients are accompanied by debilitating side effects 
prompts a growing demand for new therapies that not only inhibit growth and 
proliferation of cancer cells, but also control invasion and metastasis. One class of 
targets gaining international attention is the aquaporins, a family of membrane-
spanning water channels with diverse physiological functions and extensive tissue-
specific distributions in humans. Aquaporins -1, -2, -3, -4, -5, -8, and -9 have been 
linked to roles in cancer proliferation, invasion and metastasis, but their 
mechanisms of action remain to be fully defined. Aquaporins are implicated in the 
metastatic cascade in processes of angiogenesis, cellular dissociation, migration and 
invasion. Cancer invasion and metastasis are proposed to be potentiated by 
aquaporins in boosting tumour angiogenesis, enhancing cell volume regulation, 
regulating cell-cell and cell-matrix adhesions, interacting with actin cytoskeleton, 
regulating proteases and extracellular-matrix degrading molecules, contributing to 
the regulation of epithelial-mesenchymal transitions, and interacting with signalling 
pathways enabling motility and invasion. Pharmacological modulators of aquaporin 
channels are being identified and tested for therapeutic potential, including 
compounds derived from loop diuretics, metal-containing organic compounds, 
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plant natural products, and other small molecules. Further studies on aquaporin-
dependent functions in cancer metastasis are needed to define the differential 
contributions of different classes of aquaporin channels to regulation of fluid 
balance, cell volume, small solute transport, signal transduction, their possible 
relevance as rate limiting steps, and potential values as therapeutic targets for 












Aquaporins (AQPs) are a family of water channels that also include a subset of 
classes shown to mediate transport of glycerol, ions and other molecules [1]. The 
first aquaporin to be cloned, aquaporin-1 (AQP1), was identified in red blood cells 
and renal proximal tubules [2, 3]. In the Xenopus laevis expression system, 
introduced AQP1 channels enabled high osmotic water flux across the plasma 
membrane as compared to non-AQP control oocytes [4], explaining the mechanism 
enabling rapid transmembrane passage of water in certain types of cells. To date, 
fifteen classes of aquaporin genes have been identified in mammals (AQP0-
AQP14), with AQPs 13 and 14 found in older lineages of mammals (Metatheria 
and Prototheria) [5-7]. The first thirteen aquaporins (AQP0-AQP12) have been 
divided into categories based on functional properties [1]. One comprises the 
classical aquaporins (AQP0, -1, -2, -4, -5, -6, -8), which were thought initially to 
transport only water, though some also transport gases, urea, hydrogen peroxide, 
ammonia, and charged particles [4, 8-22]. A second category consists of the 
aquaglyceroporins (AQP3, -7, -9 and -10), which are permeable to water and 
glycerol, with some also exhibiting urea, arsenite, and hydrogen peroxide 
permeability [23-31]. A possible third category consists of AQP11 and AQP12, 
distantly related paralogs with only 20% homology with other mammalian AQPs 
[32], which appear to carry both water and glycerol [33, 34]. The permeability of 
AQP11 to glycerol could be important for its function in human adipocytes, in 
which it is natively expressed [35]. Aquaporins assemble as homo-tetramers, with 
monomers ranging 26 to 34kDa [36]. In most AQPs, each monomer is composed 
of six transmembrane domains and intracellular amino and carboxyl termini, with 
highly conserved asparagine-proline-alanine (NPA) motifs in cytoplasmic loop B 
and in extracellular loop E [37]. The NPA motifs in loops B and E contribute to a 
monomeric pore structure that mediates selective, bidirectional, single-file transport 
of water in the classical aquaporins [38], and water and glycerol in 
aquaglyceroporins [39].  
 
Intracellular signalling processes regulate AQP channels by altering functional 
activity, intracellular localization, and levels of expression in different cells and 
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tissues. For example, the peptide hormone vasopressin regulates excretion of water 
in the kidney by augmenting water permeability of collecting duct cells. 
Vasopressin induces phosphorylation of AQP2 [40], stimulating the reversible 
translocation of AQP2 from intracellular vesicles to the apical plasma membrane 
[41]. Guanosine triphosphate (GTP) stimulates AQP1-induced swelling of 
secretory vesicles in the exocrine pancreas [42], with functional implications in 
pancreatic exocrine secretions. Additionally, AQP1 ion channel activity is activated 
by intracellular cGMP [8], and phosphorylation of Y253 in the carboxyl terminal 
domain regulates responsiveness of AQP1 ion channels to cGMP (Campbell et al., 
2012). Given the diverse array of functional properties, mechanisms of regulation, 
and tissue-specific distributions being discovered for aquaporins, it is not surprising 
that different classes of aquaporins (AQP-1, -2, -3, -4, -5, -8, and -9) have been 
implicated specifically in the complex steps associated with cancer invasion and 
metastasis (Tab 1.1), suggesting specialized roles for these channels have been 
arrogated into the pathological processes. 
 
1.3.2 Cancer Invasion and Metastasis 
Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 
2012 [43]. The incidence of cancer is rising steadily in an aging population, with 
numbers expected to increase 70% in the next two decades [43]. Current treatments 
involve chemotherapy, radiation therapy, and surgery [44], associated with an array 
of side effects including nausea [45], impaired fertility and premature menopause 
[46, 47], painful neuropathy [48, 49], increased risk of cardiovascular disease [50, 
51], and loss of bone density [52]. Inhibiting proliferation remains the primary 
focus of cancer treatments, although the predominant cause of death is cancer 
metastasis [53, 54]. Less devastating cancer therapies might be achievable via a 
combination of strategies that not only inhibit proliferation, but also control 
metastasis of tumour cells from their primary site to distant organs (Friedl & Wolf, 
2003). Cancer cell migration through the body exploits pathways including blood 
stream, lymphatic system, and transcoelomic movement across body cavities [55-
57]. The hierarchical nature of the metastatic cascade suggests it should be 
vulnerable to intervention at multiple levels including angiogenesis, detachment of 
cells from the primary tumour, and infiltration of dissociated tumour cells into and 
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out of circulatory pathways via intravasation and extravasation, respectively (Fig 
1.1). AQPs that serve as rate-limiting steps in the metastatic cascade should have 
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NO [59] & 
NH3 [19] 
 
 Water reabsorption 
in proximal tubule 
of the kidney for 
concentrating urine 
[60, 61] 
 Secretion of 
aqueous fluid from 
ciliary epithelium 
in the eye, and 
cerebrospinal fluid 
from the choroid 
plexus [62, 63] 
















[71], & multiple 
myeloma 
(microvessels) [72]  
 Upregulated in response 
to tumour tissue 
hypoxia. Enables 
recruitment of new 
tumour vasculature by 
enhancing endothelial 
cell migration. 
 Polarizes to leading and 
trailing edge of 
migrating cell, and 
enhances tumour cell 
migration and invasion 
by enabling rapid 
membrane protrusion 
formation via cell 
volume regulation and 
interaction with 
cytoskeletal dynamics 
 Enhances mesenchymal 
stem cell migration via 
FAK and β-catenin 
pathways  
 Might contribute to 
EMT 




AQP2 Water [11]  Water reabsorption 
in collecting duct 





 Enables “traction” for 
migrating cell by 
contributing to the 
regulation and recycling 
of focal adhesion 
proteins (e.g. integrin) 
 Necessary in estradiol-
induced invasion and 
adhesion of endometrial 
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[31] & NH3 
[77] 
 
 Water reabsorption 
in collecting duct 
of the kidney to 
concentrate urine 
[78] 
 Skin hydration 
[79] 
 Skin wound 
healing [80]  
 
Lung cancer [81], 
hepatocellular 
carcinoma [82], 
gastric cancer [83], 
prostate cancer 
[84], oesophageal 
and oral squamous 
cell carcinoma [85], 
colorectal 
carcinoma [69], 
skin squamous cell 
carcinoma [86],  
ovarian cancer [87], 
pancreatic cancer 
[88], and breast 
cancer [89] 
 Upregulated by EGF, 
and contributes to EGF-
induced EMT and 
cancer migration 
 Contributes to 
chemokine-dependent 
cancer migration via 
enabling H2O2 influx 
and its downstream cell 
signalling. 
 Interacts with ECM-
degrading proteases  
 Might enhance tumour 
cell migration and 
invasion via regulation 




AQP4 Water [12]  Water reabsorption 
in collecting duct 
of the kidney to 
concentrate urine 
[90] 
 Transport of water 
into and out of the 
brain and spinal 
cord via blood-
brain barrier [91] 
 Neuroexcitation 
[92] 





Glioma [94] & 
meningioma [95] 
 Co-localizes with ion 
channels at leading and 
trailing edges of 
migrating cancer cells 
 Enhances tumour cell 
migration and invasion 
by enabling rapid 
membrane protrusion 
formation via cell 
volume regulation and 
interaction with 
cytoskeletal dynamics 
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 Secretion of saliva 
[96] and airway 









lung cancer [101], 
cervical cancer 
[102], pancreatic 
cancer [88], & 
breast cancer [103] 
 
 Promotes EMT  
 Co-localizes with ion 
channels at leading and 
trailing edges of 
migrating cancer cells 
 Enhances tumour cell 
migration and invasion 
by enabling rapid 
membrane protrusion 
formation via cell 
volume regulation 
 Might interact with 
EGFR/ERK1/2 
signalling pathway 
AQP8 Water, urea 
[17], H2O2 
[21] & NH3 
[77, 104] 
 Canalicular bile 
water secretion 
[105] 





 Not yet known 













 Route for 
excretion of 










 Overexpression might 
correspond with reduced 
EMT and growth in 
hepatocellular 
carcinoma 
 Might interact with 
ERK1/2 and MMP9 to 
enhance prostate cancer 





Both cancer invasion and metastasis are enhanced by angiogenesis. Angiogenesis, 
activated in response to inadequate oxygen perfusion, triggers extracellular matrix 
breakdown; endothelial cell proliferation, differentiation and migration; and 
recruitment of periendothelial cells (Clapp & de la Escalera, 2006) which form 
discontinuous layers around vessels and exert developmental and homeostatic 
control (Njauw et al., 2008). Under physiological conditions, angiogenesis is seen 
in the proliferative phase of the menstrual cycle (Demir et al., 2010), development 
of fetal and placental vasculature (Demir et al., 2007), and skeletal muscle 
following physical activity (Egginton, 2009). In pathological scenarios such as 
tumourigenesis, tissue hypoxia stimulates the formation of new vasculature, 
enabling tumours to better obtain nutrients, exchange gases, and excrete waste 
(Nishida et al., 2006). Folkman and colleagues (1966) showed that tumours up to 
2mm in diameter could survive via passive diffusion from surrounding tissue; but 
angiogenesis was essential for support of larger tumours. 
 
AQP1, expressed in peripheral vascular endothelial cells, is involved in tumour 
angiogenesis (Nielsen et al., 1993; Endo et al., 1999; Saadoun et al., 2002a; El 
Hindy et al., 2013; Verkman et al., 2014). AQP1 knock-down in chick embryo 
chorioallantoic membrane resulted in a dramatic inhibition of angiogenesis  
(Camerino et al., 2006). Saadoun and colleagues (2005) found AQP1-deficient mice 
exhibited reduced tumour growth and angiogenesis as compared to wild type, 
following subcutaneous or intracranial B16F10 melanoma cell implantation. Their 
work showed AQP1-null endothelial cells from mouse aorta had reduced motility 
as compared to wild-type, suggesting AQP1 was needed to facilitate cell migration 
for angiogenesis. Monzani and colleagues (2009) confirmed a reduced migration 
capacity in human microvascular endothelial cells (HMEC-1) after AQP1 
knockdown by siRNA. AQP1 mRNA and protein levels are increased in response 
to tissue hypoxia (Kaneko et al., 2008; Abreu-Rodríguez et al., 2011). AQP1 




Figure 1.1: Flow diagram summarizing the steps in cancer metastasis. Metastasis 
involves the migration of cells from the primary tumour to distant organs. Large 
tumours with tissue hypoxia rely on angiogenesis for vascular exchange of nutrients 
and waste. Primary tumour cells undergo phenotypic changes including loss of cell-
cell adhesions which enables cells to dissociate from primary tumour, invade the 
adjacent extracellular matrix (ECM), and intravasate into the blood or lymph 
systems. Circulating tumour cells extravasate to seed secondary sites at which the 




Angiogenesis is regulated by growth factors such as vascular endothelial growth 
factor (VEGF), which stimulates endothelial cell proliferation and angiogenesis in 
response to hypoxia (Suzuki et al., 2006), through processes that could augment 
AQP1 activity indirectly. Pan and colleagues (2008) found a positive correlation 
between levels of AQP1 expression, intratumoural microvascular density, and 
VEGF in endometrial adenocarcinoma. Similarly, AQP1 gene deletion correlated 
with reduced VEGF receptor expression in mouse primary breast tumour cells 
(Esteva-Font et al., 2014), and knockdown of AQP1 in human retinal vascular 
endothelial cells with concurrent inhibition of VEGF caused an additive inhibition 
of hypoxia-induced angiogenesis (Kaneko et al. 2008). However, application of 
VEGF-neutralizing antibodies did not alter AQP1 expression (Kaneko et al., 2008), 
and levels of VEGF in primary breast tumours were not different between AQP1-
null and wild-type mice (Esteva-Font et al., 2014), supporting the idea that VEGF 
is regulated independently of AQP1 expression or activity.    
 
Other angiogenic factors, such as hypoxia-inducible factor 1-alpha (HIF-1α), 
induce AQP1 expression in low oxygen conditions (Abreu-Rodríguez et al., 2011).  
The AQP1 gene promoter carries a HIF-1α binding site which drives AQP1 
expression in response to hypoxia in cultured human retinal vascular endothelial 
cells (HRVECs) (Tanaka et al. 2011), and involves phosphorylation of p38 
mitogen-activated protein kinase (MAPK) (Tie et al. (2012)). Estrogen signalling 
also targets the promoter region of the AQP1 gene to increase transcription, 
inducing enhanced tubulogenesis of vascular endothelial cells as a model for 
angiogenesis (Zou et al., 2013). In summary, AQP1 is upregulated by angiogenic 
factors in response to hypoxia, and necessary for endothelial cell migration and 
angiogenesis. Therapies aimed at blocking transcriptional activation of AQP1 could 
impede cancer angiogenesis, if the treatment could be spatially limited to the 
tumour site without impacting normal cell functions. 
 
1.5 Cellular Dissociation and Epithelial-Mesenchymal Transition 
Epithelial-mesenchymal transition (EMT) occurs in normal physiological 
conditions such as implantation, embryogenesis and organ development, as well as 
pathological processes such as cancer invasion and metastasis [119, 120]. During 
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EMT, polarized epithelial cells undergo biochemical changes to adopt a 
mesenchymal phenotype, characterized by a loss of cell polarity, reduced cell-cell 
adhesiveness, and enhanced invasive capacity [120-124]. Epithelial cadherin (E-
cadherin), a transmembrane glycoprotein, enables calcium-dependent tight 
adhesions between epithelial cells and links to cytoskeletal elements [125, 126]. 
Downregulation of E-cadherin is a hallmark feature of EMT [127-129]. EMT in 
cancer is induced by signals from the tumour-associated stroma, including 
epidermal growth factor (EGF), platelet-derived growth factor (PDGF), hepatocyte-
derived growth factor (HGF), and transforming growth factor beta (TGF-β) [130-
134]. These signals stimulate transcription factors such as SNAI1 (SNAIL), SNAI2 
(SLUG), zinc finger E-box binding homeobox 1 (ZEB1), Mothers against 
decapentaplegic homolog 2 (SMAD-2) and Twist, which are all E-cadherin 
transcription repressors [135, 136].  
 
Classes of aquaporins such as AQP3 have been implicated in the EMT process. 
AQP3 up-regulation in response to EGF in colorectal, gastric, and pancreatic 
cancers, is associated with augmented cell migration, invasion, and metastasis [137-
139]. In gastric cancer, EGF-induced AQP3 upregulation enhances the 
mesenchymal transformation [140]. Chen et al. (2014) determined that mRNA and 
protein levels of vimentin and fibronectin (proteins associated with mesenchymal 
phenotype) were significantly increased in cells with high levels of AQP3 
expression but decreased in AQP3-deficient cells. Conversely, E-cadherin 
expression was significantly lower in cells with high AQP3 and increased in AQP3-
knockdown cells. The mechanisms for AQP3-facilitated pancreatic and colorectal 
cancer cell migration have not yet been determined. It will be interesting to 
investigate whether AQP3 promotes EMT in these cancers. 
 
In addition to AQP3, AQPs 1, 4, 5 and 9 also have been linked to EMT in different 
types of cancer cells. In lung adenocarcinoma cells, AQP1 overexpression 
correlated with the down-regulation of E-cadherin, and up-regulation of vimentin 
[141].  AQP4 knockdown in human breast cancer was associated with increased 
levels of E-cadherin, and in glioma cells with increased β-catenin (involved in actin 
reorganization and cell-cell adhesion) and connexin-43 (a gap junction protein that 
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contributes to cell-cell signalling and adhesion) [142, 143], suggesting AQP4 might 
enhance cell detachment from primary tumours. However, opposing evidence 
showed knockdown of AQP4 in primary human astrocytes correlated with down-
regulation of connexin-43 [144]; and transfection of wild type AQP4 into glioma 
cell lines caused enhanced adhesion [145]. In primary glial cells, AQP4 expression 
levels had no appreciable effect on cell-cell adhesion under the conditions tested 
[146].  In human non-small cell lung cancer cells (NSCLCs), AQP5 increased 
invasiveness; conversely, expression of AQP5 mutant channels lacking membrane 
targeting signals or the S156 phosphorylation site did not augment invasiveness 
(Chae et al. (2008)). Overexpression of AQP5 in NSCLCs was associated with a 
reduction in epithelial cell markers such as E-cadherin, α-catenin and γ-catenin, and 
an increase in mesenchymal cell markers such as fibronectin and vimentin, 
concomitant with a mesenchymal change in morphology. Similarly, AQP3 and 
AQP5 overexpression in pancreatic ductal adenocarcinoma is accompanied by 
downregulation of E-cadherin and upregulation of vimentin [88]. The invasion-
promoting properties of AQP5 expression appear to depend on the c-Src signalling 
pathway,  a potent trigger of EMT [101, 147]. High AQP5 expression correlated 
with an increase in phosphorylated SMAD2, promoting EMT in colorectal cancer, 
whereas AQP5 silencing was associated with a down-regulation of phosphorylated 
SMAD2, and a repressed EMT response [148]. AQP9 is downregulated in 
hepatocellular carcinoma; overexpression corresponds to reduced growth and 
EMT, thus reducing cancer invasion and metastasis [149, 150]. Evidence suggests 
that AQPs have different effects depending on the type of cancer. Moreover, the 
state of cancer progression, environmental factors, and the types of assays used will 
be complicating factors; nevertheless, AQPs have clear potential as diagnostic and 
prognostic biomarkers, and as therapeutic targets for modulation of EMT, cell-cell 
adhesion, and dissociation phases of cancer progression. 
 
1.6 Invasion and Cell Migration 
Cell migration involves the translocation of individual and collective groups of cells 
through fluid or tissues, relevant for survival in multicellular and single-celled 
organisms [151, 152]. Migration enables physiological morphogenesis, immunity, 
and tissue repair [152, 153]. In most mammalian cells, migration is highest during 
26 
 
development and morphogenesis and decreases after terminal differentiation. In 
pathological circumstances such as cancer, migration machinery can be reactivated. 
AQPs -1, -3, -4, and -5, -8, and -9 are known to contribute to cancer cell migration 
and invasion. Translocation of cancer cells can be initiated by chemokines released 
from host tissues, and growth factors such as EGF secreted by stromal cells [154, 
155].  
 
AQP3 has been suggested to increase EGF-induced cancer growth and migration 
by mediating H2O2 flux [28, 156]. H2O2 is known as an oxidative stressor, but is 
also a second messenger in cell proliferation, differentiation and migration [157, 
158]. AQP3 knockdown in skin and lung cancer cell lines reduced EGF-induced 
H2O2 influx, and attenuated EGF signalling cascades [156], reducing migration and 
growth. H2O2 also influenced chemokine-dependent migration of T-cells and breast 
cancer cells [159, 160]. AQP1, -3, -5, -8, and -9 have all been suggested to transport 
H2O2 [20-22, 28, 29]. All of these classes also have been linked with cancer cell 
migration [98, 149, 161-163]; however, H2O2 transport has thus far been linked 
only to AQP3 as a control mechanism in cancer cell migration. Further work might 
show H2O2 transport in other classes of AQPs regulates cell motility and invasion. 
 
1.6.1 Polarization 
Key molecular and cellular events involved in cell migration can be classified into 
five inter-dependent stages, which are polarization, protrusion, cell-matrix 
adhesion, extracellular matrix (ECM) degradation and retraction (Figure 1.2). Cell 
polarization provides functionally specialized domains in the membrane and 
cytoplasm [164], typified by asymmetric distributions of organelles, signalling 
mechanisms,  and membrane channels, transporters and receptors  [165]. In 
movement, changes in cell polarization generate leading and trailing edges, 
predominantly regulated by small GTPases such as CDC42 [166, 167], which 
controls the recruitment of partitioning-defective (PAR) proteins, atypical protein 
kinase C (aPKC), and actin polymerization machinery [168, 169]. AQPs -1, -4, -5, 
and -9 have been shown to show polarized localization at the leading edges of 
migrating cells. Specific co-distributions with ion transporters such as the Na+/H+ 
exchanger, the Cl-/HCO3
- exchanger, and the Na+/-HCO3 co-transporter, suggest 
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sophisticated mechanisms for regulation of fluid influx and efflux [170-174], 
potentially driving membrane protrusions for cell locomotion [175].  
 
1.6.2 Protrusion 
A migrating cell extends its leading edge into the ECM by assembling a branched 
network of intracellular actin filaments, predicted to yield a physical force that 
dynamically pushes the membrane out, alternating with relaxation and actin 
depolymerization [176-178]. Membrane expansion requires the vesicle fusion to 
support the increase in surface area [179-181]. Three types of protrusions found in 
motile cells are lamellipodia, filopodia, and invadopodia. Lamellipodia are broad, 
flat, actin-rich protrusions that extend in the direction of locomotion and provide a 
foundation on which the cell moves forward [182]. Filopodia are long, thin 
protrusions of the membrane thought to be exploratory, “sensing” the local 
environment [183]. Lamellipodial and filopodial formations are modulated by small 
GTPases in the Rho family, such as Rac1 and CDC42 [184-187], which stimulate 
actin polymerization in response to growth factor [185] and integrin receptor 
activations [188]. Interestingly, AQP9-facilitated water flux appears to critical for 
filopodial protrusion formation in fibroblasts, via the CDC42 pathway [189]. The 
Arp2/3 (actin-related protein 2/3) complex regulates the formation of new actin 
filaments in migrating cancer cells, and is regulated by Scar/WAVE complex 
(otherwise known as WANP), which interacts with the small GTPase Rac1 for 
lamellipodial assembly [190]. Invadopodia are actin-rich, matrix-degrading 
protrusions that appear when ECM degradation and cell deadhesion are needed to 
create space for movement, involving proteases such as MMP2, MMP9, and MT1-
MMP and src tyrosine kinase [191]. Changes in cell volume during protrusion are 
assumed to require rapid water flow [192], and could occur in part in response to 
osmotic gradients governed by ion transport and actin polymerization state [175, 
193, 194].  
 
AQPs at the leading edges of migrating cells are well positioned to facilitate cell 
volume changes and cytoskeletal modifications during protrusion formation [195-
199]. AQP1 overexpression in B16F10 melanoma cells and 4T1 mammary gland 
tumour cells enhanced cell migration and lamellipodial width in vitro, and 
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augmented metastasis in a mouse model [161]. AQP1 is proposed to enhance 
lamellipodial formation by increasing membrane osmotic water permeability [161, 
171, 200], allowing water entry at the leading edge to impose hydrostatic pressure, 
drive membrane extension, and create space for actin polymerization. In addition 
to water channel activity, AQP1 is also thought to be an ion channel, proposed to 
allow gated conduction of monovalent cations through the central tetrameric pore 
[8, 201]. The dual water and ion conductance of AQP1 is essential for colon cancer 
cell migration in vitro [202]. Conversely, in clinical cases of cholangiocarcinoma, 
high AQP1 expression has been correlated with low metastasis  [203, 204], 
suggesting that AQP1 might play different roles in different types of cancers.   
 
Other classes of AQP water channels are not necessarily interchangeable with 
AQP1 in facilitating cell migration [145], suggesting features of AQP1 other than 
simple osmotic water permeability are involved. AQP1-enhanced cell migration 
might also be due to interactions with cytoskeletal proteins. For example, Monzani 
et al. (2009) demonstrated that AQP1 knockdown dramatically impeded actin 
cytoskeletal organization in migrating human melanoma and endothelial cell lines 
via interaction with Lin-7/β-catenin. The Lin-7/β-catenin complex enables 
asymmetrical organization of filamentous actin (F-actin). AQP1 might act as a 
scaffolding protein at the leading edges. Jiang (2009) found that knocking down 
AQP1 was associated with re-localization of actin in migrating HT20 colon cancer 
cells, and a reduction in the activity of actin regulatory factors RhoA and Rac. A 
PDZ domain in Lin-7 could mediate interaction with rhotekin protein, which 
inhibits Rho GTPase signalling that is involved in cell migration, invasion, and 
cytoskeletal reorganization [205].  Rhotekin merits further evaluation in models of 
AQP1-dependent cytoskeletal organization. 
  
A role for AQP4 in glioma cell migration has similarly been proposed to occur 
through regulation of cell volume and cytoskeletal interactions. Protein kinase C 
(PKC)-mediated phosphorylation of AQP4 at serine 180 correlated with a 
decreased glioma cell invasion [206]. AQP4-facilitated glioma invasion is 
dependent on co-expression of chloride channels (ClC2) and the potassium-
chloride co-transporter 1 (KCC1) in invadopodia, which could provide the ionic 
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driving force for water efflux leading to cell shrinkage that could augment 
invasiveness through ECM [206, 207]. AQP4 effects on actin cytoskeleton suggest 
a role for α-syntrophin,  interacting with the C-terminal domain of AQP4 at a PDZ-
binding site [208]. In human glioma and primary astrocytes, reduced AQP4 
expression correlated with dramatic morphological elongation, reduced 
invasiveness, and impaired F-actin polymerization  [142, 144]. 
 
AQP5 facilitates protrusion formation, volume regulation, cell migration, and 
metastasis. AQP5 expression is correlated with cell invasiveness and metastasis of  
human prostate cancer [98], lymph node metastasis in patients with colon cancer 
[209] and  metastatic potential of lung cancer cells [210]. Moreover, Jung et al. 
(2011) showed that a shRNA-induced reduction in AQP5 expression in MCF7 
breast cancer cells was associated with significantly reduced cell proliferation and 
migration. The mechanism of AQP5-facilitated cancer cell invasion and metastasis 
might be due to its direct or indirect interaction with the epidermal growth factor 
receptor/extracellular signal-regulated kinase (ERK1/2) pathway [210, 211], 
known to be important in cancer metastasis and aggressiveness [212]. Additionally, 
AQP5 mediates lung cancer cell membrane osmotic water permeability, and has 
been suggested to contribute to cancer cell migration and invasion by enabling rapid 
cell volume regulation and subsequent protrusion formation [213]. The 
complementary role of ion transport for migration in AQP5-expressing cells was 
supported by Stroka et al. (2014), who found that cell migration through physically 
confined spaces occurred despite block of actin polymerization and myosin 
contraction, but relied on co-expression of the Na+/H+ exchanger with AQP5, 
supporting AQP5-induced cell volume regulation and its importance in cell 
motility. 
 
AQP8 expression influences migration and invasion of cervical cancer cells, and 
AQP3 expression enhances pancreatic and colorectal cancer cell invasion and 
metastasis [137, 139, 163]. Further work is needed to investigate whether 
mechanisms of AQP3- and AQP8-facilitated cancer cell migration and invasion 
involve cell volume regulation, protrusion formation, cytoskeletal interaction, or 




1.6.3 Cell Matrix Adhesion 
Cell-matrix adhesions, first observed in cultured fibroblasts, connect the 
extracellular matrix to the actin cytoskeleton [214]. During migration, contacts with 
substratum must form to facilitate extension, and must detach to allow forward 
displacement of the cell. Insufficient anchoring causes protrusions to collapse, 
leading to a “membrane ruffling” phenomenon [215]. Protrusions adhere to ECM 
via integrin receptors, in turn linked to intracellular actin filaments [216]. The 
extracellular binding of integrin receptors to ECM ligands initiates integrin 
clustering, and activates protein tyrosine kinases and small GTPases. The 
organization of actin cytoskeleton and cell polarity controls the positions of focal 
adhesions for cell locomotion [217, 218]. Cell-matrix adhesions create the focal 
points for generation of traction to pull the cell forward over the substratum.  
 
Classes of aquaporins (AQP1-4) have been shown to interact with adhesion 
molecules and to influence adhesive properties of migrating cells.  Increased AQP1 
in mesenchymal stem cells enhances migration by a mechanism involving β-catenin 
and the focal adhesion kinase (FAK) [219], which regulates integrin signalling at 
focal adhesion sites [220-222]. Whether AQP1 and FAK also interact in cancer cell 
migration remains to be tested. AQP2 appears to promote cell migration by 
modulating integrin β1 at focal adhesion sites, by a mechanism thought to involve 
an arginine-glycine-aspartate (RGD) motif in the second extracellular loop of 
AQP2 [223]. When AQP2 is absent, integrin β1 is retained at focal adhesion sites, 
delaying recycling of focal adhesions, thus reducing migration rate. AQP2 also 
enables estradiol-induced migration and adhesion of endometrial carcinoma cells 
by mechanisms involving annexin-2 and reorganization of F-actin [74]. 
Knockdown of AQP3 in human esophageal and oral squamous cell carcinoma with 
siRNA correlated with reduced phosphorylation of FAK, impaired cell adhesion 
and cell death [85]; these effects would be predicted to impair cancer cell migration. 
AQP4 expression has been suggested to enhance cell-matrix adhesion in cancer 
cells [145]. More research is needed to identify the intracellular signalling 
mechanisms and to determine whether other AQP classes alter cell migration via 




1.6.4 Extracellular Matrix Degradation 
Extracellular matrix degradation widens pathways through which cells can 
penetrate tissues, and reduces the distortion of the rounded cell body needed for 
physical progress [224, 225]. Invadopodia sprout from leading edge filopodia, 
extending through tiny channels in the ECM, and adhere to ECM collagen fibers 
[191, 226]. To accommodate displacement of the cell body, constraining ECM 
fibers are cleared by local proteolysis, using surface proteases such as zinc-
dependent matrix metalloproteinases (MMP) and serine proteases [227-229]. AQPs 
-1, -3, -4, and -9 have been shown to interact with specific MMPs to facilitate ECM 
degradation and invasion.  
 
In lung cancer cells, migration was facilitated by AQP1 expression, linked to 
expression of MMP2 and MMP9 [198]. In gastric cancer cells (SGC7901), AQP3 
levels were correlated with  MMP2, MMP9, and MT1-MMP levels, and enhanced 
invasiveness via phosphoinositide 3-kinase signalling [230]. Positive correlations 
between AQP3, MMP2, and MMP9 and cancer invasiveness also occur in lung 
cancer [231, 232]. In prostate cancer, AQP3 expression is correlated with up-
regulation of MMP3 via ERK1/2 signalling, with increased cell motility and 
invasion [162].  In  glioma, AQP4 levels correlated with migration and invasiveness 
in vitro and in vivo through a mechanism involving MMP2 [142]. AQP9  
upregulation in prostate cancer could enhance growth, migration, and invasion 
involving  ERK1/2 signalling; reduced levels of phosphorylated ERK1/2 and 
MMP9 were observed in AQP9-deficient cell lines [118]. These studies suggest one 
of the key components of AQP-mediated facilitation of cancer cell invasion is the 
regulation of MMP proteases needed for degradation of ECM.  
 
1.6.5 Retraction 
Following integrin-ligand binding, cross-linking proteins such as myosin II contract 
the actin filament strands [233], developing tension against the intact adhesion 
points [234]. The final step in the cycle of cell movement is retraction of the trailing 
edge. A working model is that membrane tension opens stretch-activated Ca2+ 
channels, activating calpain and triggering disassembly of focal adhesion proteins 
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on the trailing edge, while concurrent K+ efflux drives volume loss at the cell rear, 
resulting in detachment and net translocation along the substrate. In this model, the 
role of AQP channels is to facilitate osmotic water efflux in response to K+ efflux 
[175, 235, 236] presumably in parallel with electroneutral efflux of chloride ions. 
 
1.7 AQP Pharmacology and Therapeutic Implications in Cancer Invasion and 
Metastasis 
Aquaporin pharmacological agents have attracted keen interest for their potential 
therapeutic uses in diseases involving impaired fluid homeostasis. Aquaporins in 
cancer metastasis are new translational targets for AQP modulators. Known and 
proposed inhibitors of AQPs include cysteine-reactive metals such as mercury (II) 
chloride (HgCl2) [237], gold-based compounds [238], carbonic anhydrase inhibitor 
acetazolamide [239, 240], and small molecule inhibitors such as 
tetraethylammonium (TEA+) [241], although the small molecule blockers vary in 
efficacy between preparations. The pharmacological panel for AQPs has been 
expanding steadily, with new compounds being discovered around the world, 
including for example the University of Niigata, Japan [242], Radboud University, 
Netherlands [243], the Faculty of Pharmacy, University of Lisbon, Portugal [244], 
the Institute of Food and Agricultural Research and Technology, Barcelona, Spain 
[245], the University of Adelaide, Australia [246, 247], the University of 
Groningen, Netherlands [238], the University of Kiel, Germany [248], and others. 
This review focuses specifically on selected AQP pharmacological agents that to 





























Figure 1.2: Key contributions of aquaporins in cell migration. (A) Forward 
movement is preceded by establishing specialized loci within the cell, with 
redistribution of aquaporins, ion transporters/exchangers, and actin polymerization 
machinery to the leading edge. AQP-1, -4, -5, or -9 can be found on leading edges 
of migrating cancer cells. (B) Protrusions of the membrane might use water influx 
(down an osmotic gradient established by ion transporters/exchangers) and actin 
polymerization beneath the plasma membrane to dynamically push the membrane 
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forward. AQP-1, -4, and -5 are implicated in water influx for protrusion extension 
in cancer cells; AQPs-1 and -4 also appear to interact with actin cytoskeleton. (C) 
Protrusions adhere to the ECM using integrin to generate “traction” for cellular 
movement. AQP2 might modulate turnover of integrin at adhesion sites, enabling 
forward cellular movement. (D) ECM degradation by enzymes can widen gaps 
through which the cell body can penetrate. AQP-1, -3, -4 and -9 are suggested to 
interact with ECM-degrading enzymes. (E) The final step is retraction of the cell 




1.7.1 Acetazolamide and Topiramate 
Acetazolamide and topiramate are FDA-approved drugs that inhibit carbonic 
anhydrase. Acetazolamide at 100M was reported to inhibit water channel activity 
by 39% for AQP1 expressed in human embryonic kidney (HEK293) cells  [240], 
and by 81% at 10M in the Xenopus oocyte expression system  [239]. AQP4 
activity was inhibited by 47% at 1250 M in proteoliposomes  [249]. However, 
acetazolamide (at doses up to 10,000 M) did not block water flux in erythrocytes 
with native AQP1 expression, or epithelial cells transfected with AQP1 [250, 251]. 
Acetazolamide inhibited angiogenesis in a chick chorioallantoic membrane assay, 
and tumour growth and metastasis in mice with Lewis lung carcinoma [252, 253], 
perhaps as a result of reduced AQP1 expression [254]. Topiramate reduces Lewis 
lung carcinoma growth and metastasis, with effects similarly attributed to 
suppression of AQP1 expression [255]. It will be of interest to compare the effects 
of acetazolamide and topiramate on angiogenesis, tumour growth, and metastasis 
with those of AQP1 channel inhibitors.   
 
1.7.2 Tetraethylammonium 
TEA+ is an inhibitor of voltage-gated potassium channels, calcium-dependent 
potassium channels, the nicotinic acetylcholine receptor, and it has also been shown 
to block AQP-1, -2, and -4 water permeability in Xenopus laevis oocytes and kidney 
derived cell lines [241, 243, 256]. However, inhibition of AQP1 water permeability 
by TEA+ is variable, having been confirmed by some groups [243], and challenged 
by others [251]. Yang et al. (2006) reported no block of water flux by TEA+ in 
erythrocytes with native AQP1, or in epithelial cells transfected with AQP1, and 
suggested previous positive results might have been due to inhibition of K+ channels 
and altered baseline cell volume; however, the observation that site-directed 
mutation of AQP1 altered TEA sensitivity [241] ruled out this alternative 
explanation. TEA+ block of AQP1 water permeability reduced cell migration and 
invasion in in vitro models of osteosarcoma and hepatocellular carcinoma [196], 
with outcomes interpreted as consistent with action of TEA+ as a possible AQP1 
inhibitor. However, given the variability in efficacy and cross-talk with other 
channels, TEA+ is not an ideal candidate for clinical development, although the 
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targets causing the observed block of cancer cell migration and invasion might 
merit further investigation. 
 
1.7.3 Bumetanide Derivatives 
Bumetanide is a sulfamoylanthranilic acid derivative used clinically to increase 
diuresis by blocking sodium cotransporter activity at the loop of Henle in the 
nephron. Molecular derivatives of bumetanide have been synthesized and found to 
exhibit inhibitory effects on classes of AQP channels. For example, the bumetanide 
derivative AqB013 blocks osmotic water fluxes mediated by mammalian AQP1 and 
AQP4 channels expressed in Xenopus laevis oocytes [257]. The water channel 
blocker AqB013 was shown to inhibit endothelial tube formation and colon cancer 
cell migration and invasion in vitro [258]. Other bumetanide derivatives, AqB011 
and AqB007, block the AQP1 ion conductance, but not water flux [202]. In AQP1, 
the central tetrameric pore is thought to be permeable to monovalent cations, CO2, 
and NO [58, 59, 201, 259], although some work questioned AQP1-mediated CO2 
and cation transport properties [260-262]. An ionic conductance in AQP1-
expressing Xenopus oocytes stimulated with forskolin was first reported in 1996 
(Yool et al., 1996); however, the forskolin response proved to be inconsistent when 
repeated by other groups [263]. Further work showed the forskolin effect was 
indirect; the direct regulation of the AQP1 cation conductance depended on cGMP 
binding [8]. The reason that AQP1 cation channels have low opening probability 
[264] or are not detectable [260] reflects the availability of AQP1 to be gated by 
cGMP, which depends on tyrosine phosphorylation status of the carboxyl terminal 
domain, suggesting the AQP1 ion channel function is highly regulated [265]. With 
the discovery of AQP1 ion blocking agents, AqB011 and AqB007, the 
physiological function of the ion channel activity could finally be addressed. When 
applied to AQP1-expressing HT29 colon cancer cells, these inhibitory compounds 
significantly reduced cancer cell motility  [202], suggesting a physiological role of 
AQP1 ion conductance in cell migration. Mutation of the candidate binding site in 
the AQP1 intracellular loop D domain removed sensitivity to AqB011, showing 
that the inhibitory mechanism directly involved the AQP1 channel and could not 
readily be attributed to off-target actions on other channels or transporters [266]. 
Another bumetanide derivative AqB050 was shown to inhibit mesothelioma cell 
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motility and metastatic potential in vitro, but not in vivo [197]. The mechanism of 
action of AqB050 in blocking mesothelioma cell motility in vitro remains to be 
determined.  
 
1.7.4 Plant-Based Derivatives 
Plant-based derivatives that reduce cancer cell migration and invasion include 
agents that have also been found to inhibit AQPs. Bacopa monnieri is a perennial 
herb native to the wetlands of India that is used in alternative medicinal therapies. 
Chemical constituents bacopaside-I and bacopaside-II, were shown to block AQP1 
but not AQP4 water channels [267]. Pei and colleagues also found that bacopaside-
I and bacopaside-II attenuated migration of colon cancer cell lines expressing high 
levels of AQP1, but had no effect on lines with low AQP1, suggesting the inhibitory 
effects were AQP1-specific. Ginsenoside Rg3 from a traditional Asian medicinal 
plant Panax ginseng is an intriguing candidate for possible anti-metastatic therapies. 
Ginsenoside Rg3 inhibited prostate cancer cell migration and was associated with 
downregulation of AQP1 expression via the p38 MAPK pathway and transcription 
factors [268]. Effects of Ginsenoside Rg3 directly on water channel activity, or on 
expression levels of other aquaporins, remain unknown. Curcumin is a naturally 
occurring ingredient in turmeric, used as therapeutic tool for pathologies including 
cancer [269]. Curcumin was found to inhibit EGF-induced upregulation of AQP3 
and migration in human ovarian cancer cells, via inhibition of AKT/ERK and PI3K 
pathways [87]; however, curcumin affects a number of biochemical pathways and 
might not be suited when AQP-specific modulation is required [270]. Research on 
the effects of curcumin in other cancers such as gastric cancer, in which EGF-
induced AQP3 up-regulation occurs, might further understanding of the role of 
AQP3 in cell migration and invasion [138]. 
 
1.7.5 Metal-Based Inhibitors 
Mercury has classically been used as an AQP1 inhibitor. In the human AQP1 
monomer, the NPA motif in loop E is near cysteine 189, which is the site at which 
mercury inhibits osmotic water permeability [271]. Lack of a cysteine in the 
corresponding position is consistent with mercury insensitivity in mammalian 
AQP4 [237]. However, mercury is not a promising candidate for AQP-specific 
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modulation or therapeutic application due to its toxicity and non-specific side-
effects. Metal-based inhibitors that have been tested in models of cancer include 
AQP3 inhibitors such as NiCl2 [272] and CuSO4 [273], which inhibited EGF-
induced cell migration in human ovarian cancer cells. Auphen is a gold-based 
compound which, when administered at concentrations of 100µM, blocks AQP3 
glycerol transport by 90%, and water transport by 20% in human red blood cells 
[244]. Auphen also blocks proliferation in various mammalian cell lines, including 
human epidermoid carcinoma, by inhibiting AQP3 glycerol transport [274]. This 
merits more research into the importance of AQP3-facilitated glycerol transport in 
cancer invasiveness, and whether gold-based compounds such as auphen can also 
be used to suppress cancer invasion and metastasis. 
 
1.8 Conclusion 
Aquaporin-dependent mechanisms serve as key steps throughout the process of 
metastasis, in angiogenesis, cellular dissociation, cell migration and invasion. 
AQPs-1, -2, -3, -4, -5, -8, and -9 contribute to one or more processes, generally 
potentiating cancer invasion and metastasis by boosting tumour angiogenesis, 
enhancing cell volume regulation, regulating cell-cell and cell-matrix adhesions, 
interacting with the actin cytoskeleton, regulating proteases and ECM degrading 
molecules, contributing to the regulation of epithelial-mesenchymal transition in 
cancer cells, and interacting with specific signalling pathways important in cancer 
cell motility and invasions. Pharmacological agents for aquaporin channels have 
therapeutic promise for improving cancer treatment, and include derivatives of 
bumetanide, organic metal compounds, plant medicinal agents, and other small 
molecule compounds. Although conflicting evidence has been raised for some 
compounds, there is nevertheless a compelling need to continue identifying novel 
candidates for AQP-specific modulators relevant not only for the treatment of 
cancer, but other pathological conditions. In conclusion, although much remains to 
be defined for molecular mechanisms in cancer invasion and metastasis, the roles 
of AQP channel function in cancer progression will inspire new therapeutic targets 
for improving treatment of malignant and invasive carcinomas.  
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1.9 Thesis Hypothesis and Aims 
AQP1 enhances cell migration in some cancer cell lines. Knockdown of AQP1 
expression in cancer impairs cell migration in vitro [172, 219, 276], and increasing 
AQP1 levels by transfection into deficient lines accelerates cell migration in vitro 
and increases the likelihood of lung metastases in mice in vivo [161]. AQP1 also 
possesses a dual function, mediating water and ion flow [38, 201, 277]. There is a 
gap in knowledge regarding the properties of AQP1 that permit its migration-
enhancing effect, but both the ion and water channel activities appear to be involved 
[175] 
 
Thus, three hypotheses were tested with human cancer cell lines in vitro.  
1. AQP1 water and ion channels exhibit a coordinated role in AQP1-
facilitated cancer cell motility.  
2. Efficacy of AQP1 inhibitors depends on plasma membrane localisation of 
AQP1.  
3. The biologically active component of the AqB051 mixture inhibits 
chemokine-dependent glioblastoma invasiveness, independently of 
interaction with local extracellular matrix.  
 
These hypotheses led to the generation of 4 main aims: 
1. To test whether pharmacological block of AQP1 ion channel will impede 
cell migration and invasion in AQP1-expressing cancer cell lines. 
2. To see if combined pharmacological block of AQP1 water and ion 
channels will enhance the inhibitory effect on cancer cell motility. 
3. To see if the efficacy of AQP1 inhibitors depends on membrane 
localisation of the channel, by testing inhibitors in cells that express 
intracellular AQP1 compared to cells that express membrane-bound 
AQP1. 
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Chapter 2 is a methodology chapter that presents novel adaptations to existing 
protocols for measuring two-dimensional cell migration, as performed for work in 
this thesis. It incorporates a published paper: An Accurate and Cost-Effective 
Alternative Method for Measuring Cell Migration with the Circular Wound Closure 





Cell migration is important in many physiological and pathological processes. 
Mechanisms of two-dimensional cell migration have been investigated most 
commonly by evaluating rates of cell migration into linearly scratched zones on the 
surfaces of culture plates. Here, we present a detailed description of a simple 
adaptation for the well-known and popular wound closure assay, using a circular 
wound instead of a straight line. This method demonstrates improved precision, 
reproducibility, and sampling objectivity for measurements of wound sizes as 
compared to classic scratch assays, enabling more accurate calculations of 
migration rate. The added benefits of the method are simplicity and low cost as 









Cell migration is a multistep process that is essential for diverse life functions in 
multicellular and single-celled organisms, and includes both collective and 
individual cell movements across extracellular spaces or through tissues [1, 2]. In 
normal physiological processes, migration enables morphogenesis, immunity, and 
tissue repair [2, 3]; in pathological processes migration has been linked to cancer, 
atherosclerosis, rheumatoid arthritis, multiple sclerosis, and others [4-9]. 
Understanding the mechanisms of cell migration could facilitate development of 
therapeutic interventions for a wide range of diseases.  
 
Existing literature provides a comprehensive comparison of advantages and 
disadvantages of approaches for measuring two-dimensional (2D) cell migration 
[10]. A technique commonly used for measuring 2D cell migration is the scratch 
wound assay. In brief, the 2D scratch wound assay involves creating a linear 
“scratch” or wound across a confluent monolayer of cultured cells, and capturing 
images to measure cell migration rate by the decrease in distance across the open 
wound as a function of time [11, 12]. Though useful, the 2D scratch wound assay 
has disadvantages (summarized in Table 2.1), stemming primarily from the fact that 
the scratch wound is usually longer (but not wider) than the field of view used 
during analysis. Without live-cell imaging facilities (to capture images in identical 
locations at repeated intervals), experimenters are faced with the challenge of 
recapturing the same position on the scratch at multiple time points without 
subjective error. This is especially difficult for high-throughput assays with multi-
well plates, and is likely to result in reduced reproducibility of results. A second 
disadvantage is that typically scratch wound images are quantified by visually 
estimating the positions of the boundaries of the scratch, assuming lines to 
approximate the walls, and measuring the distances across the gap. Manually taking 
multiple measurements of the gap distances at various locations is intended to 
reduce variability by generating an average value of the distance across the scratch 
[13], but the reliability is handicapped by the fact that the boundary edges are 
ragged; the selected positions for the boundaries will vary between samples and 
within samples. Analyses with the classic scratch method must be done blinded to 
reduce the risk of unintentional bias in the acquisition of data.  Improvements on 
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the method have used image analysis software to find lines of best fit to measure 
the boundaries or areas of wounds [14, 15], but the scratch method is still vulnerable 
to variability in the image locations selected at each time-point. The third 
consideration is that most studies with the 2D scratch wound assay have not 
accounted for the potentially confounding effects of cell proliferation on the 
apparent rate of closure of the wound, a factor that might not be addressed fully by 
a “serum-starvation” step prior to commencing the assay [16-18]. 
  
The concept for generating a circular wound for measuring 2D cell migration has 
been previously established [19-21]. The circular wound closure assay (CWCA) 
permits the analyst to easily relocate the wound at any time point, and it enables 
accurate analysis by calculating the area or the radius of the circular wound using 
image analysis software. Current techniques to generate circular wounds such as 
exclusion zone assays [22] involve growing the cells around circular barriers (poly-
dimethylsiloxane micropillars, stoppers, or biocompatible gels) of uniform size 
[21], or using a stabilized, rotating, silicone-tipped drill press to create uniform, 
circular wounds in an intact confluent monolayer of cells (Tab. 2.1) [19]. One 
advantage to these techniques is that they can generate highly consistent initial 
wounds; however, they are more complex and costlier than the CWCA described 
here. The CWCA uses a sterile 10uL (P10) micropipette tip attached to an aspirator 
to remove a small circular area of cells (Fig 2.1). The complete wound can be 
reliably re-located for manual or automatic imaging at all subsequent time points. 
Processing images of circular wounds for analysis can be done with the freely 
available cross-platform Fiji (ImageJ) software [23]. Use of a mitotic inhibitor 
minimizes confounding effects of proliferation on apparent wound closure rates; 
this step is optional depending on cell type and assay duration. In summary, with 
this protocol easily relocatable, clean, sufficiently uniform circular wounds can be 
generated in diverse cell lines (Fig 2.2) that are amenable to streamlined computer-
assisted data analysis, without costly equipment or reagents. These modifications 





Table 2.1: Summary of assays used previously for measuring 2D cell 
migration, including advantages and disadvantages. 
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2.4 Materials and Methodology 
2.4.1 Cell lines 
Lines used for this study were: (1) human colorectal adenocarcinoma HT29 
(supplied by the American Type Culture Collection (ATCC®), catalogue number 
HTB-38™) and SW480 (ATCC®, catalogue number CCL-228™); (2) Human 
glioblastoma cell line U251-MG (supplied by the European Collection of Cell 
Cultures (ECACC; Salisbury, United Kingdom), catalogue number 09063001 
purchased from CellBank Australia (Westmead, NSW, Australia)); (3) Mammary 
adenocarcinoma MDA-MB-231 (ATCC®, catalogue number HTB-26™); and (4) 
human embryonic kidney HEK-293 (ATCC®, catalogue number CRL-1573™). 
2.4.2 Reagents 
 Cell culture medium and supplements appropriate for cell line.  
 5-Fluoro-2’-deoxyuridine (FUDR) (100 ng/mL final solution)  
 Lifting solution, 0.25 mM EDTA with 0.25% trypsin (2.5%, Gibco) 
 Phosphate buffer saline (PBS, Gibco) 
2.4.3 Equipment 
 Cell culture incubator at 37 C with 5% CO2  
 Inverted light microscope with camera attachment 
 Flat bottom 96 well plate 
 Vacuum pump for molecular biology (Welch Laboratory, 2511B-01, 
219 mmHg vacuum pressure) 
 p10 pipette tips (Labcon, LC1038-290) 
 Hemocytometer 
2.4.4 Free software 
 XnConvert version 1.73 
(https://www.xnview.com/en/xnconvert/#downloads) 
 Fiji (ImageJ) version 1.51h (http://imagej.nih.gov/ij/)  
2.4.5 Procedure 
Note: Perform assays under sterile conditions. See figure 2.1 for short summary 
and example of wound and outline appearance. 
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5. Passage the cells. When the cells to be used for the assay are 
approximately 70-80% confluent, detach the cells with trypsin and EDTA 
cell-lifting solution and centrifuge cells at 125G for 5 to 7 minutes. Re-
suspend cells and perform a cell count using a hemocytometer. Note: The 
CWCA can be used to generate wounds in diverse cell lines (Fig 2.2A). 
6. Plate the cells. Prepare an appropriate volume of working cell solution at 
5x105 cells/ml. Plate the working cell solution at 500 l/well for 24-well 
plate or 100 l/well for 96-well plate. Incubate the plate until cells reach 
90% confluency. Note: Incubation time will vary depending on the cell 
line.  
7. Mitotic inhibitor and serum starvation. When the cells reach 90% 
confluency, exchange the media with FUDR-containing reduced-serum 
medium (1-2% serum), and incubate overnight. Use FUDR at a 
concentration of 100ng/mL. Note: The use of a mitotic inhibitor is not 
required although recommended to reduce potential overestimation of 
apparent migration due to cell proliferation (Supp. Fig 2.1). The serum-
starvation step is essential. 
8. Create wound using vacuum pump. Attach a p10 pipette tip to the end 
of vacuum tube (to do this, it may be necessary to first attach a p200 
pipette tip to the tubing, and then overlay a p10 pipette tip on the p200 
pipette tip). With medium still in the well, position the pipette tip 
perpendicularly above the center of the well. Gently lower the tip and 
make brief contact with the base to aspirate off a circular layer of cells 
and create a circular wound (Fig 2.1). Figure 2.2B shows the consistency 
of initial wound sizes generated using this technique. Note: Gentle 
perpendicular contact between the pipette tip and the cell monolayer is 
important for clean and consistent wounds. Practicing the technique in 
several wells prior to the first experiment is recommended (see Supp. Fig 
2.2 for examples of good and bad wounds). Flat pipette tips from 2 
different vendors (Labcon, LC1038-290 and Brand Z740066) and vacuum 
pumps with different pressure settings (219 mmHg and 449 mmHg) have 
been tested in our lab with no distinctive differences in wound quality. 
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9. Wash the wound. Aspirate any remaining medium from the edge of the 
well, and wash with PBS. One wash is usually sufficient, but some cell 
lines will require an extra washing step to clear any residual cellular 
debris.  
10. Apply treatments. Remove the PBS/media from wells and replace with 
culture medium containing the treatments or control samples that are 
being tested. Prepare treatments and controls in the same FUDR-
containing reduced-serum medium as used previously. For example, if 
certain chemicals are being tested for their effect on cell migration, 
dissolve these chemicals at the appropriate final concentration in FUDR-
containing reduced-serum medium. 
11. Imaging. Using microscopy imaging facilities, capture images of each 
complete circular wound centered in the field of view. Once all wells have 
been imaged, return the plate back to the incubator until the next time 
point (if imaging is being performed manually). If desired, wound closure 
can be monitored over multiple time points (Fig 2.2C). The final time-
point for imaging depends on the cell line, as some cells migrate faster 
than others. Note: The maximal duration of the experiment should ensure 
the wounds do not fully close during the treatment period of interest.  
12. XnConvert. This software can be used for batch image processing to crop 
to regions of interest or to change resolution of pictures.  
13. Process images in ImageJ. Use NIH ImageJ software to calculate the 
wound area and to generate an outline of the perimeter of the wound area. 
The following steps illustrate how to analyze the wound area on ImageJ, 
and also how to use the “macro” feature to semi-automate the analysis for 
each image, improving consistency and objectivity of measurements. The 
same macro settings should be used for all sampled images collected in 
an experiment.  
a. Download and open Fiji (ImageJ) 
b. Select File>Open and then select the image file to be analyzed 
c. Go to Analyze>Set Scale and input the scale information relative 
to your image. 
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d. To begin recording the macro to be used for all images, select 
Plugins>Macro>Record… A “Record” box will appear, and the 
macro will now begin to record all following selections. 
e. Select Image>Type>8-bit. This will convert the image to binary 
image. 
f. Select Process>Find Edges 
g. Select Process>Sharpen 
h. Select Image>Adjust>Threshold… Be sure the settings are set to 
“Default” and “B&W” and untick the “Dark background” and 
“Stack histogram” boxes. 
i. Move the two bars until the best clarity and contrast is achieved for 
the image. See image below for how the image should look 
following adjustment. 
 
j. Select Set and a “Set Threshold Level” box should appear. Select 
OK 
k. Now select Apply in “Threshold” box. 
l. Select Process>Find Edges 
68 
 
m. Select Image>Lookup Tables>Invert LUT. See image below for 
how the image should look after LUT inversion. 
 
n. Select Analyze>Analyze Particles… 
o. In the “Size (pixel^2)” section, select minimum and maximum pixel 
areas you would like the program to identify. For example, if there 
are artifacts (“holes”) that are visible in the current image, and you 
do not want to program to mistake these “holes” for wounds, it is 
important to input the range of areas within which wounds are likely 
to fall. Try “2000-Infinity” to begin, and adjust accordingly. If the 
program is detecting “holes” that are not wounds, increase the first 
value. If the program is not detecting anything at all, including 
wounds, decrease the first value. 
p. Set “Circularity” to “0.00-1.00”. 
q. In the “Show” section, choose “Bare Outlines” to generate an 
outline of the wound.  
r. Be sure “Summarize” is ticked to generate data of the wound area.  
s. Select OK.  
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t. A summary box will appear, which will include the area value of 
the wound to be used for further statistical analysis. An outline of 
the wound will also appear. See below image for summary and 
outline following this step. 
 
u. Find the “Record” box for the macro and select Create. 
v. A new box will appear labelled, “Macro.ijm”. In this box, select 
Save As, and save as a .txt file. 
w. Now go to Plugins>Macros>Install… 
x. Find and select the .txt macro file from step v. 
y. Open a new wound image for analysis. 
z. Select Plugins>Macros>“Your Macro”. Your macro should be 
located at the bottom of the dropdown box. 
14. Check for initial wound size consistency. Run an ANOVA statistical 
test to confirm the absence of significant differences between the initial 
wound areas across all the control and treatment groups in an experiment. 
This rules out the possibility that differences in wound closure observed 
between treatment groups were an indirect result of initial wound size.  
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15. Analyze wound closure. The wound area measured at time zero (the start 
of the treatment) serves as a reference point for standardization. 
Subsequent samples can be evaluated in different ways to estimate the 
magnitude of cell migration. One method is to calculate the radius of the 
initial wound minus the radius of the end wound. This method determines 
distance moved but assumes circularity of the wound shapes. A second 
method is to calculate the final wound area as a percentage of the initial 
wound area. This method requires consistency of initial wound sizes, but 
is more tolerant of non-circular wounds. The percent closure method has 
been the analysis of choice for published work [24, 25]; however, results 
from both methods show a robust correlation, demonstrating reliability 





Figure 2.1: Schematic summary of procedures and examples of results for the 
circular wound closure assay in HT29 cells. (A) 1. Seed the cells in a 96-well 
plate, and grow to full confluence. 2. Connect a p10 pipette tip to a vacuum pump 
and gently press the end of the pipette tip perpendicularly down onto the cell 
monolayer (without lateral movement) to detach cells from the substratum, creating 
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a circular wound. 3. Image the wound at various time points. 4. Measure cell 
migration by calculating the percent change in wound area over time, standardised 
to the initial area at time zero. (B) Raw images of the same circular wound at 0 (B1) 
and 24 hours (B4). Outlines of circular wound perimeters at 0 (B2) and 24 (B5) 
hours were generated by ImageJ software. Magnified superimposed views of 
circular wounds show outlines at 0 (B3) and 24 (B6) hours, illustrating the precision 





Figure 2.2: Wounds can be generated consistently for various cell lines using 
CWCA. (A) Start-point represents 0 hours and end-point represents various time 
points depending on the cell line. The end points for cell lines shown are: U251-
MG 20 hours, HT29 24 hours, SW480 24 hours, HEK-293 24 hours, and MDA-
MB-231 20 hours. White bar represents 100µm; the scale is consistent for all 
images. (B) Wounds were generated by two different experimenters (subjects) for 
two different cell lines (MDA-MB-231 and HT29), using the CWCA technique 
described here. The initial wound sizes were calculated (in mm2), and the data sets 
from each subject were combined for each cell line. The plots depict Gaussian 
distributions of the resulting initial wound areas. For MDA-MB-231, the mean (µ) 
wound area is 0.728mm2 (standard deviation (σ) ±0.119mm2). N-value is 160. For 
HT29, µ is 0.697mm2 (σ ±0.110mm2). N-value is 146. (C) Wound closure was 
recorded as the percent change in wound area with time (3, 6, 9, 12 and 24 hours) 
in HT29 and SW480 cells. SW480 cells show a faster rate of migration than HT29 
cells. Non-linear (sigmoidal) regression functions showed the best fit of wound 
closure as a function of time, yielding a correlation coefficient of r2 = 0.95 for 





Figure 2.3: Results obtained from calculations of percent wound closure and 
wound radius decrease are strongly correlated. Plots generated from the 
experimental results obtained by two different experimenters (subjects). Each 
experiment had various treatment groups, with some treatments exhibiting 
inhibitory effects on cell migration (explaining that wide range of wound closure in 
both plots). Analysis was done by calculating both the percentage wound closure 
and the change in wound radius for each wound image. The results from each 
method were compared and linear regression yielded a correlation coefficient of 
r2=0.96 for subject 1, and r2=0.9 for subject 2. N-value is 73 for each subject. These 




2.5 Supplementary Figures 
 
Supplementary Figure 2.1: Analyses of proliferation with and without mitotic 
inhibitor FUDR. For the proliferation assay, cells were plated at 105 cells/ml in a 
flat-bottom 96-well plate in 2% serum DMEM culture medium with and without 
100ng/mL FUDR for 24 hours. Four images were acquired for each treatment (one 
image per well), standardised with XnConvert software, and used to count the total 
numbers of individual cells in each field of view. FUDR (100ng/mL) significantly 
reduced cell proliferation measured at 24 hours in HT29 and SW480 colorectal 





Supplementary Figure 2.2: Examples of high and low-quality wounds. Images 
of cultured HT29 cells in two wells of a 96-well plate, immediately after wounding. 
(A) A high-quality wound, with a clean wound area and well-defined border, in a 
uniform background of cells grown to near 100% confluence. (B) A low-quality 
wound (inadequate for further analysis) littered with cellular debris, ragged borders, 
and gaps in the cell monolayer, due to lack of confluency as well as inadequate 





This CWCA technique provides a simple and reliable alternative method with 
distinct advantages over older methods such as the scratch wound assay or cell 
exclusion zone assays. Accurate data measurements enable straightforward 
objective computer-assisted analyses. This simple adaptation of a well-established 
protocol generates results that are comparable in consistency and quality to 
expensive commercial options, and supports relatively high throughput screening 
of novel therapeutic agents that regulate cell migration rates [24, 25]. The main 
limitation of CWCA is that manual wound generation can yield higher variability 
in initial wound sizes and shapes as compared to cell exclusion zone or silicone-
tipped drill wounding methods; however, this limitation exists for any assays 
involving the manual generation of wounds. Variability is reduced with practice. 
Ruling out the potential impact of variability is addressed by running an ANOVA 
statistical test on initial wound sizes across all treatment groups in a given 
experiment. Absence of a significant difference rules out non-specific effects of 
initial wound sizes on measures of closure. Analyzing data by determining wound 
radius change, as opposed to percentage wound closure, is less sensitive to initial 
wound size, but more sensitive to the circularity of wound shape; however, both 
methods are reliable. In summary, this protocol offers a quality advance in 
methodology that is possible without specialized equipment or costly resources. 
Cutting edge research on cell migration can be carried out by laboratories, including 







1. Klausen, M., et al., Involvement of bacterial migration in the development 
of complex multicellular structures in Pseudomonas aeruginosa biofilms. 
Molecular microbiology, 2003. 50(1): p. 61-68. 
2. Friedl, P., Y. Hegerfeldt, and M. Tusch, Collective cell migration in 
morphogenesis and cancer. International Journal of Developmental 
Biology, 2004. 48: p. 441-450. 
3. Friedl, P. and B. Weigelin, Interstitial leukocyte migration and immune 
function. Nature immunology, 2008. 9(9): p. 960-969. 
4. Yamaguchi, H., J. Wyckoff, and J. Condeelis, Cell migration in tumors. 
Curr Opin Cell Biol, 2005. 17(5): p. 559-564. 
5. Ross, R., The pathogenesis of atherosclerosis: a perspective for the 1990s. 
Nature, 1993. 362(6423): p. 801. 
6. McInnes, I.B., et al., The role of interleukin–15 in T–cell migration and 
activation in rheumatoid arthritis. Nature medicine, 1996. 2(2): p. 175. 
7. Leppert, D., et al., Interferon beta‐1b inhibits gelatinase secretion and in 
vitro migration of human T cells: A possible mechanism for treatment 
efficacy in multiple sclerosis. Annals of neurology, 1996. 40(6): p. 846-852. 
8. Billuart, P., et al., Oligophrenin-1 encodes a rhoGAP protein involved in X-
linked mental retardation. Nature, 1998. 392(6679): p. 923. 
9. De Ieso, M.L. and A.J. Yool, Mechanisms of Aquaporin-Facilitated Cancer 
Invasion and Metastasis. Frontiers in Chemistry, 2018. 6. 
10. Ascione, F., et al., Comparison between fibroblast wound healing and cell 
random migration assays in vitro. Experimental cell research, 2016. 347(1): 
p. 123-132. 
11. Liang, C.-C., A.Y. Park, and J.-L. Guan, In vitro scratch assay: a convenient 
and inexpensive method for analysis of cell migration in vitro. Nature 
protocols, 2007. 2(2): p. 329. 
12. Justus, C.R., et al., In vitro cell migration and invasion assays. JoVE 
(Journal of Visualized Experiments), 2014(88): p. e51046-e51046. 
13. Dorward, H.S., et al., Pharmacological blockade of aquaporin-1 water 
channel by AqB013 restricts migration and invasiveness of colon cancer 
cells and prevents endothelial tube formation in vitro. Journal of 
Experimental & Clinical Cancer Research, 2016. 35(1): p. 36. 
14. Pan, X.Y., et al., Ginsenoside Rg3 attenuates cell migration via inhibition 
of aquaporin 1 expression in PC-3M prostate cancer cells. Eur J Pharmacol, 
2012. 683(1-3): p. 27-34. 
15. Meng, F., et al., Aqp1 enhances migration of bone marrow mesenchymal 
stem cells through regulation of FAK and beta-catenin. Stem Cells Dev, 
2014. 23(1): p. 66-75. 
16. Saxena, N.K., et al., Concomitant activation of the JAK/STAT, PI3K/AKT, 
and ERK signaling is involved in leptin-mediated promotion of invasion and 
migration of hepatocellular carcinoma cells. Cancer research, 2007. 67(6): 
p. 2497-2507. 
17. Hu, J. and A.S. Verkman, Increased migration and metastatic potential of 
tumor cells expressing aquaporin water channels. FASEB J, 2006. 20(11): 
p. 1892-4. 
18. Jiang, Y., Aquaporin-1 activity of plasma membrane affects HT20 colon 
cancer cell migration. IUBMB Life, 2009. 61(10): p. 1001-9. 
79 
 
19. Kam, Y., et al., A novel circular invasion assay mimics in vivo invasive 
behavior of cancer cell lines and distinguishes single-cell motility in vitro. 
BMC cancer, 2008. 8(1): p. 198. 
20. Daniel, T.O., et al., Thromboxane A2 is a mediator of cyclooxygenase-2-
dependent endothelial migration and angiogenesis. Cancer research, 1999. 
59(18): p. 4574-4577. 
21. Li, D.S., J. Zimmermann, and H. Levine, Modeling closure of circular 
wounds through coordinated collective motion. Physical biology, 2016. 
13(1): p. 016006. 
22. Hulkower, K.I. and R.L. Herber, Cell migration and invasion assays as tools 
for drug discovery. Pharmaceutics, 2011. 3(1): p. 107-124. 
23. Schindelin, J., et al., Fiji: an open-source platform for biological-image 
analysis. Nature methods, 2012. 9(7): p. 676. 
24. Kourghi, M., et al., Bumetanide Derivatives AqB007 and AqB011 
Selectively Block the Aquaporin-1 ion Channel Conductance and Slow 
Cancer Cell Migration. Molecular pharmacology, 2015: p. mol. 
115.101618. 
25. Pei, J.V., et al., Differential Inhibition of Water and Ion Channel Activities 
of Mammalian Aquaporin-1 by Two Structurally Related Bacopaside 
Compounds Derived from the Medicinal Plant Bacopa monnieri. Molecular 
Pharmacology, 2016. 90(4): p. 496-507. 
80 
 
Chapter 3: Pharmacological evidence that the AQP1 ion 
conductance is rate-limiting for cell migration and invasion in 
glioma, breast and colorectal cancers. 
Michael L De Ieso1, Saeed Nourmohammadi1, Jinxin Pei1, Pak Hin Chow1 and 
Andrea J Yool1  
1Department of Physiology, Adelaide Medical School, University of Adelaide, 




Aquaporin-1 (AQP1) is a dual water and ion channel that facilitates cancer cell 
migration and invasion, and in certain cancers, has been linked with metastasis 
which is a leading cause of cancer-related deaths. Other AQPs with water channel 
function are not able to substitute for AQP1 in facilitating cell migration, and there 
is a gap in knowledge regarding the properties of AQP1 that permit its migration-
enhancing effect. We hypothesised that AQP1 ion channel activity facilitates cell 
migration in AQP1-expressing cancer cell lines. Cell lines derived from colorectal 
adenocarcinoma, glioblastoma, mammary adenocarcinoma, and embryonic kidney 
cells were analysed by western blot to determine presence or absence of AQP-1, -
3, -4, and -5.  Rates of cell migration were measured with two-dimensional circular 
wound closure and live cell imaging assays, and three-dimensional invasion was 
measured by transwell assay, with and without pharmacological inhibitors of AQP 
channels and ion transporters. siRNA-mediated knockdown of AQP1 and AQP5, 
as compared with scrambled control siRNA transfections, was confirmed with real-
time polymerase chain reaction and western blot. Cell viability was measured with 
alamarBlue. The sodium-hydrogen-antiporter 1 inhibitor, ethylisopropylamiloride, 
inhibited HT29 colorectal cancer wound closure as did the AQP1 ion channel 
blockers AqB011, AqB007, and AqB006, suggesting multiple pathways for Na+ 
entry are involved in enabling cell motility. AqB011 (80M) produced the strongest 
block of wound closure (58  3.1%) in HT29 cells as compared to vehicle-treated, 
and also significantly inhibited wound closure in glioblastoma lines U87-MG (36  
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2.4%.) and U251-MG (25  4.4%.), without cytotoxicity. AQP5-knockdown in 
HT29 colorectal carcinoma cells resulted in increased sensitivity of wound closure 
to inhibition by AqB011, suggesting AQP1 was recruited as a compensatory 
mechanism. Live cell imaging confirmed at the single cell level that the mean 
overall distance migrated by U87-MG cells in 24 hours (649 ± 27 µm) was 
significantly reduced by AqB011 (525 ± 27 µm). Invasiveness also was inhibited 
significantly by AqB011 in glioblastoma U87-MG (49 ± 7.1%) and U251-MG (63 
± 12%), and in breast cancer MDA-231-MB (40 ± 9.4%), as compared to vehicle-
treated controls in the same lines. This is the first demonstration that the AQP1 ion 
channel blocker, AqB011, significantly inhibits cell migration and invasion in 
diverse AQP1-expressing cancer cell lines, including glioblastoma, breast, and 
colon cancers. This discovery highlights the AQP1 ion conductance as a new 












Aquaporins (AQPs) are a family of water channels with functions including 
maintaining structure; regulating cell volume and osmotic membrane water 
permeability; enabling fluid flow across barrier tissues; and supporting metabolic 
demands and cellular migration [1, 2]. The first aquaporin to be cloned, aquaporin-
1 (AQP1), was identified in red blood cells and renal proximal tubules [3, 4]. In the 
Xenopus laevis expression system, introduced AQP1 channels enabled high 
osmotic water flux across the plasma membrane as compared to non-AQP1 control 
oocytes [5], explaining the mechanism behind rapid transmembrane water flux in 
certain cell types. So far, fifteen classes of aquaporin genes have been discovered 
in mammals (AQP0-AQP14) [6-8]. The first thirteen aquaporins (AQP0-AQP12) 
have been separated into groups based on functional properties, including the 
classical aquaporins (AQP0, -1, -2, -4, -5, -6, -8), the aquaglyceroporins (AQP3, -
7, -9 and -10), and the distantly related paralogs (AQP11 and AQP12) [9]. 
Aquaporins assemble as homo-tetramers, with monomers ranging 26 to 34kDa [2]. 
In most AQPs, each monomer is composed of six membrane spanning helices and 
five loops (A to E); the amino and carboxyl terminal domains are intracellular [10]. 
Each monomer has highly conserved asparagine-proline-alanine (NPA) motifs in 
cytoplasmic loop B and in extracellular loop E [10], which contribute to a 
monomeric pore configuration that facilitates bidirectional, selective, single-file 
transport of water in the classical aquaporins [11], and water and glycerol in 
aquaglyceroporins [12]. The classical aquaporins (AQP0, -1, -2, -4, -5, -6, -8) were 
originally thought to transport only water, though aquaporin-0, -1, and -6 have also 
been shown to conduct charged particles [13-15].  
 
AQP1 ion conductance was first discovered in AQP1-expressing Xenopus oocytes 
stimulated with forskolin [16]; however, the forskolin response proved to be 
inconsistent when tested by other groups [17]. Further work showed the forskolin 
effect was indirect; the non-selective monovalent cation conductance is gated by 
cGMP [13, 18, 19]. It was later discovered that cGMP-gated ion conductance in 
AQP1 depends on the structural integrity of the loop D domain [20], and that 
monovalent cations permeate the central tetrameric pore [21, 22]. Conversely, 
AQP0 and AQP6 possess different physiological roles, and enable ion flow through 
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the monomeric pores and not the central tetrameric pore (see Box 3.1). It has been 
suggested that there is no physiological function of the AQP1 ion pore, as AQP1 
ion channels have a low opening probability [23] or are not detectable in some 
expression systems [24]. However, the cGMP-mediated gating of AQP1 is subject 
to additional regulation including tyrosine phosphorylation [25], and the 
physiological relevance of AQP1 ion channel activity has been shown for fluid 
secretion across choroid plexus epithelium [26].  
 
Dual water and ion conductance in AQP1 might play a role in AQP1-facilitated 
cancer cell migration and invasion. AQP1 is upregulated in certain aggressive 
cancers including colorectal cancer, glioma, breast cancer, lung adenocarcinoma, 
laryngeal cancer and cholangiocarcinoma [27-32], and contributes to tumour cell 
migration and metastasis [33]. This was demonstrated when AQP1 levels were 
increased by transfection into deficient lines (B16F10 melanoma, and 4T1 
mammary gland tumour), resulting in accelerated cell migration in vitro and an 
increased likelihood of lung metastases in mice in vivo [34]. Moreover, AQP1 
knockdown in cancer lines using small-interfering RNAs resulted in substantial 
impairment of cell migration in vitro [35, 36]. Interestingly, other mammalian water 
channels such as AQP4 did not substitute for AQP1 in facilitating cell migration in 
AQP1-dependent cell lines [37], suggesting that the migration-enhancing property 
of AQP1 in some cases relies on more than membrane water permeability. In 
addition to water, membrane ion permeability is also important in cell migration. 
The Na+/H+ exchanger (NHE1) plays an important role in cell migration by 
polarizing to the leading edge of migrating cells [38], maintaining the polarity and 
directionality of migrating cells [39, 40]; controlling cell adhesion [41]; and 
regulating uptake of Na+ at the leading edge to create an osmotic gradient, which 
triggers the local influx of water via AQPs [42]. This local influx of water increases 
local hydrostatic pressure, causing the cell membrane to protrude at the leading 
edge, which makes room for actin polymerization and subsequently lamellipodial 
formation. Here, we hypothesise that AQP1 possesses a dual function of enabling 
the uptake of Na+ and water at the leading edge, contributing to AQP1-facilitated 
cell migration in AQP1-expressing cancer cell lines. We aimed to test the role of 
the AQP1 ion conductance in cancer cell migration and invasion using small 
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molecule AQP1 ion channel inhibitors AqB011 and AqB007 [43], and compare the 
effects with compounds shown to inhibit AQP1 water flux; bacopaside II and 
acetazolamide. Bacopaside II is a derivative of the perennial herb, Bacopa 
monnieri, and was shown to block water flux through AQP1 but not AQP4 channels 
[44]. Acetazolamide is a carbonic anhydrase inhibitor that also has been suggested 
to inhibit AQP1-mediated water flux [45]. Results here demonstrate a physiological 
role for the AQP1 ion conductance in cell migration and invasion in AQP1-
dependent cancer cell lines.  
 
Box 3.1: Mechanisms and physiological roles of ion conductance in AQP0 and 
AQP6 
AQP0 
To date, AQP1, AQP0, and AQP6 have been uncovered as dual water and ion 
channels, however, AQP0 and AQP6 have different physiological roles and 
mechanisms of ion transport as compared to AQP1 (see Table 3.1). AQP0, once 
known as MIP or MIP26, is the most abundant intrinsic membrane protein of the 
ocular lens fibres [46], and is the major protein component of isolated lens 
junctions. AQP0 has been shown to function as a water channel exogenously in 
Xenopus oocytes [47, 48] and endogenously in membrane vesicles freshly isolated 
from mouse, frog and rabbit lens fibres [49-51]. However, compared to AQPs 1-5, 
AQP0 has the lowest water permeability [52] with single channel water 
permeability about 1/40th that of AQP1 [47]. It has been postulated that the primary 
functions of AQP0 in the lens are more than just increasing membrane water 
permeability. Liu et al. (2011) suggested that lens AQP0 functions in cell to cell 
adhesion of lens fibres, and regulation of gap junction channels [53].  Chepelinsky 
(2009) suggested AQP0 is required for maintaining the transparency and optical 
accommodation of the ocular lens [54]. AQP0-null humans and mice were found to 
have congenital cataracts [54, 55], and heterozygous loss of AQP0 in mice similarly 
triggered cataractogenesis  [56]. 
 
AQP0 is thought to have ion channel pores in each monomer, unlike AQP1 which 
enables ion flow via the central tetrameric pore [15, 57-60]. In bilayer preparations, 
bovine AQP0 showed high single channel conductance that was voltage- and pH-
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sensitive [15, 59]. Opening probability increased with increasing H+ concentration, 
and was low at neutral pH showing a current amplitude similar to control bilayers 
[59]. Bovine AQP0 channels that were reconstituted in unilamellar vesicles had two 
preferred conductance states with amplitudes of 380 and 160 pS [15]. AQP0 
displayed slight anion selectivity, symmetrical voltage dependence, and rapid 
opening and slow closing rates [59]. The water channel activity of AQP0 was 
shown to be regulated by pH and calcium [61], suggesting regulatory mechanisms 
control both the water and ion conductance of AQP0. Ehring et al. (1990) proposed 
that the role of AQP0 in maintaining optimal lens transparency was linked with its 
dual water and ion channel functions [15]. AQP0 might promote the uptake of Na+ 
from the extracellular space, minimising extracellular fluid volume; this would act 
to reduce light scattering and improve optical transparency of the lens [15].  
 
AQP6 
Aquaporin-6 (AQP6) is unusual among mammalian AQPs in functioning more 
effectively as an ion channel than a water channel, and in being activated rather 
than blocked by mercuric chloride (HgCl2) [14]. In the AQP6 tetramer, individual 
monomeric pores carry anion currents with a permeability sequence of 
NO3>I>>Br>Cl>>F, showing minimal water permeability in standard conditions 
[62, 63]. Covalent modification of AQP6 by HgCl2 (300µM) increased the ion 
conductance more than six-fold, and activated water permeability  [14, 62, 64], in 
stark contrast to the potent blocking effect of mercurial compounds known for 
AQP1, AQP2, and AQP5 water channel activities. Activation of AQP6 ion 
conductance by HgCl2 is due to the interaction of HgCl with two cysteines (C155 
and C190), implicating these residues in the gating mechanism [65]. AQP6 water 
and anion fluxes were also reversibly potentiated by low pH, providing evidence 
for a possible physiological role [62].  In the broader MIP family, the insect AQP 
channel Big Brain (BIB) similarly functions as an ion channel, lacking water 
channel activity [66] 
 
AQP6 is expressed in intracellular vesicles of renal collecting duct, colocalized with 
H+/ATPase transporters in α-intercalated cells that function in urinary acid secretion 
[62, 65, 67]. A role in acid/base regulation in α-intercalated cells is supported by 
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evidence showing significant upregulation of AQP6 expression in rats exposed to 
chronic alkalosis or water loading, but not those with chronic acidosis [68, 69]. 
AQP6 might also function as a pH-sensitive chloride channel in kidney endosomes 
[70].  AQP6  is located in rat gastrointestinal epithelium near tight junctions, in 
secretory granule membranes of parotid acinar cells, and is expressed in some 
ovarian cancers [71-73], although its physiological roles in these tissues are not yet 
understood. Susceptibility to viral infection in host cell lines was decreased 
following overexpression of AQP6, suggesting a possible protective role. Molinas 
et al. (2016) found GFP-AQP6 transduced C3H10T1/2 chimeric cells showed 
reduced infectivity of Hazara virus (used as a model for Crimean–Congo 
haemorrhagic fever virus), and conversely that infection with the Hazara virus 





Table 3.1: A summary of gating mechanisms, selectivity, and physiological 
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3.4 Materials and Methodology 
3.4.1 Cell lines 
Lines used for this study were: (1) human colorectal adenocarcinoma HT29 (from 
the American Type Culture Collection (ATCC), catalogue number HTB-38), and 
SW620 (ATCC; catalogue number CCL-227); (2) Human glioblastoma cell lines 
U251-MG (from the European Collection of Cell Cultures (ECACC; Salisbury, 
United Kingdom), catalogue number 09063001 purchased from CellBank Australia 
(Westmead, NSW, Australia)), A-172 (ECACC, catalogue number 88062428), and 
U87-MG (ECACC, catalogue number 89081402); (3) Mammary adenocarcinoma 
MDA-MB-231 (ATCC; catalogue number HTB-26); (4) Human embryonic cell 
line HEK-293 (ATCC; catalogue number CRL-1573). Cells were cultured in T-75 
plates in Dulbecco’s Modified Eagle Medium (DMEM;  Life Technologies, Grand 
Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), 1% Gibco 
GlutaMAX (all cells except MDA-MB-231 were treated with GlutaMAX) and 100 
units/ml each of penicillin and streptomycin. Cell cultures were grown at 37°C in a 
humidified 5% CO2 incubator.  
 
3.4.2 Inhibitors 
Bumetanide derivatives AqB011 (MW 434.9), AqB006 (MW 413.9), and AqB007 
(MW 470.0) were synthesised by Dr Gary A. Flynn (SpaceFill Discovery LLC, 
West Yellowstone, MT, USA) [43] and dissolved in dimethyl sulfoxide (DMSO) 
to create 1000x stock solutions. 5-(N-Ethyl-N-isopropyl)amiloride (EIPA; 
catalogue number A3085; Sigma-Aldrich, St. Louis, MO) and acetazolamide 
(catalogue number A6011; Sigma-Aldrich) were also dissolved in DMSO to create 
1000x stock solutions. Bacopaside II was purchased from Sigma-Aldrich (St. Louis, 
MO), solubilised in methanol to yield 100x stock solutions, and stored at -20°C in 
an airtight vial to minimize evaporation. Stock solutions were diluted in culture 
medium to final concentrations for testing in the circular wound closure [75], 




3.4.3 Western Blot Analysis  
Cells were seeded at 4-5x105 cells per well in 6-well tissue culture plates in normal 
growth medium, and incubated for 24 hours at 37°C in 5% CO2. For siRNA 
experiments, transfection was initiated 48 hours before protein extraction. Once 
cultures reached 70-80% confluence, cells were washed with ice-cold Dulbecco’s 
phosphate buffered saline, and incubated on ice for 5 minutes in 
radioimmunoprecipitation assay lysis and extraction buffer (Life Technologies) 
containing 1% Halt protease inhibitor (Thermo Scientific™). Cells were dislodged 
using a clean Corning® Cell Lifter, and homogenised with a 26-gauge needle and 
syringe. Homogenised lysates were collected into 1.5 mL centrifuge tubes, and 
centrifuged at 17,000 G for 10 minutes at 4°C. The cell debris pellet was discarded, 
and the supernatant was carefully transferred to a new 1.5 mL centrifuge tube. After 
Bradford protein estimation, 40 g protein samples were prepared in 10 µL 
Novex™ 4X Bolt™ LDS Sample Buffer (Life Technologies; cat # B0007), 4 µL 
10X Bolt™ Sample Reducing Agent (Invitrogen™; cat # B0009), with deionised 
water added to 40 µL total. After heating at 70oC for 10 minutes, samples were 
resolved by SDS-PAGE on Bolt 4-12% Bis-Tris Plus gel (Invitrogen™; cat # 
NW04122BOX), and transferred onto 0.2m polyvinylidenefluoride membrane 
using the iBlot 2 Gel Transfer System (Invitrogen™; cat # IB21001). 
Immunodetection was performed with the iBind Western System using the iBind™ 
Western Device (Invitrogen™; cat # SLF1000), iBind™ cards (Invitrogen™; cat # 
SLF1010), and iBind™ Solution Kit (Invitrogen™; cat # SLF1020). Antibody 
details are as follows: Secondary antibody IRDye® anti-rabbit 800CW (1:2000; 
Abcam; ab216773) was used for the following primary antibodies: rabbit 
polyclonal AQP1 (1:1000; obtained from the Department of Ophthalmology, Duke 
University, Durham, NC, USA [76, 77]); rabbit polyclonal AQP3 (1:1000; Abcam; 
ab125219); rabbit polyclonal AQP4 (1:1000; Abcam; ab46182); rabbit monoclonal 
AQP5 (1:1000; Abcam; ab92320). Secondary antibody IRDye® anti-mouse 680RD 
(1:2000; Abcam; ab216778) was used for GAPDH antibody (1:200; Abcam; 
ab9484). Western blots were assessed using ImageStudio® Lite, version 5.2. Signal 
intensities were determined relative to local background. For siRNA experiments, 
data were standardised to the loading control (GAPDH). Band intensities from 
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CTRL siRNA-treated cells were used as the reference point for normalization of 
AQP1 and AQP5 siRNA-treated cells.   
 
3.4.4 AQP1 and AQP5 siRNA knockdown 
Cells were plated in a 96-well plate and incubated in normal growth conditions 
(37°C 5% CO2) until 60-80% confluent. Transfection was performed as per 
manufacturer’s instructions with Lipofectamine RNAiMAX Reagent (Life 
Technologies, Grand Island, NY, USA). Ambion® Silencer Select Negative Control 
#1 siRNA (cat # 4390843), validated Ambion® Silencer Select AQP1 siRNA (cat # 
4390824), and SMARTpool siGENOME AQP5 siRNA (Dharmacon™; cat # M-
004520-01-0005) were used at a final concentration of 50 nM. BLOCK-iT™ Alexa 
Fluor® Red Fluorescent Oligo (cat # 14750100) was used to determine transfection 
efficiency. Experimental assays commenced at 48h post-transfection.  
 
3.4.5 Real-time quantitative reverse-transcription polymerase chain reaction 
Following siRNA transfection, PureLink™ RNA Mini Kit (Invitrogen™) was used 
to extract total RNA; cDNA synthesis required 1 µg total RNA. QuantiTect® 
Reverse Transcription Kit (Qiagen®) was used to synthesize cDNA. NanoDrop™ 
(Life Technologies) was used to quantify cDNA; 50 ng cDNA was used in the 
polymerase chain reaction. Real-time qRT-PCR analyses were performed using 
SYBR™ Green PCR Master Mix (Applied Biosystems™) in a final volume of 10 
µl with StepOne Plus™ Real-Time PCR system (Applied Biosystems™). Data 
were analysed by StepOne Plus™ Real-Time PCR software v2.3. The primer 
sequences for AQP1 were forward: 5′-CGCAGAGTGTGGGCCACATCA- 3′, and 
reverse: 5′ -CCCGAGTTCACACCATCAGCC- 3′, amplifying a product of 217 bp. 
The primer sequences for AQP5 were forward: 5′ -
CGTTTGGCCTGGCCATAGGCA- 3′, and reverse: 5′ -
TGGCCCTGCGTTGTGTTGTTG- 3′, amplifying a product of 247 bp. RPS13 was 
used as a standard and target mRNA levels relative to RPS13 were calculated using 




3.4.6 Circular wound closure assay 
Two-dimensional (2D) collective cancer cell migration was measured with the 
circular wound closure assay as described by De Ieso and Pei (2018) [75]. Cells 
were seeded at 1 x 105 cells/ml in normal culture medium with 10% fetal bovine 
serum (FBS), and incubated at 37°C in 5% CO2 in a 96-well plate. When cells 
reached 80-90% confluence, cells were incubated in reduced-serum (2% FBS) 
media and 400nM of the mitotic inhibitor 5-fluoro-2'-deoxyuridine (FUDR) 
overnight to achieve a confluent monolayer. Circular wounds were generated with 
a sterile p10 pipette tip; drug-treated media (with 2% FBS and FUDR) was applied 
following wounding. Complete wounds were imaged at 10x magnification with a 
Canon 6D camera on a Nikon inverted microscope. Images were standardised using 
XnConvert software, and wound areas were quantified using NIH ImageJ software 
(U.S. National Institutes of Health). Closure was calculated as a percentage of the 
initial wound area for the same well as a function of time. All experiments were 
repeated twice. 
 
3.4.7 Live Cell Imaging 
U87-MG cells were seeded on flat-bottomed 96-well plates at a density of 1x105 
cells/mL. A confluent monolayer was achieved 2-3 days after plating. Cells were 
conditioned in low serum culture medium (2% FBS) in the presence of FUDR (400 
nM) for 12-18 hours before wounding. A circular wound was created in each well 
using techniques described above for the wound closure assays. Plate was mounted 
on a Nikon Ti E Live Cell Microscope (Nikon, Tokyo, Japan) in an enclosed 
humidified chamber kept at 37°C with 5% CO2. Images were taken at 30-minute 
intervals for 20 hours, using Nikon NIS-Elements software. AVI files were 
exported from NIS-Elements and converted into TIFF files using Fiji (ImageJ). 
Converted files were analyzed using Fiji software [80] with the Manual Tracking 
plug-in. Total distance per cell was calculated as the cumulative distance travelled 
over the full duration of the experiment.  
 
3.4.8 Transwell Invasion Assay 
Three-dimensional (3D) cancer cell invasion was measured with the transwell 
invasion assay, which was performed using 6.5 mm Corning® Transwell® 
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polycarbonate membrane cell culture inserts with 8m pore size (cat #3422; Sigma-
Aldrich). The upper surface of the filter was coated with 40 L of water-diluted 
extracellular matrix (ECM) gel from Engelbreth-Holm-Swarm murine sarcoma 
(250 g/mL for each cell line; Sigma-Aldrich, St. Louis, MO). The transwells with 
the ECM gel are left to dehydrate overnight, and rehydrated 2 hours prior to cell 
seeding with 50 L of serum-free DMEM per transwell insert. Cells were grown to 
approximately 40% confluence under normal conditions, and transferred into 
reduced serum (2% FBS) medium for 12-18 hours prior to seeding. Cells were 
detached (at ≤80% confluency) and resuspended in serum-free culture media with 
and without pharmacological treatments at 5x104 cells per well. Cells were then 
seeded in transwell inserts (total 150L of cell suspension per transwell, including 
50 L of rehydration medium added earlier). 600 L of culture medium with 10% 
serum (chemoattractant) and the pharmacological treatment was added to the lower 
chamber. Cells were incubated for 4 hours, at 37°C in 5% CO2. Non-migrated cells 
were scraped from the upper surface of the membrane with a cotton swab; migrated 
cells remaining on the bottom surface were counted after staining with crystal violet 
[81].  
 
3.4.9 Cell viability assay 
Cell viability was quantified using an alamarBlue assay [82], as per the 
manufacturer's guidelines (Life Technologies). Cells were plated in FUDR-
containing culture media with 2% FBS, at 105 cells/ml in a 96-well plate. 
Treatments were applied 12-18 hours after plating, and cells were incubated for 24 
hours. At 24 hours, cells were treated with 10% alamarBlue in culture media as 
above, for 1-2 hours (this depends on the cell type). Fluorescence signal levels were 
measured with a FLUOstar Optima microplate reader for control and treatment 
groups. The mean signal obtained from the no-cell control group was subtracted 
from every value in each treatment to correct for background fluorescence. 
Mercuric chloride (HgCl) was used as a positive control for cytotoxicity. The assay 




3.4.10 Statistical Analyses 
Statistical analyses performed with GraphPad Prism 7.02 software involved one-
way ANOVA and post-hoc Bonferroni tests. Statistically significant outcomes are 
represented as p<0.05 (*), p<0.01 (**), p<0.001 (***), or p<0.0001 (****); NS is 
not significant. All data are presented as mean ± standard error of the mean (SEM); 
n values for independent samples are indicated in italics above the x-axes in 
histogram figures.  
 
3.5 Results 
3.5.1 AQP-1, -3, -4 and -5 expression in cell lines 
AQP protein was measured in seven cell lines by western blot (Fig 3.1). An equal 
amount of total protein was added in each lane (40 g), as determined by Bradford 
protein estimation. AQP1 was present in all cell lines; the major bands near 37kD 
were consistent with glycosylated forms of the 28kD AQP1 monomer [83]. AQP3 
and AQP4 were also present in all cell lines near 37kD and 75kD, thought to be 
monomers and dimers [84, 85]. AQP5 was present in HT29 and HEK-293, but not 
detected in MDA-231-MB, SW620, U87-MG, A172, and U251. AQP5 bands near 
25kD and 37kD are thought to be non-glycosylated and glycosylated forms of 
AQP5 [86, 87]. Thus, expression patterns for various AQPs differed between cell 
lines; however, all cell lines expressed AQP1 and were therefore suitable for testing 





Figure 3.1 Western blot depicting bands for AQP-1, -3, -4, and -5 in each cell line. 
AQP-1, -3, and -4 protein were present in all cell lines. AQP5 was present only in 
HT29 and HEK-293. Definitions for abbreviations are as follows: protein ladder 
(Lad.); HT29 (HT2); HEK-293 (HEK); MDA-231-MB (MDA); SW620 (SW6); 




3.5.2 Ethylisopropylamiloride and bumetanide derivatives inhibited wound 
closure of AQP1-expressing cell lines 
The dependence of cell migration on water and ion fluxes across the membrane was 
tested with antagonists of the AQP1 ion channel, AQP1 water channel, and a Na+-
dependent exchanger shown previously to influence motility [88]. The cell lines 
tested here were selected based on their positive AQP1 expression. As shown 
previously, bumetanide derivatives AqB011, AqB007, and AqB006  inhibited 
AQP1 ion currents in the oocyte expression system, and blocked 2D migration of 
HT29 cells (Fig 3.2A) [43]. Interestingly, the effectiveness of the bumetanide 
derivatives in blocking cell migration followed the same order of potency as 
measured for inhibition of the AQP1 ion channel conductance. AqB011 (50 M) 
blocked wound closure by 60  2.3%; AqB007 (50 M) blocked wound closure by 
29  8.5%; AqB006 (50 M) blocked wound closure by 27  4.6%. The bumetanide 
derivatives were non-toxic at all doses tested, with the exception of 100M AqB011 
which resulted in 85  1.4% cell viability, as referenced to 100% viability in 
untreated cells (Fig 3.2E). AqB011 was identified as the most potent of the 
bumetanide series of antagonists in reducing migration. To determine the possible 
contribution of NHE1 in HT29 and A172 cell migration, the antagonist EIPA was 
tested in wound closure assays (Fig 3.2B). EIPA (20M) caused a small but 
significant block of wound closure in HT29 (by 33  3.4%) in contrast to the strong 
block that was seen with AqB011 (Fig 3.2A). EIPA blocked A172 migration by 38 
 3.4%. EIPA had no effect on cell viability at any of the doses tested (Fig 3.2E). 
These results indicated that membrane sodium flux is important for cell migration 
in both HT29 and A172, and that more than one transport mechanism is involved, 
though the relative contributions of each pathway depend on the cell type.  
 
To determine whether AQP1 water conductance was physiologically important for 
cancer cell migration, we tested two agents shown to have antagonistic effects on 
AQP1 water conductance; acetazolamide and bacopaside II. Acetazolamide is a 
carbonic anhydrase inhibitor that has been shown to block AQP1 water flow in 
some preparations [89]. Bacopaside II has been shown to block AQP1 water flow 
but not AQP1 ion conductance in Xenopus oocytes [44]. Acetazolamide did not 
significantly reduce HT29 wound closure at any dose tested (1M to 300M; Fig 
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2C) and was non-toxic (Fig 3.2E). In contrast, bacopaside II (7.5M) did 
significantly block wound closure in HT29 (27  7.0%; Fig 3.2D), without evidence 
of cytotoxicity (Fig 3.2E). A172, HEK-293, and U87-MG cell migration were 
unaffected by bacopaside II (Fig 3.2D) at doses that had no effect on cell viability 
(Fig 3.2E). Thus, HT29 cell migration was reduced after treatment with bacopaside 
II and not acetazolamide, suggesting that acetazolamide and bacopaside II do not 




Figure 3.2 Effect of acetazolamide, EIPA, bacopaside II, and bumetanide 
derivatives on wound closure in AQP1-expressing cell lines. (A) Box and whisker 
plot depicting block of HT29 wound closure following treatment with bumetanide 
derivatives AqB006, AqB007, and AqB011. All treatments significantly blocked 
wound closure; AqB011 100M produced the strongest block. (B) Box and whisker 
plots depicting block of HT29 and A172 wound closure following treatment with 
EIPA. EIPA significantly reduced wound closure at 10M and 20M for both cell 
lines. (C) Box and whisker plot depicting block of HT29 wound closure following 
acetazolamide treatment. Acetazolamide had no effect on wound closure for all 
doses tested. (D) Box and whisker plot depicting block of wound closure following 
bacopaside II treatment. Bacopaside II blocked wound closure in HT29 cells. (E) 
Histograms depicting cell viability following treatment with all of the above tested 
compounds. AqB011 100M produced a slight but significant reduction in HT29 
cell viability. Bacopaside II (≥15µM) reduced cell viability in all cell lines.   
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3.5.3 AqB011 inhibited wound closure in multiple AQP1-expressing cancer cell 
lines 
To see whether AQP1 ion conductance played a role in cell migration across 
multiple AQP1-expressing cell lines, we tested AqB011 in AQP1-expressing  U87-
MG, A172, U251-MG, SW620, HEK-293, and MDA-231-MB. AqB011 inhibited 
wound closure in U87-MG (at 20 to 80M), A172 (40 to 80M), and U251-MG 
(80M) (Fig 3.3A). AqB011 had no effect on wound closure for SW620, HEK-293, 
and MDA-231-MB cell lines (Fig 3.3A). AqB011 had no significant effect on cell 
viability in any cell lines other than A172 (Fig 3.3B). In A172, AqB011 (40M) 
treatment resulted in 80  3.3% cell viability as referenced to untreated. Therefore, 
inhibition of A172 wound closure by AqB011 might be partly attributable to 
reduction in cell viability. Overall, these data suggested that the presence of AQP1 





Figure 3.3 Effect of AqB011 on wound closure in other AQP1-expressing cell 
lines. (A) Box and whisker plots depicting block of wound closure following 
treatment with AqB011. Cell lines tested are glioblastoma cell lines U87-MG, 
A172, and U251-MG; colorectal adenocarcinoma cell line SW620; human 
embryonic cell line HEK-293; and breast cancer cell line MDA-231-MB. AqB011 
produced a significant block in U87-MG, A172, and U251-MG. (B) Histogramss 
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depicting cell viability of each cell line following treatment with AqB011. AqB011 
did not significantly reduce cell viability in any cell line except A172. AqB011 





3.5.4 AqB011 inhibited individual glioblastoma cell migration as assessed by 
live cell imaging 
Important mechanisms of cancer invasion and metastasis are cell migration and 
disassociation of cell-cell adhesions [33]; these processes are not entirely captured 
in collective cell migration analyses such as the wound closure assay. Over 20 
hours, U87-MG individual cell motility was measured following AqB011 and 
bacopaside II administration. The U87-MG cell line was selected for individual cell 
motility analysis based on the robust response to AqB011, which was depicted in 
figure 3.3A. Figure 3.4A illustrates 5-hour intervals of U87-MG cells treated with 
and without AqB011; there was a noticeable reduction in the distance covered by 
AqB011-treated cells as compared to vehicle treated cells. Impaired cell migration 
was evident from the shortened trajectories in the AqB011 (80M) treatment group 
as compared with untreated and vehicle control (Fig 3.4B). Trajectory analysis 
showed that U87-MG cells treated with AqB011 80µM migrated significantly 
shorter total distances in 20 hours (525 ± 27 µm) than vehicle-treated cells (649 ± 
27 µm) (Fig 3.4C). Bacopaside II (7.5M) alone and combined with AqB011 
(20M) had no effect on U87-MG individual cell migration. Thus, AqB011 
inhibited individual cell movement as well as collective cell migration in U87-MG 





Figure 3.4 The effect of AqB011 on individual U87-MG glioblastoma cell 
migration. (A) Panels of five images each from time-lapse series are shown at 5-
hour intervals. Vehicle and AqB011 80μM treatments are depicted. (B) Trajectory 
plots of individual cells (n=15) per treatment group, monitored by the position of 
the cell nucleus at 30 minute intervals over 20 hours; X and Y values are in m. (C) 
Box and whisker plot depicting cell trajectory analysis; U87-MG cells treated with 
AqB011 80µM migrated significantly shorter total distances in 20 hours than 
vehicle-treated cells (**).  
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3.5.5 AQP5-knockdown in HT29 colorectal carcinoma cells resulted in 
increased sensitivity to inhibition of wound closure by AqB011 
Results from the wound closure assay revealed that the presence of AQP1 protein 
did not guarantee inhibition of wound closure by AqB011, suggesting dependence 
on AQP1 ion conductance for rapid cell migration might vary between cell types. 
To determine the selectivity of AqB011 for AQP1, we tested AqB011 following 
mRNA knock-down of AQP1 and AQP5 in HT29 cells. Figure 3.5A depicted bands 
for western blot protein analysis following AQP1 and AQP5 siRNA treatments. 
Band intensities were standardised to the housekeeping protein, GAPDH. AQP5 
bands were identified near 37kD and 25kD, and AQP1 bands were identified near 
37kD, consistent with results in Figure 3.1. AQP1 protein expression was not 
significantly reduced following AQP1 siRNA transfection (Fig 3.5B); however, 
AQP5 protein expression was significantly reduced to 39  0.1% of control siRNA-
transfected cells following AQP5 siRNA transfection (Fig 3.5B). Interestingly, both 
AQP1 and AQP5 mRNA levels were significantly reduced following siRNA 
treatment (Fig 3.5C), suggesting the siRNAs had been effective in decreasing their 
targeted transcripts, but that a much slower turnover rate for AQP1 protein in HT29 
allowed for persistence of the AQP1 channels. Figure 3.5D illustrates the high 
transfection efficiency achieved for HT29 cell lines. AQP1- and AQP5-siRNA-
tranfected cells did not exhibit any significant reduction in wound closure as 
compared to control siRNA transfected cells (Fig 3.5E). Combined AQP1 and 
AQP5 siRNA treatments also did not produce any significant inhibition of wound 
closure as compared to control siRNA. Sensitivity to AqB011 in the inhibition of 
wound closure was not altered following AQP1 siRNA treatment (consistent with 
continued presence of AQP1 channels).  The AQP1 siRNA treatment did not alter 
HT29 wound closure rates or AQP1 protein levels in HT29 cell lines, and thus 
served as an unintended control, showing that the experimental manipulations did 
not affect cell properties. In contrast, AQP5-siRNA treatment successfully reduced 
AQP5 protein levels, and the potency of AqB011 inhibition of wound closure was 
increased (Fig 3.5E), consistent with an amplified dependence on AQP1 for cell 






Figure 3.5 Effect of AQP1 and AQP5 knockdown on HT29 wound closure and 
AqB011 sensitivity. (A) Image depicting western blot analysis of AQP1 and AQP5 
protein expression levels in HT29 cells following knockdown of AQP1, AQP5, or 
combined knockdown of AQP1 and AQP5. GAPDH is used as a reference protein 
for quantification. (B) Graphs depicting quantified AQP1 and AQP5 protein levels 
following knockdown. AQP5 protein levels were significantly reduced in AQP5 
siRNA-transfected cells as compared to control siRNA-transfected cells (**). 
AQP1 siRNA-transfected cells did not show any significant reduction in AQP1 
protein levels as compared to control siRNA-transfected cells. Control siRNA 
represented by double negative symbol. (C) Graphs depicting quantified AQP1 and 
AQP5 mRNA levels following respective siRNA knockdown. (D) Images depicting 
high transfection efficiency in HT29 cells. Top panel depicts brightfield image of 
cells, and bottom panel shows fluorescing (transfected) cells of the same image. (E) 
Graph depicting block of wound closure in AQP1- and AQP5-knockdown cells, 
following treatment with AqB011. AQP1- and AQP5-knockdown cells did not 
exhibit any significant reduction in wound closure as compared to control siRNA. 
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Cells with reduced AQP5 showed an increased sensitivity to AqB011 (*). WT is 
wild-type, meaning the cells have not been transfected.   
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3.5.6 AqB011 inhibited cell invasion in glioblastoma and breast cancer cell 
lines  
In addition to cell motility, the process of cancer metastasis requires the movement 
of cells through extracellular matrix (ECM), an attribute not tested in standard 2D 
wound closure models. Thus, we aimed to test the role of AQP1 ion conductance 
in cancer invasiveness. The effects of AqB011 were tested on glioblastoma and 
breast cancer cell lines with transwell filter chambers in which cells migrated 
through an ECM layer towards a chemoattractant (FBS), and were stained and 
counted (Fig 3.6A). The cell lines were chosen based on their high invasive capacity 
and positive AQP1 expression. Moreover, the U87-MG and U251-MG cell lines 
were sensitive to block of wound closure by AqB011, whereas MDA-231-MB cells 
were not; this allowed for an investigation as to whether the effects of AqB011 were 
consistent in both 2D and 3D cell migration assays. AqB011 significantly inhibited 
cell invasion in U87-MG (40  to 100 M), U251-MG (80 M), and MDA-231-MB 
(80 M) (Fig 3.6B). U87-MG cells treated with AqB011 at 80 M invaded at 49 ± 
7.1%; U251-MG cells treated with AqB011 80 M invaded at 63 ± 12%; MDA-
231-MB cells treated with AqB011 80 M invaded at 40 ± 9.4%; as compared to 
vehicle. These results showed that AqB011 inhibited invasiveness in glioblastoma 
and breast cancer cells, in addition to impairing 2D cell migration in wound closure 
assays. Interestingly, these results also showed that MDA-231-MB cells were 
sensitive to block of invasion by AqB011, despite a lack of sensitivity to AqB011 
when measuring wound closure. The effect of bacopaside II was tested on U87-MG 
invasiveness; U87-MG cells treated with bacopaside II at 7.5 M invaded at 40 ± 
3.9% compared to vehicle (Fig 3.6B). Combined treatment with bacopaside II and 





Figure 3.6 Invasive capacities of U87-MG, U251-MG, and MDA-231-MB cells 
following treatment with AqB011. (A) Images depicting cells that successfully 
crossed the ECM layer to reach the trans side of the transwell membrane in 
treatments with vehicle and AqB011 80M (B) Box plots depicting U87-MG, 
U251-MG, and MDA-231-MB cell invasiveness after 4 hours with AqB011. 
AqB011 significantly inhibited cell invasiveness in all three cell lines.   
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3.5.7 AqB011 inhibited cell proliferation in U87-MG glioblastoma cell line 
AQP1 enables proliferation in some cancer cells [90], so we proposed AQP1 ion 
conductance might play a role. Proliferation rate of U87-MG cells was measured 
with the alamarBlue assay, in the absence of FUDR. Over 24 hours, non-toxic doses 
(40 and 80M) of AqB011 significantly inhibited cell growth; cells treated with 
AqB011 (80M) proliferated at 83 ± 1.7% compared to vehicle treated cells. 
Bacopaside II 7.5M had no effect on cell growth (Fig 3.7). Considering doses that 
reduced proliferation were not previously shown to be cytotoxic, it would be 
reasonable to assume that AqB011 inhibited glioblastoma cell proliferation, 
uncovering another possible role for AQP1 ion conductance. Alternatively, 
AqB011 might have other targets besides AQP1 ion conductance, which might play 
a role in cell proliferation. Although, AqB011 has not been shown to have any effect 
on cell motility in cells lacking AQP1 expression thus far, suggesting it is selective 
for AQP1 [43]. 
 
Figure 3.7 Graph depicting proliferation of U87-MG cells following treatment with 






Pharmacological modulators of AQP1 are useful for investigating channel 
characteristics, gating mechanisms, and physiological roles of AQP1. The first 
AQP1 inhibitor to be discovered was mercuric chloride, which inhibited AQP1 
water permeability through binding with a cysteine residue in loop E [91]. Despite 
high toxicity, mercuric chloride proved useful for uncovering novel AQP gating 
mechanisms [16, 92]. Tetraethylammonium (TEA) inhibited AQP1 water 
permeability in Xenopus ooctyes, playing a key role in revealing the involvement 
of loop E in AQP1 water conductance [93]. Acetazolamide reduced water 
permeability of AQP1 in Xenopus ooctyes [45], and AQP1-transfected HEK cells 
[89]. Both TEA and acetazolamide were not effective AQP1 blockers in some 
preparations [94], however they crucially indicated that pharmacological 
modification of AQP activity was possible. Later, the discovery of AQP1 inhibitors 
derived from bumetanide (the AqB compounds) enabled further investigation into 
physiological roles of AQP1. Proposed AQP1 blocker, AqB050, inhibited cancer 
cell motility and invasiveness in vitro, but not in vivo [95]. AqB013 also blocked 
the AQP1 water channel [96], and inhibited cancer cell migration, invasion, and 
angiogenesis in vitro [97]. AqB007 and AqB011 blocked AQP1 ion conductance 
[43], enabling investigation as to the role of AQP1 ion conductance in cancer 
motility. For the first time, we showed that AqB011 inhibited cell migration and 
invasion in AQP1-expressing glioblastoma, breast cancer, and colon cancer cell 
lines, suggesting AQP1 ion conductance might be a valuable pharmacological 
target for cancer therapy.  
 
AQP1-enabled ion flux might contribute to cell migration via a similar mechanism 
as NHE1. NHE1 blocker, EIPA, was previously shown to inhibit cell migration in 
sarcoma and breast cancer cells [88], and for the first time we show that EIPA also 
inhibits cell migration in colon cancer and glioblastoma. During cell movement, 
process extension occurs via the reversible assembly of actin filaments [98-100], 
and local cell volume increases are enabled by water and ion influxes [42, 101, 
102]. NHE1 plays an important role in cell migration by regulating uptake of Na+ 
at the leading edge to create an osmotic gradient, which triggers the local influx of 
water via AQPs; this enables the generation of cell membrane protrusions at the 
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leading edge of a migrating cell [42, 88]. AQP1-facilitated Na+ flux might also 
contribute to a local osmotic gradient driving simultaneous AQP1-mediated water 
influx at leading edges, leading to cell volume changes linked with process 
extension and cell migration [42, 88]. However, the physiological relevance of 
AQP1-mediated Na+ transport over that of dedicated Na+ channels is not 
understood. Future work will involve testing migration in cells transfected with 
AQP1 constructs that have been mutated so that AQP1 ion conductance is 
inactivated or activated without affecting water permeability. Additionally, AQP1 
facilitates K+ flux via the central pore [16, 21], and dedicated K+ channels including 
the BK channel and inward rectifying K+ channel-1 regulate cell migration [42, 
103]. Therefore, AQP1-facilitated K+ flux should not be excluded as an alternative 
mechanism underlying AQP1-facitated cell migration.  
 
To determine the importance of AQP1-facilitated water permeability in cancer cell 
migration, we tested the effects of bacopaside II and acetazolamide on cancer cell 
migration and invasion. Acetazolamide has failed to inhibit AQP1 water channel 
activity in some preparations [94], which might explain why HT29 cell migration 
was unchanged following acetazolamide administration. Bacopaside II (7.5 M) 
was non-toxic, and inhibited wound closure in HT29 colon cancer cells, and 
invasiveness in U87-MG glioblastoma cells, suggesting that AQP1 water flux plays 
a role in facilitating cell motility in these cell lines. However, bacopaside II (7.5M) 
had no effect on 2D cell migration in every other cell line tested. IC50 for block of 
AQP1 water flux by bacopaside II in Xenopus oocytes is 18 M [44]; bacopaside II 
started to exhibit toxicity beyond 7.5 M (Fig 3E), and a limiting factor of the 
project was that higher doses could not be tested, which might have explained 
insensitivity to bacopaside II in some cell lines. It is also not known whether effects 
of bacopaside II on cell migration and invasion are due to AQP1 inhibition or off-
target interactions; therefore, determining bacopaside II selectivity for AQP1 is 
crucial. This work highlights the importance of developing novel AQP1 water 
channel blockers with higher potency and reduced cytotoxicity in order to properly 





Similar to bacopaside II, block of 2D cell migration by AqB011 was not consistent 
across all AQP1-expressing cell lines. HT29, U87-MG, A172, U251-MG were all 
sensitive to block by AqB011, but SW620, HEK-293, and MDA-231-MB were 
insensitive. Membrane localization of AQP1 has been shown to affect sensitivity to 
inhibitors [104], which might have accounted for the differences in sensitivity to 
block by AqB011 and bacopaside II. Moreover, sensitivity to AqB011 and 
bacopaside II was boosted during cell invasion. MDA-231-MB invasiveness was 
inhibited by AqB011, although wound closure was not. Additionally, U87-MG 
invasiveness was inhibited by bacopaside II, although wound closure was not. 
Unlike the wound closure assay, the transwell invasion assay encourages dynamic 
cell volume regulation to fit through narrow spaces. This might result in increased 
activity of AQP1 dual water and ion conductances, explaining increased sensitivity 
to AqB011. We also showed that AqB011 inhibited U87-MG cell proliferation, 
which could hint at another putative role for AQP1 ion conductance. However, 
more work is needed to elucidate the mechanisms of AqB011-induced reduction in 
cell proliferation, and to test the effects of AqB011 on cell proliferation in other 
lines used in this study. 
 
A key element for establishing that AQP1-mediated ion conductance is important 
for cancer cell migration and invasion is to determine AqB011 selectivity for AQP1 
over other ion channels. Recent work showed that AqB011 selectively inhibits 
AQP1 ion conductance in Xenopus oocytes via interaction with the loop D domain 
of AQP1 [20]; however more work is needed to confirm the specificity of AqB011 
to AQP1 in cancer cells. To test this, we attempted to measure the effect of AqB011 
after knocking down AQP1 in HT29 cells using siRNA. Unexpectedly, the AQP1 
siRNA-transfection did not result in a concomitant reduction in sensitivity to 
AqB011; this was likely due to poor efficacy of AQP1 knock-down. In HT29, we 
successfully knocked down AQP5 protein, but not AQP1; this was despite the high 
transfection efficiency achieved (Fig 3.5D), the use of a validated AQP1 siRNA, 
and successful mRNA downregulation (Fig 3.5C). The failure to achieve significant 
knockdown of AQP1 protein might have been due to low AQP1 turnover in HT29 
cells, which would explain why protein levels did not immediately decrease 
following a decrease in mRNA [105], and why HT29 wound closure was unchanged 
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between AQP1 and control siRNA-transfected cells. Rates of protein degradation 
can vary, which also could lead to differences in AQP1 and AQP5 turnover [8]. 
More work is needed to confirm the specificity of AqB011 for AQP1, and to test 
effects of AqB011 on other cell lines with endogenous AQP1 that are more 
amenable to knock-down. Other tests for selectivity might include 
electrophysiological analysis of AqB011 in an AQP expression system  [106]. 
 
AQP5 promotes lymph node metastasis in patients with colon cancer [107], and 
colocalizes with ion channels such as NHE1 to enable local cell volume regulation 
at the leading edge of a migrating cell [88]. So, it was surprising that AQP5-
knockdown cells did not exhibit any variation in wound closure as compared to 
cells treated with control siRNA. However, the AQP5-knockdown cells did exhibit 
a significantly increased sensitivity to block of wound closure by AqB011. HT29 
cells might have compensated for loss of AQP5 by activating or upregulating 
AQP1, and subsequently becoming more sensitive to block by an AQP1-specific 
inhibitor such as AqB011. Future work should characterise effects of AQP1 and 
AQP5 knockdown in models of cell invasion and individual cell motility to rule out 
any additional effects that might not be apparent in the wound closure assay.  
 
In conclusion, we demonstrated the efficacy of AQP1 ion channel blocker, 
AqB011, and AQP1 water channel blocker, bacopaside II, in blocking invasion and 
migration in various AQP1-expressing cancer types. This new discovery 
highlighted the importance of AQP1 ion conductance as a potential 
pharmacological target in cancer migration and invasion. Future directions involve 
testing whether AqB011 and bacopaside II can be administered in combination to 
inhibit dual AQP1 water and ion conductance for an amplified effect, and to test 
whether these compounds are effective blockers of metastasis and invasion in 
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Aquaporin-1 (AQP1) is a transmembrane water and cation channel that is 
upregulated in some colorectal cancers and enhances cell migration rates; however, 
the mechanism remains unknown. AqB011 and bacopaside II selectively block 
human AQP1 ion and water pores, respectively. HT29 and SW480 colorectal 
adenocarcinoma cell lines showed expression of AQP1 as determined by 
quantitative PCR and western blot. 2D migration rates were quantified using 
circular wound closure assays and live-cell tracking. Invasiveness was measured 
using transwell filters coated with an extracellular matrix. AQP1 expression and 
subcellular localisation were confirmed by immunofluorescence. Combined 
treatment with both AqB011 and bacopaside II produced a greater inhibitory effect 
on cell 2D migration than either treatment alone in HT29 and SW480 cells.  
AqB011, but not bacopaside II, significantly inhibited invasiveness. The high 
efficacy of AqB011 in blocking HT29 cell motility correlated with high levels of 
AQP1 protein localisation in the plasma membrane, in contrast to AqB011-
insensitive SW480 cells in which most AQP1 protein is intracellular. Results here 
are the first to demonstrate a key role for the AQP1 ion channel in the invasiveness 
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of colon cancer cells, and to show that the effectiveness of AQP1 pharmacological 















Cancer is a leading cause of death worldwide, accounting for 8.2 million deaths in 
2012 according to the World Health Organization [1], primarily due to metastasis 
[2, 3]. Colorectal cancer is the second most common cancer in women and the third 
in men [1].  A link between colon cancer severity and upregulation of aquaporin-1 
(AQP1) expression has been previously documented [4, 5]. In humans, AQP1 
normally serves essential roles in fluid absorption and secretion in tissues including 
the kidney, brain, eye and vascular system of humans [6, 7]. However, AQP1 water 
channels also are upregulated in subtypes of aggressive cancer types including 
colorectal cancers, gliomas, lung adenocarcinoma, laryngeal cancer and 
cholangiocarcinoma [8-12]. Positive correlations have been demonstrated between 
levels of AQP1 and angiogenesis, tumour progression, growth, migration and 
metastasis [13]. Knockdown of AQP1 in cancer lines using small-interfering RNAs 
resulted in substantial impairment of cell migration in vitro [14, 15]. Conversely, 
increasing AQP1 levels by transfection into deficient lines (B16F10 melanoma, and 
4T1 mammary gland tumour) accelerated cell migration in vitro and increased the 
likelihood of lung metastases in mice in vivo [16]. Colon cancer cells (HT20) 
transfected with AQP1 similarly exhibited increased cell migration rates and 
enhanced extravasation after injection via  the tail vein in mice [17].  
 
The water channel activity of AQP1 has been proposed to facilitate extension of the 
leading edges of migrating cells to speed the rate of movement [18]. Bacopaside II 
from the medicinal plant Bacopa monnieri  was shown to bind deep in the 
cytoplasmic vestibule of the AQP1 water pore, inhibiting AQP1 water flux without 
affecting AQP1 ion conductance; bacopaside II also slowed cell migration in a 
colon cancer line highly expressing AQP1 [19]. Other AQP1 inhibitors such as 
AqB013 and proposed AQP1 inhibitor, AqB050, have also been shown to reduce 
cancer cell migration rates in vitro [20, 21]. Interestingly, other mammalian water 
channels such as AQP4 do not substitute for AQP1 in facilitating cell migration in 
AQP1-dependent cell lines [22], suggesting that the migration-enhancing property 
in some cases relies on more than transmembrane water permeability. There is a 
gap in knowledge regarding the properties of AQP1 that permit its migration-
126 
 
enhancing effect, but both the ion and water channel activities appear to be involved 
[23]. AQP1 dual water and ion channels mediate osmotic water flow through 
individual subunit pores, and a cation conductance through the central pore of the 
tetramer [24-26]. The non-selective monovalent cation conductance is gated by 
cGMP, which depends on loop D domain structural integrity for channel activation 
[25, 27-30].  In some expression systems, AQP1 ion channels have a low opening 
probability [31] or are not detectable [32], suggesting cGMP-mediated gating of 
AQP1 is subject to additional regulation including tyrosine phosphorylation [33]. 
Physiological relevance of AQP1 ion channel activity has been proposed for fluid 
secretion across barrier epithelia, and local volume control in cell migration. 
Blocking native AQP1 ion channels in choroid plexus was shown to alter net 
cerebrospinal fluid transport [34]. AqB011 is a bumetanide derivative that 
selectively blocks the ion pore of AQP1, without affecting AQP1 water flux [35]. 
Mutation of the AQP1 intracellular loop D domain removed sensitivity to AqB011, 
suggesting that loop D is the likely binding site for AqB011 to AQP1 [30]. AqB011 
was used to show that AQP1 ion channels are needed for rapid migration of AQP1-
expressing cancer cells [35]. To date, pharmacological modulators for AQP1 ion 
conductance include cadmium [34], calcium [36] and pharmacological derivatives 
of bumetanide such as AqB007 and AqB011 [35]. Functional evidence indicates 
that the AQP1 cation pore at the four-fold axis of symmetry is separate from the 
individual water pores in each monomer [25, 33, 37], and the pathways differ in 
pharmacological sensitivities [31, 38].      
 
This study tested the hypotheses that cancer cell invasiveness is reduced by 
inhibition of the AQP1 ion channel, and that combined treatment with bacopaside 
II and AqB011 enhances the inhibitory effect on cell motility. Results here show 
the efficacy of AQP1 inhibitors was dependent on localization of AQP1 protein in 
the plasma membrane, and that combined administration of AQP1 water and ion 
channel blockers produced an amplified block of colon cancer cell migration. Thus, 
AQP1 water and ion channels appear to exhibit a coordinated role in AQP1-
facilitated cancer cell migration. The discovery of pharmacological modulators of 
AQP1 has allowed dissection of the mechanisms of action of AQP1 in cell 
migration at a level not possible previously. Results support AQP1 as a novel 
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potential target for developing treatments aimed at the prevention of cancer 
metastasis. 
 
4.4 Materials and Methods 
4.4.1 AQP1 Inhibitors 
The bumetanide derivative AqB011 (Aquaporin ligand; Bumetanide derivative; 
number 11 in a series) was synthesized by Dr Gary A. Flynn (SpaceFill Discovery 
LLC, West Yellowstone, MT, USA) [35]. Powdered AqB011 was dissolved in 
dimethyl sulfoxide (DMSO) to create 1000x stock solutions and diluted in culture 
medium to final concentrations for testing in the circular wound closure [39], 
transwell invasion, live cell imaging, and alamarBlue assays. Bacopaside II was 
purchased from Sigma-Aldrich (St. Louis, MO), solubilized in methanol to yield 
100x stock solutions, and stored at -20°C in an airtight vial to minimize evaporation. 
For experimental use, bacopaside II stocks were diluted at 1/100 in culture medium. 
A combination of DMSO (1 L/mL) and methanol (10 L/ml) in culture medium 
was used as the vehicle control.   
 
4.4.2 Cell Lines  
Human colorectal adenocarcinoma cell lines HT29 (ATCC HTB-38TM) and 
SW480 (ATCC CCL-228TM) were cultured in T-75 plates in Dulbecco’s Modified 
Eagle Medium (DMEM;  Life Technologies, Grand Island, NY, USA) 
supplemented with 10% fetal bovine serum (FBS; Life Technologies), 1% Gibco 
GlutaMAX (Life Technologies) and 100 units/ml each of penicillin and 
streptomycin (Life Technologies). Cell cultures were grown at 37°C in a humidified 
5% CO2 incubator.  
 
4.4.3 Immunofluorescence 
Cells were seeded 2-3 days prior to cell fixation on 8-well uncoated Ibidi® µ-Slides 
(Ibidi, Munich, Germany) at a density of 5x104 cells/well. Once 80% confluent, 
cells were stained with MemBrite™ Fix Cell Surface Staining Kit (Biotium, 
Fremont, CA, USA; cat # 30093), and purchased from Gene Target Solutions 
(Dural, NSW, Australia). Membrane staining was performed prior to cell fixation, 
128 
 
as per manufacturer’s instructions. Cells were fixed with 1:1 (v/v) acetone and 
methanol at -20°C and incubated for 15 min at room temperature. 
Immunofluorescence staining was conducted as previously described by Wardill et 
al.  (2016) [40]. The AQP1 primary antibody used for immunofluorescence was H-
55 rabbit polyclonal (Santa Cruz Biotechnology, Dallas, TX, USA). The secondary 
antibody was Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, 
Alexa Fluor 568 (Life Technologies; cat# A-11011). For nuclear staining, cells 
were incubated for 10 minutes at room temperature in a 1:1000 dilution of Hoechst 
33258 (cat # 861405; Sigma-Aldrich, St. Louis, MO). The µ-Slide was imaged 
using an Olympus FV3000 Confocal Microscope. For the signal emitted by Hoechst 
33258, excitation (Ex=405nm) and emission (Em=461nm) settings were used. For 
Alexa Fluor 568, settings were Ex=561nm and Em=603nm. For MemBrite™, 
settings were Ex=488nm and Em=513nm. Fiji (ImageJ) software (U.S. National 
Institutes of Health) was used to measure relative intensities of AQP1 signal 
standardised to membrane marker signal as a function of cross-sectional distance 
per cell.  
 
4.4.4 Western Blot Analysis 
Cells were seeded at 4-5x105 cells per well in 6-well tissue culture plates in normal 
growth medium, and incubated for 24 hours at 37°C in 5% CO2. Once cultures 
reached 70-80% confluence, cells were washed with ice-cold Dulbecco’s phosphate 
buffered saline, and incubated on ice for 5 minutes in radioimmunoprecipitation 
assay lysis and extraction buffer (Life Technologies) containing 1% Halt protease 
inhibitor (Life Technologies). Cells were dislodged using a clean Corning® Cell 
Lifter, and homogenized with a 26-gauge needle and syringe. Homogenized lysates 
were collected into 1.5 mL centrifuge tubes, and centrifuged at 17,000G for 10 
minutes at 4°C. The cell debris pellet was discarded, and the supernatant was 
carefully transferred to a new 1.5 mL centrifuge tube. After Bradford protein 
estimation, 40 g protein samples were prepared in 10 µL Novex™ 4X Bolt™ LDS 
Sample Buffer (Life Technologies; cat # B0007), 4 µL 10X Bolt™ Sample 
Reducing Agent (Invitrogen™; cat # B0009), with deionized water added to 40 µL 
total. After heating at 70oC for 10 minutes, samples were resolved by SDS-PAGE 
on Bolt 4-12% Bis-Tris Plus gel (Invitrogen™; cat # NW04122BOX), and 
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transferred onto 0.2 m polyvinylidenefluoride membrane using the iBlot 2 Gel 
Transfer System (Invitrogen™; cat # IB21001). Immunodetection was performed 
with the iBind Western System using the iBind™ Western Device (Invitrogen™; 
cat # SLF1000), iBind™ cards (Invitrogen™; cat # SLF1010), and iBind™ 
Solution Kit (Invitrogen™; cat # SLF1020). Antibody details are as follows: 
Secondary antibody IRDye® anti-rabbit 800CW (1:2000; Abcam; ab216773) was 
used for polyclonal AQP1 primary antibody (1:1000; obtained from the Department 
of Ophthalmology, Duke University, Durham, NC, USA [41, 42]). Secondary 
antibody IRDye® anti-mouse 680RD (1:2000; Abcam; ab216778) was used for 
GAPDH antibody (1:200; Abcam; ab9484). Western blots were assessed using 
ImageStudio® Lite, version 5.2. Signal intensities were determined relative to local 
background. Expression of AQP1 protein was normalised using GAPDH as a 
loading control, and was relative to HT29.  
 
4.4.5 Quantitative PCR analysis of AQP1 expression  
Cells plated in triplicate wells at 4×105 cells/well were incubated at 37°C in a 
humidified 5% CO2 incubator overnight. Total RNA was extracted using 
PureLink™ RNA Mini Kit (Invitrogen™); 1 µg total RNA was used for cDNA 
synthesis. cDNA was synthesized using QuantiTect® Reverse Transcription Kit 
(Qiagen®). cDNA was quantified using NanoDrop™ (Life Technologies); 50 ng 
cDNA was used in the polymerase chain reaction. Real-time qRT-PCR analyses 
were performed using SYBR™ Green PCR Master Mix (Applied Biosystems™) in 
a final volume of 10 µl with StepOne Plus™ Real-Time PCR system (Applied 
Biosystems™). Data were analysed by StepOne Plus™ Real-Time PCR software 
v2.3. The primer sequences for AQP1 were forward: 5′-
CGCAGAGTGTGGGCCACATCA- 3′, and reverse: 5′ -
CCCGAGTTCACACCATCAGCC - 3′, amplifying a product of 217 bp. RPS13 
was used as a standard and target mRNA levels relative to RPS13 were calculated 




4.4.6 Circular Wound Closure Assay 
Circular wound closure assays were performed using methods described by De Ieso 
and Pei (2018) [39]. In brief, cells were plated at 1 x 105 cells/mL in DMEM culture 
medium with GlutaMAX and antibiotics (as above), reduced serum (2% FBS), and 
400nM of the mitotic inhibitor 5-fluoro-2'-deoxyuridine (FUDR). A confluent 
monolayer was achieved at 2-3 days following plating; circular wounds were 
created with a sterile p10 pipette tip. After washing two to three times with 
phosphate-buffered saline to remove cell debris, media were applied with and 
without AQP inhibitors or vehicle in low serum (2% FBS) DMEM with FUDR for 
the wound closure assay. Complete wounds were imaged at 10x magnification with 
a Canon 6D camera on a Nikon inverted microscope. Images were standardised 
using XnConvert software, and wound areas were quantified using Fiji software 
(ImageJ; version 1.51h; U.S. National Institutes of Health). Closure was calculated 
as a percentage of the initial wound area for the same well as a function of time. All 
experiments were repeated in duplicate wells. 
 
4.4.7 Cytotoxicity Assay 
Cell viability was quantified using an alamarBlue assay [45], following 
manufacturer's guidelines (Life Technologies). Cells were plated at 105 cells/mL in 
96-well plates, in the same FUDR-containing low serum culture media as used in 
the migration assays. At 12-18 hours after plating, treatments were applied, and 
cells were incubated 24 hours. At 24 hours, cells were treated with 10% alamarBlue 
solution for 1-2 hours. Fluorescence signal levels were measured with a FLUOstar 
Optima microplate reader for control and treatment groups. Mercuric chloride 
(HgCl2) served as a positive control for inducing cytotoxic cell death, and a no-cell 
control was included to confirm low background fluorescence. 
 
4.4.8 Live Cell Imaging 
Cells were seeded on eight-well uncoated Ibidi -Slides (Ibidi) at a density of 1x105 
cells/mL. A confluent monolayer was achieved 2-3 days after plating. Cells were 
conditioned in low serum culture medium (2% FBS) in the presence of FUDR (400 
nM) for 12-18 hours before wounding. Three circular wounds were created in each 
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well using techniques described above for the wound closure assays. Slides were 
mounted on a Nikon Ti E Live Cell Microscope (Nikon, Tokyo, Japan) in an 
enclosed humidified chamber kept at 37°C with 5% CO2. Images were taken at 30-
minute intervals for 24 hours, using Nikon NIS-Elements software. AVI files were 
exported from NIS-Elements and converted into TIFF files using Fiji (ImageJ). 
Converted files were analyzed using Fiji software [46] with the Manual Tracking 
plug-in. Total distance per cell was calculated as the cumulative distance travelled 
over the full duration of the experiment. Displacement was calculated as the net 
distance travelled between the first and last time points. 
 
4.4.9 Transwell Invasion Assay 
Assays were performed using 6.5 mm Corning® Transwell® polycarbonate 
membrane cell culture inserts with 8 m pore size (cat #3422; Sigma-Aldrich, St. 
Louis, MO). The upper surface of the filter was coated with 40 L of water-diluted 
extracellular matrix (ECM) gel from Engelbreth-Holm-Swarm murine sarcoma 
(final concentration 25 g/mL; Sigma-Aldrich, St. Louis, MO), and left to 
dehydrate overnight, and rehydrated 2 hours prior to cell seeding with 50 L of 
serum-free DMEM per transwell insert. Cells were grown to approximately 40% 
confluence under normal conditions, and transferred into reduced serum (2% FBS) 
medium for 32-34 hours prior to seeding. Cells were harvested, resuspended in 
serum-free DMEM, and 2.5 x 105 cells in 100 L was added to the upper chamber 
(total 150 L of cell suspension per transwell, including 50 L of rehydration 
medium added earlier). To the lower chamber, 600 L of pharmacological 
treatment in DMEM supplemented with 10% serum (chemoattractant) was added, 
and cells were incubated for 24 hours at 37°C in 5% CO2. Non-migrated cells were 
scraped from the upper surface of the membrane with a cotton swab; migrated cells 
remaining on the bottom surface were counted after staining with crystal violet [47].  
 
4.4.10 Statistical Analyses 
Statistical analyses performed with GraphPad Prism 7.02 software involved one-
way ANOVA and post-hoc Bonferroni tests. Statistically significant outcomes are 
represented as p<0.05 (*), p<0.01 (**), p<0.001 (***), or p<0.0001 (****); NS is 
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not significant; other characters indicating significance (# and +) use the same 
pattern for defining p values. All data are presented as mean ± standard error of the 
mean (SEM); n values for independent samples are indicated in italics above the x-
axes in histogram figures.  
 
4.5 Results 
4.5.1 AQP1 expression levels in HT29 and SW480 cell lines. 
Levels of AQP1 expression were quantified in HT29 and SW480 cell lines by 
western blot and real-time reverse-transcription polymerase chain reaction (qRT-
PCR). Western blot analyses showed no significant difference (p=0.055) between 
total AQP1 protein levels in HT29 (1.0 ± 0.05; n=4), and SW480 cells (0.84 ± 0.05; 
n=4), normalised to a reference protein GAPDH (Fig 4.1A and 4.1B). A 
supplementary figure shows the full length gel depicting anti-AQP1 signal (see 
Supplementary figure 4.1) and anti-GAPDH signal (see Supplementary figure 4.2). 
Main bands were identified near 37kD, consistent with glycosylated forms of the 
28kD AQP1 monomer [48]. AQP1 mRNA levels as determined by qRT-PCR were 
approximately 15-fold higher in HT29 than in SW480 cell lines (Fig 4.1C).  
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Figure 4.1 HT29 cells have comparable levels of AQP1 to SW480 cells. (A) AQP1 
protein expression was determined by western blot, with GAPDH used as a 
reference protein. AQP1 protein levels were similar in HT29 (n=4) and SW480 
(n=4) cell lines (p=0.055). AQP1 signal intensities were standardised to HT29 
AQP1 level. (B) Western blot images of AQP1 and GAPDH in HT29 and SW480 
cells. Main bands for AQP1 were located near 37kD. (C) AQP1 mRNA levels were 




4.5.2 Combined treatment with bacopaside II and AqB011 produced additive 
block of wound closure in colon cancer cells.  
The combined effects of AqB011 and bacopaside II on 2D cell migration of HT29 
and SW480 colorectal cell lines were tested using circular wound closure (Fig 4.2). 
At 24 h, significant block of HT29 cell migration was observed with AqB011 alone 
(at 20 to 100 µM), and with bacopaside II alone (at 7.5 to 15 µM), as compared to 
vehicle control (Fig 4.2A), consistent with previous findings [19, 35].  While 
migration was reduced 38 ± 2.9% by AqB011 (at 20 µM), and 44 ± 3.1% by 
bacopaside II (at 15 µM), the combined treatment produced a block of 81 ± 1.3%, 
significantly greater than that seen with either agent alone. In contrast, SW480 cells 
showed no sensitivity to AqB011 or bacopaside II in 2D migration (Fig 4.2B), with 
no significant differences after 24 hours in AqB011 (at 1 to 100 µM) or bacopaside 
II (at 7.5 to 15 µM) as compared with vehicle-treated cells (Fig 4.2B). However, 
combined treatment of SW480 cells with AqB011 (20 µM) and bacopaside II (15 
µM) blocked 2D migration by 50.4 ± 5.4%, which was significantly greater than 
bacopaside II or AqB011 alone. In summary, these results showed that AqB011 and 
bacopaside II additively block wound closure in both HT29 and SW480 cell lines, 






Figure 4.2 Wound closure assay showing the block of cell migration in HT29 cells 
with combined treatment (bacopaside II and AqB011), as compared with each 
compound alone. (A) Box plot depicting dose-dependent block (%) of HT29 wound 
closure after 24 hours. White bars represent single treatment; grey bars represent 
combined treatment with AqB011 and bacopaside II. AqB011 (20μM) and 
bacopaside II (15μM) treatment yielded block that was significantly greater than 
vehicle (****), AqB011 (20μM) alone (####), and bacopaside II (15μM) alone 
(++++), suggesting an additive interaction; n-values are in italics above the x-axis 
for A and B. (B) Box plot depicting wound closure block (%) of SW480 after 24 
hours. White bars represent single treatment; grey bars represent combined 
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treatment with AqB011 and bacopaside II. SW480 cells were insensitive to block 
by AqB011 and bacopaside II. AqB011 (20μM) and bacopaside II (15μM) 
treatment yielded block that was significantly greater than vehicle (****), AqB011 
(20μM) alone (####), and bacopaside II (15μM) alone (++++), suggesting an 
additive interaction. (C) Representative images showing HT29 cells treated with 
vehicle, bacopaside II (15M), and combined treatment at 0 hours (upper row) and 
24 hours (bottom row). Scale bar applies for both C and D. (D) Representative 
images showing SW480 cells treated with vehicle, bacopaside II (15M), and 




4.5.3 Effects of bacopaside II and AqB011 on individual colon cancer cell 
migration assessed by live cell imaging.  
The effects of AQP1 modulators on single cell migration were measured by 
tracking individual cell trajectories over 24 hours in cultures of HT29 (Fig 4.3), and 
SW480 (Fig 4.4). The effects of the treatments on total distance travelled and net 
displacement were quantified from analyses of the live cell imaging results (Fig 
4.5). In HT29 cells, impaired directional migration was evident from the short 
convoluted trajectories in each treatment group as compared with untreated and 
vehicle control (Fig 4.3B). HT29 cells treated with 20 µM AqB011 migrated 
significantly shorter total distances in 24 hours (162 ± 9 µm) than vehicle-treated 
cells (250 ± 13 µm) (Fig 4.5A).  HT29 cells treated with bacopaside II at 15 µM 
also showed a significant reduction in total distance travelled (153 ± 7 µm) as 
compared to vehicle control. Interestingly, the HT29 cells treated with both 
AqB011 (20 µM) and bacopaside II (15 µM) displayed a mean total migration 
distance of 105 ± 6µm, which was significantly lower than with either agent alone. 
In contrast, SW480 cells showed comparable trajectories in all treatment groups 
(Fig 4.4B), and no effect of AqB011 at doses up to 100 µM. SW480 cells travelled 
a mean total distance of 379 ± 29 µm following treatment with 100 µM AqB011 
which was not significantly different from vehicle treated cells at 451 ± 42 µm (Fig 
4.5B). There were no significant differences in total distances travelled by SW480 
cells treated with vehicle, bacopaside II (15 µM) alone (518 ± 39 µm), or combined 
AqB011 (20 µM) and bacopaside II (15 µM) treatment (347 ± 35 µm). 
 
Net displacement (the linear distance between the start and end points for individual 
cells) in HT29 cells was significantly different from vehicle for all treatment groups 
(Fig 4.5C). The results of the treatment conditions closely paralleled those seen for 
total distance travelled (Fig 4.5A), in magnitude of block and dose dependence. 
Although migration trajectories were reduced, the directions of movement in 
successive intervals remained roughly oriented in the same direction for HT29 cells 
(Fig 4.3B). A significant decrease of net displacement in SW480 cells was seen 
only with the combined treatment (169 ± 19 µm), and not with bacopaside II alone 
(273 ± 31 µm) or AqB011 alone (349 ± 25 µm) as compared with vehicle-treated 
cells (296 ± 20 µm). This result contrasted with the absence of an effect of combined 
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treatment on the cumulative total distance travelled by SW480 cells. Although 
SW480 cells moved well, their failure to achieve a commensurate net displacement 
suggested that the directionality of movement (i.e., maintaining a consistent vector 
over successive intervals) was compromised by combined treatment. The reduction 
of HT29 displacement can be attributed to decreased total distance travelled, but 
the reduction of SW480 displacement appears to be due to reduced directionality. 






Figure 4.3 Live cell imaging of HT29 cell trajectories in treatments with 
bacopaside II and AqB011 alone, and in combination. Single cells at the boundaries 
of circular wounds were tracked with time-lapse images taken at 30 minute intervals 
for 24 hours at 37°C. (A) Panels of six images each from time-lapse series are 
shown at 4-hour intervals. Vehicle, AqB011 (20μM), bacopaside II (15μM), and 
combined (dual) treatment of AqB011 (20μM) and bacopaside II (15μM) are 
depicted. (B) Trajectory plots of individual cells (n=9-11 per treatment group), 
monitored by the position of the cell nucleus at 60 minute intervals over 24 hours. 
Data were referenced to the starting position at 0,0 on the graph axes; X and Y 




Figure 4.4 Live cell imaging of SW480 cell trajectories in treatments with 
bacopaside II and AqB011 alone, and in combination. Single cells at the boundaries 
of circular wounds were tracked with time-lapse images taken at 30-minute 
intervals for 24 hours at 37°C. (A) Panels of six images each from time-lapse series 
are shown at 4-hour intervals. Vehicle, AqB011 (20μM), bacopaside II (15μM), and 
combined (dual) treatments are depicted. (B) Trajectory plots of individual cells 
(n=10-12) per treatment group, monitored by the position of the cell nucleus at 60 





Figure 4.5 Summary plots of total distances travelled and net displacement of HT29 
and SW480 cells in each treatment group, measured by live cell imaging. (A) 20μM 
AqB011 or 15μM bacopaside II treatments alone significantly reduced total 
distance migrated for HT29 cells as compared to vehicle treated.  The level of 
inhibition was significantly enhanced by combined treatment as compared with 
either agent alone. (B) No significant block of SW480 total distance was seen in 
any treatment as compared with vehicle. (C) Net displacement in HT29 cells was 
reduced by all treatments as compared to vehicle. Combined treatment showed 
significantly greater block of HT29 net displacement than either treatment alone. 
(D) Only the combined treatment reduced SW480 net displacement as compared to 
vehicle. (E) SW480 mean migration velocity was significantly greater than that of 




4.5.4 Effects of bacopaside II and AqB011 on lamellipodial formation 
An important step in cell migration is protrusion formation [13]. Lamellipodia are 
broad, flat, actin-rich protrusions that extend in the direction of locomotion and 
provide a base on which the cell moves forward [49]. Loss of the elongated cell 
morphology associated with lamellipodial extension is an effect consistent with 
reduced rates of migration [50]. Figure 4.6 depicts cells that were representative of 
the ensemble behavior in each treatment group for HT29 and SW480 cell lines. 
Images of vehicle-treated cells illustrate the high proportion of migrating cells with 
membrane protrusions. Lamellipodia in HT29 cells normally appeared as flat sheet-
like protrusions (Fig 4.6A; middle image in the vehicle treatment 'veh' row) or as 
“winged” processes (left and right images in 'veh'). All treatments resulted in 
reduced lengths of HT29 lamellipodial formations as compared to vehicle-treated 
cells (Fig 4.6A), and a lower proportion of cell population that possessed 
lamellipodial protrusions. A supplementary movie file shows this in more detail 
(see Supplementary video 4.1).  Lamellipodia in SW480 cells were more slender 
and longer, with flattened sheet-like protrusions at the distal end of the extensions 
(Fig 4.6B; 'veh'), and showed no impairment of lamellipodial extensions with 
AqB011 treatment; however, protrusions appeared to be reduced in size and number 
in the bacopaside II alone, and combined treatment conditions (Fig 4.6B). A 
supplementary movie file shows this in more detail (see Supplementary video 4.2). 
The insensitivity of SW480 morphology to AqB011 was consistent with the lack of 
effect of AqB011 in 2D and 3D assays of SW480 cell motility.  In summary, 
pharmacological treatment with the AQP1 ion channel blocker, AqB011, impaired 
process formation selectively in HT29, consistent with inhibition of cell motility 
observed in wound closure and live cell imaging assays. Treatment with bacopaside 
II impaired the generation of polarized cellular processes in HT29 and SW480 cells. 
In both HT29 and SW480 cells (Fig 4.3A and 4.4A), bacopaside II treatment 
interestingly also appeared to facilitate a decrease in intercellular adhesion, 
suggested by the increased proportion of individual cells at the wound edge that 






Figure 4.6 Images of actively migrating cells from different treatment groups for 
HT29 (A) and SW480 (B) cell lines, showing three representative examples each. 
Vehicle-treated cells (A and B; top row) showed distinct membrane protrusions in 
both cell lines. AqB011 and bacopaside II treated HT29 cells showed protrusions 
that were reduced in size as compared to vehicle in all treatment groups (A; rows 
2-4). For SW480 cells, cellular protrusions appeared decreased in size in treatments 




4.5.5 AqB011, but not bacopaside II, inhibits colon cancer cell invasiveness.  
An important aspect of cancer metastasis is the movement of cells in three-
dimensional space, across tissue boundaries and through ECM, involving attributes 
that are not fully captured in a 2D wound closure model.  The effects of AQP1 
inhibitors were tested on colon cancer invasiveness using the transwell invasion 
analysis, in which cells migrated through an ECM layer and a semi-permeable 
membrane towards a chemoattractant (FBS), and were stained and counted (Fig 
4.7C).  
 
Treatment with AqB011 alone resulted in approximately 40% block of HT29 cell 
invasiveness at concentrations ≥10 µM (Fig 4.7A). For HT29 treated with AqB011 
(10 µM), 63 ± 5.3% of cells invaded the lower chamber as compared to vehicle 
treated (Fig 4.7A). The highest dose of AqB011 (80 µM) also impaired SW480 cell 
invasiveness (49.7 ± 10%); lower doses had no significant effect (Fig 4.7B). 
Unexpectedly, application of bacopaside II alone at 15 µM potentiated colon cancer 
cell invasiveness in both cell lines. HT29 cells treated with bacopaside II showed a 
2.7-fold increase in invasion, and SW480 cells showed a 4.5 fold increase. 
Interestingly, the potentiating effect in HT29 cells was negated in full by co-
application of AqB011 (Fig 4.7A). In contrast, SW480 showed only a small effect 
of AqB011 co-application on the invasion-promoting effect of bacopaside II. Cell 
invasion responses required the presence of a chemotactic gradient (FBS), and an 
ECM gel layer (Fig 4.7D). HT29 cells were significantly more invasive (269 ± 16 
cells per field of view; n=15) than SW480 (90 ± 8 cells per field of view; n=15) 
(Fig 4.7E). This work is the first to show the anti-invasive effects of AQP1 ion 
channel blocker AqB011 in colon cancer cells, suggesting a novel role for AQP1 
ion conductance in facilitating cancer invasion. HT29 was more sensitive to the 
inhibitory effect of AqB011 than SW480, consistent with observations from 2D 
assays. In contrast, bacopaside II surprisingly enhanced cancer cell invasion in both 






Figure 4.7 Invasive capacities of HT29 and SW480 cells during treatments with 
bacopaside II, AqB011, and both in combination, measured with transwell assays. 
Box plots depicting (A) HT29 and (B) SW480 cell invasiveness after 24 hours with 
AqB011 (top row), bacopaside II (row 2), or both (row 3). AqB011 significantly 
inhibited HT29 cell invasiveness at 10 to 80μM. Bacopaside II significantly 
potentiated HT29 invasiveness at 10 and 15μM. Combined treatment with AqB011 
ablated the pro-invasive effect of bacopaside II in HT29 cells. AqB011 inhibited 
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SW480 cell invasiveness only at the highest dose tested (80μM). Bacopaside II 
significantly potentiated SW480 invasiveness at 15μM. AqB011 showed a small 
but significant reversal of the pro-invasive effect of bacopaside II in SW480. (C) 
Images depicting HT29 and SW480 cells that successfully crossed the ECM layer 
to reach the trans side of the transwell membrane in treatments with vehicle, 
AqB011 80M, and bacopaside II 15M. (D) Histograms summarizing the reduced 
invasiveness of HT29 and SW480 cells in the absence of ECM (no matrix gel 
(NMG)), or in the absence of a serum gradient (no serum (NS)), as compared with 
vehicle controls containing both serum gradient and ECM (vehicle). (E)  HT29 cells 
were significantly more invasive than SW480 cells, except in the presence of 




4.5.6 Cell viability is not reduced by AqB011 or bacopaside II at doses that 
impair migration. 
AqB011- and bacopaside II-mediated impairment of cell migration and invasion 
did not result indirectly from reduced cell viability. Cell viability was measured 
with the alamarBlue assay. Data were standardised to results for untreated groups 
in each cell line (Fig 4.8). HT29 cell viability was 99.6 ± 1.4% in AqB011 (100 
µM); 94.5 ± 0.7% in combined treatment; and 3.1 ± 0.04% in mercuric chloride (5 
µM). SW480 cell viability was 97.6 ± 0.2% in AqB011 (100 µM); 96.2 ± 0.6% in 
combined treatment; and 2.4 ± 0.04% in mercuric chloride (5 µM). These data 
showed that the AQP1 modulatory agents affected viability by less than 6%, 
demonstrating that cytotoxicity did not account indirectly for the substantial 






Figure 4.8 Summary histogram of cytotoxic effects of treatments, measured by 
alamarBlue assay for HT29 and SW480 cells. "Dual" indicates combined treatment 
with AqB011 (20 µM) and bacopaside II (15 µM). A slight but significant decrease 
in cell viability was observed for HT29 cells with the combined AQP1 inhibitor 
treatment and in SW480 cells in all treatments. Mercuric chloride served as a 
positive control causing cell death; 'no-cell' controls confirmed minimal 
background fluorescence. All treatments were n=4. Data are standardised to results 




4.5.7 Efficacy of AqB011 requires the plasma membrane localisation of AQP1. 
AqB011 was not effective in blocking cell migration and invasion in SW480 as 
compared to HT29, even though total AQP1 protein levels were similar in both cell 
lines as determined by western analysis. Prior results showing SW480 cells were 
relatively insensitive to AqB011 had been attributed to low levels of AQP1 
expression, presumed from the low levels of AQP1 transcript measured by 
quantitative PCR [35], as confirmed in Fig 4.1C. However, western blot analyses 
showed protein levels of AQP1 were comparable between HT29 and SW480 cell 
lines (Fig 4.1A and 4.1B).  To test whether the difference in sensitivity resulted 
from differences in AQP1 protein localization, AQP1 signal intensity throughout 
the cell was assessed by immunofluorescent labelling of AQP1, in combination 
with a fluorogenic membrane dye (MemBrite™), and Hoechst nuclear stain (Fig 
4.9A). We used Fiji (ImageJ) to analyse and compare intensity patterns of the AQP1 
and membrane stains for each cell line (Fig 4.9B and C). Plasma membrane levels 
of AQP1 were significantly lower in SW480 (0.3802 ± 0.043; n=6) than in HT29 
(1.046 ± 0.15; n=; p=0.0004) cell lines (Fig 4.9D), suggesting that efficacy of AQP1 





Figure 4.9 Confocal images and quantitative analyses of AQP1 subcellular 
localization measured by immunolabelling. (A) Confocal images of a single field 
of view for HT29 (top row) and SW480 (bottom row) cells. The panels in each row 
(from left to right) depict nuclear staining (blue); membrane staining (green); AQP1 
signal (red); and an overlay of the three images. (B, C) Each graph shows the 
intensities (y-axis) of the membrane stain (green) and the AQP1 signal (red), as a 
function of distance across the diameters of three individual HT29 (B) or SW480 
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(C) cells. Two cross-sections per cell were measured. (D) Calculated as signal 
intensity ratios, HT29 cells showed strong colocalization of AQP1 and membrane 




4.6 Supplementary Figures 
 
Supplementary Figure 4.1 Full-length western blot gel depicting signal for anti-
AQP1 primary antibody. Other cell lines depicted were used for this experiment but 
results were not included as part of this chapter. 
 
 
Supplementary Figure 4.2 Full-length western blot gel (the same gel as in 
supplementary figure 4.1) depicting signal for anti-GAPD primary antibody. Other 
cell lines depicted were used for this experiment but results were not included as 





Supplementary Video 4.1  
Video animation showing HT29 cell wound closure over 24 hours. Panels (from 
left to right) represent cells treated with vehicle, AqB011 (20 μM), bacopaside II 
(15 μM), and combined treatment. All treatments significantly reduced HT29 
cancer cell motility and collective cell migration, as compared to vehicle treated 
cells. Cellular extensions and lamellipodial formations were reduced in frequency 
and size in all treatment groups, as compared to vehicle. 
 
Supplementary Video 4.2 
Video animation showing SW480 cell wound closure over 24 hours. Panels (from 
left to right) represent cells treated with vehicle, AqB011 (20 μM), bacopaside II 
(15 μM), and combined treatment. Cellular extensions and lamellipodial formations 
were reduced in frequency and size in treatments with bacopaside II (with or 






Cell migration and invasion are key pathological processes of cancer metastasis. 
AQP1 expression has been shown to enhance cell migration and metastasis in 
specific subtypes of cancers [14, 16, 17], and other channels such as AQP3, AQP4, 
and AQP5 have also been linked to cancers, affecting viability, proliferation and 
migration [13, 51-54]. In cell migration, process formation is thought to be driven 
by reversible assembly of actin filaments [55-57], and local cell volume increases 
facilitated by water and ion influxes [23, 58, 59]. AQPs that are upregulated in 
cancers can be co-localized with ion channels and transporters to support cell 
volume regulation and process extension. AQP5, not known to have an intrinsic ion 
channel function under the conditions tested [27], could work in some cases by 
colocalization with separate ion channels or transporters, such as the Na+/H+ 
exchanger in breast cancer cells [58]. AQP4 colocalizes with the chloride channel 
(ClC2) and the potassium-chloride co-transporter 1 (KCC1) in glioma cells, which 
are proposed to provide a driving force for water efflux leading to cell volume 
changes that could augment invasiveness [60, 61]. Results here confirmed that 2D 
migration of HT29 colon cancer cells was impaired by blockers of the AQP1 water 
pores (bacopaside II) or ion channel (AqB011), and provided new information that 
combined treatment enhanced inhibition of migration. A testable idea for future 
work is that ionic influx through AQP1 channels might contribute to a local osmotic 
gradient driving concomitant AQP1-mediated water influx at leading edges, leading 
to local volume changes associated with process extension and cell movement [23], 
thus enhancing cancer cell motility and invasion. 
 
HT29 and SW480 exhibited comparable protein levels, however, AQP1 mRNA 
levels were significantly lower in SW480 than HT29. This is not unusual, as lack 
of correlation between mRNA and protein levels has previously been demonstrated 
in liver cells [62] and yeast [63]; some proteins expressed in lung cancer cells 
demonstrate strong negative correlation with their mRNA levels [64]. AQP1 has 
multiple isoforms, and one possible suggestion is that SW480 expresses a different 
AQP1 isoform than HT29; the isoform of AQP1 in SW480 may have been detected 
with western blot analysis, but not for RT-PCR. SW480 cells showed uniformly 
fast 2D migration as compared to HT29 cells (Fig 5E), but were unaffected by the 
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AQP1 modulator AqB011, suggesting that this class of cells employs mechanisms 
to achieve rapid motility that do not require AQP1 ion conductance. This idea fits 
with the observation that the AQP1 protein in SW480 was predominantly 
intracellular, where its functional relevance or potential regulation remains to be 
determined. SW480 cells have been shown to express high levels of AQP5 protein 
[65-67], which might be part of an alternative mechanism for enabling rapid cell 
motility in combination with co-expressed ion channels, since AQP5 is not known 
to have any ion channel function [27], but does colocalize with ion channels that 
enhance cell migration in other cancer cells [68].  
  
The insensitivity of SW480 cells to inhibition of 2D cell migration by AqB011 
showed that AqB011 does not cause non-specific effects on general channel or 
transporter function, viability, cytoskeletal structure regulation, or other essential 
processes, since SW480 cells were unaffected by the agent. Nevertheless, more 
investigation into selectivity of AqB011 for AQP1 in cancer cells is required. The 
insensitivity of SW480 cells to AqB011 showed that AQP1 ion channels are not 
essential for the migration mechanism in this cell line, and highlighted the point 
that functional contributions of AQP1 depend on its localization in the plasma 
membrane. Regulation of the membrane localization of AQP1 and its 
corresponding sensitivity to inhibitors has been previously explored. Secretin was 
shown to increase AQP1-mediated osmotic water permeability in rat 
cholangiocytes by stimulating vesicular translocation of AQP1 to the plasma 
membrane; osmotic water permeability of rat cholangiocytes gained sensitivity to 
block by mercuric chloride after stimulation by secretin [69]. The small increase in 
efficacy of combined treatment on inhibiting SW480 2D cell migration could 
suggest that the low levels of AQP1 present in the plasma membrane are partially 
contributing to an enhanced cell motility. Future work might identify signals 
analogous to secretin that induce trafficking of intracellular AQP1 to the membrane 
in SW480 cells to test if this affects migration rate, or increases sensitivity to block 
by AqB011.  
 
Two-dimensional migration and three-dimensional invasiveness do not rely on the 
same set of mechanisms. Surprisingly, bacopaside II alone strongly increased the 
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invasiveness of both HT29 and SW480 cell lines (Fig 7), contradicting expectations 
based on 2D migration assays. AqB011 fully reversed the pro-invasive effects of 
bacopaside II in HT29 cells, and partially reversed the enhanced invasion in 
SW480, following a pattern consistent with the relative levels of AQP1 plasma 
membrane localization. Bacopaside II is a chemically complex molecule, unlikely 
to be selective for AQPs alone. The mechanism of the pro-invasive effect of 
bacopaside II is not known. However, bacopaside II appeared to reduce cell size 
and promote separation of individual cells from adjacent cells (Fig 3A and 4A; Fig 
6), suggesting a boost in invasiveness might come from reduced cell-to-cell 
adhesion and decreased cell volumes, both of which could facilitate movement 
through narrow passages. The chemotactic gradient imposed by serum 
might restore the capacity for directional movement which appeared to be lost 
following bacopaside II treatment (Fig 5C and D). At high doses bacopaside II is 
cytotoxic; at non-toxic doses it inhibits colon cancer growth by inducing cell cycle 
arrest, apoptosis [70], and reduced angiogenesis [71]. Thus, bacopaside II and its 
metabolites in vivo are likely to affect a diverse array of processes, which could 
account for some of the observed effects of cell migration and invasion. These non-
specific effects might complicate the interpretation of these results, as drug 
selectivity is key to understanding the role of AQP1 water and ion channel function 
in this study. Further tests to dissect the chemical moieties in bacopaside II and 
define their biological activities are needed to better identify candidates that are 
specific for pharmacological modulation of AQP1.  
 
In summary, results here are the first to show that AQP1 ion channel blocker 
AqB011 reduces colon cancer cell invasiveness in vitro, and that sensitivity to this 
agent depends on AQP1 localization in the plasma membrane. AQP1 water fluxes 
and ion conductance appear to exhibit a coordinated role in facilitating cell 
migration in AQP1-dependent cancer cell lines. Combined pharmacological block 
of both the AQP1 water and ion channels in HT29 and SW480 colon cancer cells 
amplified the inhibition of 2D cell migration, as compared with effects of either 
inhibitor alone. The prospect of a cooperative role between the AQP1 water flux 
and ion conductance is promising, in that lower doses of two compounds when 
combined could produce a beneficial level of cell migration impairment. Combined 
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AQP1 inhibitors could act on target cells (such as migrating cancers) that require 
both the AQP1 water and ion channel activities, while minimising side effects as a 
result of being applied at lower concentrations on other cells and tissues. Future 
work is needed to explore effects of AQP1 inhibitors on other cancer cell types, 
optimize bacopaside-related compounds for modulating AQP1 water flow, and test 
the effectiveness of AQP1 agents in restraining metastasis in vivo. 
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Chapter 5 describes observations pertaining to the anti-invasive qualities of (an) 
unknown compound(s) present in the mixture, fraction E. Fraction E is a by-product 
of an error in synthesis that led to the generation of a mixture of compounds 
(AqB051) including the target molecule (AqB050) and related derivatives. It is 
important to note that this chapter is a working progress, and the future purpose of 




Glioblastoma (GBM) is the most lethal primary malignancy of the central nervous 
system, because of its high invasive capacity. Investigating therapies to reduce 
invasion is crucially important. The aim of this study was to isolate and characterise 
a novel pharmacological agent, fractionated from a mixture of synthetic 
arylsulfonamide compounds, that accounted for the strong inhibition of GBM 
invasiveness observed in transwell migration assays in vitro. During the intended 
re-synthesis of the proposed aquaporin-1 inhibitor, AqB050, an error led to 
generation of a mixture of compounds (AqB051) including the target molecule 
(AqB050) and related derivatives. This mixture was found to strongly block cancer 
transwell invasion, likely acting at sub-micromolar concentrations. Human 
colorectal adenocarcinoma, human glioblastoma, and mammary adenocarcinoma 
cell lines were used for this study. Two-dimensional rates of collective cancer cell 
migration were measured with the circular wound closure assay. Three-dimensional 
cancer cell invasion and chemotaxis were measured with the transwell invasion 
assay. Angiogenesis in human umbilical cord endothelial cells was measured with 
the Ibidi -plate angiogenesis assay. General matrix metalloproteinase activity was 
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measured using the fluorometric matrix metalloproteinase activity assay kit. Cell 
viability was quantified using an alamarBlue assay. The potent biologically active 
agent has thus far been narrowed to one of eight fractions (Fraction E) from 
AqB051. AqB051 and fraction E significantly inhibited invasiveness in all 
glioblastoma cell lines, and in one of the two colorectal adenocarcinoma cell lines. 
AqB051 (72 g/mL) blocked wound closure by 60% in U87-MG, 43% in HT29, 
and 16% in A172 cells. AqB050 (40M) blocked HT29 wound closure by 41%. 
Compared to vehicle, U87-MG cells treated with AqB051 (4.5 g/mL) invaded at 
5.2%; and fraction E (4.5 g/mL) at 20%. AqB050 had minimal effect on 
glioblastoma invasiveness, however it strongly inhibited invasiveness in mammary 
carcinoma cell line. AqB051 and fraction E also blocked A172 transwell migration 
in the absence of extracellular matrix gel, suggesting these compounds do not affect 
matrix degrading enzymes. AqB051 (36 g/mL) inhibited HUVEC tube formation 
by approximately 95%. AqB050 (20M) decreased glioblastoma cell proliferation 
to 51% of vehicle over 48 hours. Fraction E had no effect on cell proliferation. A 
novel pharmacological agent (fraction E) appears to be a potent blocker of GBM 
invasiveness in vitro. The proposed AQP1 inhibitor, AqB050, blocks brain and 
breast cancer invasiveness, and glioblastoma proliferation. With further 
investigation, these pharmacological compounds with biological activity could lead 










Glioblastoma (GBM) is the most common and aggressive primary malignancy of 
the central nervous system, classified as a grade IV glioma based on the World 
Health Organisation classification [1]. The average annual age-adjusted incidence 
rate of GBM per 100,000 persons ranges from 2.05 in England (1999-2003) [2], 
3.19 in the United States of America (2006-2010) [3], to 3.4 in Australia (2000-
2008) [4]. To date, the most effective treatment for GBM involves resection, 
followed by radiotherapy and temozolomide chemotherapy [5]. However, the 
invasive phenotype of GBM cells makes it difficult to treat, with a median 
prognosis of only 14.6 months [6-8]. Notably, current treatment is mainly focused 
on removal and destruction of the tumourous cells, despite the devastating 
consequences of GBM invasiveness. Anti-angiogenic therapies (such as anti-VEGF 
therapy) block GBM tumour growth in mice and humans, but result in a more 
invasive phenotype in the cancerous cells [9-11]. Thus, adjuvant anti-invasive 
therapy might improve effectiveness of current treatments.  
 
Mechanisms involved in glioblastoma invasion include detachment from the 
tumour mass, adherence to the extracellular matrix (ECM), degradation of the 
ECM, migration, cell volume regulation, and chemotaxis [12-14]. The molecular 
bases of these mechanisms have been a logical research focus for anti-invasive 
therapies in glioblastoma, though with limited success thus far. Transforming 
growth factor-β (TGF-β) produced by microglia promotes glioblastoma invasion by 
inducing matrix metalloproteinase (MMP) expression, and by suppressing tissue 
inhibitor of metalloproteinase (TIMP), allowing for enhanced ECM degradation 
[15-18]. Administration of the TGF-β2 antisense oligonucleotide, trabedersen 
(AP12009; 10M) in clinical trials increased median survival for patients to 39.1 
months as compared with 21.7 months for standard chemotherapy; however, the 
difference was not statistically significant [19, 20]. Epidermal growth factor 
receptor (EGFR), often overexpressed in GBMs, promotes chemotaxis, invasion, 
and migration [21]. However, EGFR kinase inhibitors such as erlotinib and gefitinib 
proved to be effective only for a small subset of GBM patients [22, 23]. Focal 
adhesion kinase (FAK), which phosphorylates cytoskeleton-associated substrates 
such as Src, is upregulated in GBM. Src tyrosine kinases contribute to cell adhesion 
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formation and disassembly [12, 24], enabling detachment of cells from the tumour 
mass and interaction with ECM. Src inhibitors CGP76030 and CGP77675 in vitro 
reduced migration, invasion, and adhesion of GBM cell lines [25]. However, the 
multitargeted tyrosine kinase inhibitor, Dasatinib, in clinical trials was ineffective 
in  recurring GBM [26]. Ion channel upregulation promotes GBM cell volume 
regulation and cell migration [13, 14, 27]. Blockade of GBM chloride channels by 
chlorotoxin (CTX), a scorpion-derived peptide, produced dose-dependent 
inhibition of tumour cell migration and invasion through a transwell membrane 
[27]. Further work is needed to assess the translational potential of CTX  in clinical 
trials. Ultimately, a combination of clinically efficacious pharmacological 
treatments might be selected to inhibit GBM invasiveness. The aim of this study 
was to identify a novel pharmacological agent that strongly inhibits GBM 
invasiveness in vitro.  
 
Aquaporin-1 (AQP1) is a member of the family of membrane-spanning water 
channels with diverse physiological functions including enhancing plasma 
membrane osmotic water permeability [28]. AQP1 also potentiates cell migration 
and invasion [29, 30]. A synthetic compound AqB050 is a proposed blocker of 
AQP1, shown to inhibit mesothelioma cell migration and invasiveness in vitro, but 
not in vivo [31, 32]. Here, we introduce a novel molecule that was serendipitously 
created during the intended re-synthesis of AqB050. An error in synthesis led to the 
generation of a mixture of compounds (nominally referred to as "AqB051"), 
including the target molecule (AqB050) and related derivatives which included an 
unknown compound (referred to nominally as “fraction E”, pending chemical 
characterisation) with high potency for block of GBM invasiveness. These findings 
introduce a new anti-invasive molecule with possible therapeutic potential in the 
treatment of GBM.  
 
5.4 Materials and Methodology 
5.4.1 Cell lines 
Lines used for this study were: (1) human colorectal adenocarcinoma HT29 
(supplied by the American Type Culture Collection (ATCC®), catalogue number 
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HTB-38™), and DLD1 (ATCC; catalogue number CCL-221™); (2) Human 
glioblastoma cell lines U251-MG (supplied by the European Collection of Cell 
Cultures (ECACC; Salisbury, United Kingdom), catalogue number 09063001 
purchased from CellBank Australia (Westmead, NSW, Australia)), A-172 
(ECACC, catalogue number 88062428), and U87-MG (ECACC, catalogue number 
89081402); (3) Mammary adenocarcinoma MDA-MB-231 (ATCC; catalogue 
number HTB-26™); (4) human umbilical vein endothelial cells (HUVEC) (ATCC; 
catalogue number CRL-1730™). Cells were cultured in T-75 plates in Dulbecco’s 
Modified Eagle Medium (DMEM;  Life Technologies, Grand Island, NY, USA) 
supplemented with 10% fetal bovine serum (FBS), 1% Gibco GlutaMAX (all cells 
except MDA-MB-231 were treated with GlutaMAX) and 100 units/ml each of 
penicillin and streptomycin. Cell cultures were grown at 37°C in a humidified 5% 
CO2 incubator.  
 
5.4.2 Inhibitors 
AqB051 mixture was separated into subsets of constituent components using thin 
layer chromatography (TLC). High resolution mass spectrometry was performed to 
evaluate the chemical components in each fraction and narrow the possible 
chemical compositions (Mass Spectrometry Facility, School of Chemistry, 
University of Sydney, NSW). TLC produced eight fractions. The intended 
molecule, AqB050, constituted the majority of one of the lower MW fractions. The 
higher MW fraction which showed striking potency in bioassays of cancer cell 
invasion (done in Adelaide by De Ieso) was in the fraction labelled “fraction E”, 
still pending further refinement and chemical characterisation. The other six 
fractions were tested for biological activity; however, none exhibited any 
substantial effect in blocking migration (data not shown). Broad spectrum MMP 
inhibitor, batimastat, was purchased in powder form (cat # SML0041-5MG; Sigma-
Aldrich). All agents were reconstituted in DMSO as 1000x stock solutions. 
 
5.4.3 Circular wound closure assay  
Two-dimensional cell migration was measured with the circular wound closure 
assay as described by De Ieso and Pei (2018) [33]. Cells were seeded at 1 x 105 
cells/ml in normal culture medium with 10% foetal bovine serum (FBS), and 
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incubated at 37°C in 5% CO2 in a 96-well plate. Once cells achieved 80-90% 
confluence, they were incubated in reduced-serum (2% FBS) media and 400 nM of 
the mitotic inhibitor 5-fluoro-2'-deoxyuridine (FUDR) overnight to achieve a 
confluent monolayer. A sterile p10 pipette tip was used to generate circular wounds; 
pharmacological compound-treated media (with 2% FBS and FUDR) was applied 
following wounding. The final time-point was dependent on cell line. Wounds were 
imaged at 10x magnification with a Canon 6D camera on a Nikon inverted 
microscope. Images were standardised using XnConvert software, and wound areas 
were quantified using NIH ImageJ software (U.S. National Institutes of Health). 
Closure was calculated as a percentage of the initial wound area for the same well 
as a function of time. All experiments were repeated twice. 
 
5.4.4 Transwell invasion and chemotaxis assay 
Three-dimensional cancer cell invasion and chemotaxis was measured with the 
transwell invasion assay, which was performed using 6.5mm Corning® Transwell® 
polycarbonate membrane cell culture inserts with 8m pore size (cat #3422; Sigma-
Aldrich). For the invasion assay, the upper surface of the filter was coated with 
40L of water-diluted extracellular matrix (ECM) gel from Engelbreth-Holm-
Swarm murine sarcoma (250 g/mL for each cell line; Sigma-Aldrich, St. Louis, 
MO). The transwells with the ECM gel are left to dehydrate overnight and 
rehydrated 2 hours prior to cell seeding with 50L of serum-free DMEM per 
transwell insert. The chemotaxis assay does not include pre-coating the membrane 
with the ECM gel, and follows the same procedure as the invasion assay from this 
point onwards. Cells were grown to approximately 40% confluence under normal 
conditions, and transferred into reduced serum (2% FBS) medium for 12-18 hours 
prior to seeding. Cells were detached (at ≤80% confluency) and resuspended in 
serum-free culture media with and without pharmacological treatments at 5x104 
cells per well (for invasion assay) and 2x104 cells per well (for chemotaxis assay). 
Cells were then seeded in transwell inserts (total 150 L of cell suspension per 
transwell, including 50 L of rehydration medium added earlier for invasion assay). 
600 L of culture medium with 10% serum (chemoattractant) and the 
pharmacological treatment was added to the lower chamber. All cells except HT29 
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and DLD1 were incubated for 4 hours (for invasion assay) and 2 hours (for 
chemotaxis assay), at 37°C in 5% CO2. HT29 and DLD1 were incubated for 24 
hours at 37°C in 5% CO2. Non-migrated cells were scraped from the upper surface 
of the membrane with a cotton swab; migrated cells remaining on the bottom 
surface were counted after staining with crystal violet [35].  
 
5.4.5 Angiogenesis assay 
Ibidi -plate angiogenesis assay was conducted as per manufacturer’s instructions 
[36]. HUVECs were seeded onto a thin layer (12 L) of matrigel in a 96-well 
angiogenesis -plate (Ibidi, Martinsried, Germany) at 1.5 x 104 cells per well either 
in vehicle (0.1% DMSO) or AqB051 at 9, 18 or 36 g/mL, made in endothelial 
growth medium (HUVEC). The numbers of loops formed were counted at 20 h.  
 
5.4.6 Fluorometric matrix metalloproteinase activity assay  
General MMP activity was measured using the Fluorometric MMP Activity Assay 
Kit (Abcam; ab112146), as per the manufacturer’s protocol [37]. In brief, A172 
cells (104) were seeded into 6-well plates in FBS-free media and incubated in 37°C 
in 5% CO2 for 18 h. Pharmacological compound treatments were then added to each 
well and cells were incubated for another 2 hours in the same conditions. The 
conditioned media was used to assay MMP activity; three 25 L samples from each 
treatment were added to three wells in a 96-well plate to make triplicate wells for 
each treatment (one triplicate condition was FBS-free media that had not been 
conditioned by cells or treated with any pharmacological compounds). 25 L of 4-
aminophenylmercuric acetate (APMA; 2mM) working solution was added to each 
well and incubated at 37°C for another 3 hours to activate MMPs. Next, 50 µL of 
the green substrate solution was added to each well (to make a total of 100 L 
solution in each well) and incubated for 1 hour in the dark at room temperature. 
Fluorescence was measured in the sample wells using a microplate reader with a 
filter set for excitation/emission of 490/525 nm. Background fluorescence 





5.4.7 Cell viability assay 
Cell viability was quantified using an alamarBlue assay [38], following the 
manufacturer's guidelines (Life Technologies). Cells were plated in FUDR-
containing culture media with 2% FBS, at 105 cells/ml in a 96-well plate. 
Treatments were applied 12-18 hours after plating, and cells were incubated for 24 
hours. Cells were treated with 10% alamarBlue in culture media at 24 hours,  and 
incubated for 1-2 hours (depending on the cell type). Fluorescence was measured 
with a FLUOstar Optima microplate reader for control and treatment groups. The 
mean signal obtained from the no-cell control group was subtracted from every 
value in each treatment to correct for background fluorescence. The proliferation 
assay followed the same procedure as above, except no FUDR was used and 
fluorescence was measured at the start and end points.  
 
5.5 Results 
5.5.1 AqB051 inhibits colon cancer and glioblastoma wound closure  
AqB051 tested in five different cell lines showed variable effects on wound closure. 
No effect of AqB051 was seen for MDA-231-MB (at 9 g/mL) or U251-MG (at 18 
to 72 g/mL). AqB051 (72 g/mL) blocked wound closure by 60  2.3% in U87-
MG cells, 43  1.8% in HT29 cells, and 16  1.9% in A172 cells (Fig 5.1); U87-
MG was most sensitive to inhibition by AqB051, with significant block recorded at 
4.5 g/mL (8.6  1.3%). AqB050 blocked HT29 wound closure at 40 M (41  
10%) and 80M (45  3.5%), but had no effect on MDA-MB-231 cells at doses 
tested. MDA-MB-231 cells also were insensitive to block by fraction E (9 g/mL). 
Block of HT29 wound closure by AqB051 was consistent with the observation that 
migration of HT29 also was inhibited by AqB050, a constituent of AqB051. Data 
for AqB050 on block of U87-MG and A172 cell migration is still needed, and 






Figure 5.1 Effect of treatments on two-dimensional wound closure in various 
cancer cell lines. Box and whisker plots depicting percentage block of cell 
migration over 24h (HT29 and MDA-MB-231) and 20h (U251-MG, A172, and 
U87-MG) time points following treatment with AqB051, AqB050, and fraction E. 
AqB051 blocked wound closure in HT29, A172, and U87-MG cell lines, and had 
no effect in MDA-MB-231 and U251-MG. AqB050 was tested in HT29 and MDA-
MB-231, and produced a significant block in HT29 cells (40-80M). Fraction E 




5.5.2 Effect of AqB051, AqB050, and fraction E on cancer invasiveness 
Cancer invasiveness through extracellular matrix (ECM) utilizes mechanisms not 
completely captured in a 2D wound closure assay. Therefore, the effects of AqB050 
at doses from 1 to 20M, and AqB051 and fraction E at doses from 0.5 to 9 g/mL, 
were measured with transwell invasion assays. In U87-MG cells, AqB051 (4.5 
g/mL) reduced invasion to 5.2  1.5%, fraction E (4.5 g/mL) limited invasion to 
20  5.6%, and AqB050 (20M) reduced invasion to 66  10% as compared with 
vehicle controls (Fig 5.2A). In HT29 cells, invasiveness was not affected by any of 
the treatments. In U251-MG cells, invasion was reduced to 36  3.7% by fraction 
E (4.5 g/mL), and to 24  4.2% by AqB051 (4.5 g/mL) as compared to vehicle; 
AqB050 had a small but significant effect (63  20%) (Fig 5.2A). In contrast in 
MDA-231-MB cells, only the treatment with AqB050 (10M) impaired invasion to 
56  8.4% of vehicle treated cells; AqB051 (4.5 g/mL) or fraction E (4.5 g/mL) 
were ineffective (Fig 5.2A). A172 cells were sensitive to block by AqB051 (2.3-9 
g/mL) and fraction E (4.5 and 9 g/mL). A172 cells treated with fraction E (4.5 
g/mL) invaded at 47  5.2% compared to vehicle (Fig 5.2A). DLD1 cells treated 
with AqB051 (9 g/mL) invaded at 1.2  1.2% compared to vehicle control (Fig 
5.2A). AqB050 impaired invasion in some but not all cell lines, suggesting it is not 
the blocking agent of primary interest in the AqB051 mixture. Fraction E was a 
potent blocker of cancer invasion in all cell lines that were highly sensitive to block 
by AqB051, suggesting Fraction E is likely to contain the unknown component of 
AqB051 that strongly blocks invasiveness in vitro.  
 
Environmental parameters influence transwell migration efficiency. The role of 
FBS in inducing chemotaxis was tested in invasion assays with and without FBS 
added to the lower chamber of the transwell. The presence of FBS was required for 
transwell migration in all cell lines tested (Fig 5.2B). Cancer invasion involves the 
degradation of local ECM by proteolysis, using surface proteases such as zinc-
dependent MMPs [39]. Effects of a broad spectrum MMP blocker, batimastat, were 
measured for wound closure in A172 cells, and for transwell invasiveness with and 
without an ECM layer. Batimastat had no effect on 2D wound closure, and did not 
alter migration through a transwell membrane in the absence of an ECM layer (Fig 
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5.2C). However, batimastat effectively blocked invasion when the ECM barrier was 





Figure 5.2 Effect of treatments on invasiveness of various cancer cell lines. (A) 
Box and whisker plots depicting cancer invasiveness as a factor of pharmacological 
compound treatment and dosage. Trends of block by AqB051 and fraction E were 
similar; both were strong blockers of invasiveness in all glioblastoma cell lines and 
DLD1. HT29 and MDA-MB-231 were both insensitive to block of invasion by 
AqB051 and fraction E. AqB050 inhibited invasion in U87-MG, U251-MG, and 
MDA-231-MB. (B) Histograms demonstrating the role of the serum (chemotactic) 
gradient in the transwell assays. All cell lines exhibited dramatically augmented 
invasiveness in the presence of a chemotactic gradient, suggesting the invasion 
assay was also a measure of chemotaxis. (C) Graphs depicting the effect of broad 
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spectrum MMP inhibitor, batimastat, on A172 two-dimensional wound closure, 
invasion through an uncoated transwell membrane, and invasion through and ECM-
coated transwell membrane. Batimastat was only able to significantly reduce cell 
motility when the ECM barrier was present, suggesting that the invasion assay used 




5.5.3 AqB051 and fraction E inhibit chemokine-activated invasiveness 
Cells activate MMPs to penetrate the ECM-coated transwell membrane. The effect 
of treatments on A172 invasiveness was tested in the absence of ECM to rule out 
pharmacological inhibition of MMP activity as a major mechanism of action (Fig 
5.3A). Compared to vehicle, treatment with fraction E (9 g/mL) impaired invasion 
to 44  13%; AqB051 (9 g/mL) impaired invasion to 9.9  7.2%; AqB050 was 
ineffective (Fig 5.3B). The presence of FBS was required for transwell migration 
(Fig 5.3C). The fluorometric MMP activity assay was used to confirm effects of 
treatments on MMP activity. Batimastat was used as a positive control, and did not 
affect MMP activity as compared to untreated or vehicle. AqB051 increased MMP 
activity compared to untreated and batimastat (Fig 5.3D). These results suggest that 
AqB051 and fraction E did not inhibit invasiveness by inhibition of MMP activity. 
Instead, AqB051 and fraction E might impede invasiveness via inhibition of 





Figure 5.3 Anti-invasive effect of AqB051 and fraction E is not due to inhibition 
of ECM degradation. (A) Images depicting the number of invasive cells on the 
underside of the transwell membrane following treatment with vehicle or fraction 
E (20M). (B) Box and whisker plot showing percentage cell migration across the 
transwell membrane (compared to vehicle) as a function of pharmacological 
compound treatments and doses. AqB051 and fraction E both inhibit A172 cell 
migration across the uncoated transwell membrane. AqB050 has no significant 
effect. (C) Histogram depicting cell migration across the uncoated membrane in the 
presence or absence of a chemotactic gradient; cells cannot sufficiently migrate in 
the absence of a chemotactic gradient. (D) Histogram representing normalised 
fluorescence intensity (relative to untreated) directly proportional to MMP activity. 
None of the treatments significantly reduce MMP activity as compared to untreated, 
however batimastat treatment significantly reduced MMP activity as compared to 




5.5.4 AqB051 inhibits endothelial tube formation 
We investigated whether AqB051 inhibited angiogenesis with the endothelial tube 
formation assay (Fig 5.4A). AqB051 (36 g/mL) clearly inhibited HUVEC tube 
formation (2  1 tubes) as compared to vehicle (39  8 tubes) (Fig 5.4B). AqB051 
(18 g/mL) had no effect on tubule formation (Fig 5.4B). Many chemotactic 
factors also stimulate angiogenesis [40-42]. Further investigation might involve 
testing the hypothesis that AqB051 inhibits one or more angiogenic factors or 






Figure 5.4 AqB051 inhibits endothelial tube formation. (A) Images representing 
endothelial tube formation in HUVECs treated with vehicle and AqB051 
(36g/mL). (B) Histogram depicting mean number of tubules formed in each 





5.5.5 AqB051 and Fraction E were non-toxic at effective doses 
AqB050-, AqB051-, and fraction E-mediated impairment of cell migration and 
invasion did not result indirectly from reduced cell viability, as measured with 
alamarBlue. Data were standardised to results for untreated groups in each cell line 
(Fig 5.5). AqB051 and fraction E were not cytotoxic; treatment with AqB050 did 
not reduce cell viability in any cell lines except A172. A172 cells treated with 




Fig 5.5. Histograms showing pharmacological compound effects on cell viability 
in each cell line (cells treated with mitotic inhibitor), as determined by alamarBlue. 
AqB051 and fraction E had no effect on cell viability as compared to untreated in 




5.5.6 Effect of AqB051, fraction E, and AqB050 on cancer cell growth 
Many chemotactic factors also stimulate cell growth [40-42]. In the absence of a 
mitotic inhibitor, we measured effects of AqB051, fraction E, and AqB050 on U87-
MG cell proliferation using the alamarBlue assay. Readings were taken at 0 and 48 
hours, and proliferation was measured in the presence (Fig 5.6A) and absence (Fig 
5.6B) of FBS; cell proliferation rate was normalised to the vehicle control of the 
corresponding timepoint (0 or 48 hours). In the absence of FBS, fraction E (9 
g/mL) potentiated growth from 99  5.4% of vehicle (0 hours), to 118  2.2% of 
vehicle (48 hours); AqB050 (20M) decreased growth from 140  8.2% of vehicle 
(0 hours) to 50.9  1.6% of vehicle (48 hours); AqB051 (9 g/mL) decreased 
growth from 113  4.6% of vehicle (0 hours) to 85  2.1% of vehicle (48 hours). In 
the presence of FBS (2%), fraction E and AqB051 had no effect on cell growth; 
AqB050 (20M) inhibited cell growth from 122  7.7% of vehicle (0 hours) to 51 
 3.2% of vehicle (48 hours). Thus, fraction E does not inhibit cell proliferation. 
AqB050 strongly inhibits proliferation and might account for the inhibitory effect 






Figure 5.6 Histograms depicting fluorescence intensity (normalised to untreated; 
as determined by alamarBlue) that is directly proportional to U87-MG cell number, 
as a function of treatment. (A) Cells were incubated without serum over 48 hours. 
Fraction E significantly potentiated cell growth in the absence of serum; AqB050 
and AqB051 significantly inhibited cell growth. (B) Cells incubated with 2% FBS 
for 48 hours. AqB050 significantly inhibits U87-MG cell proliferation in the 





The highly invasive phenotype of GBM cells enables them to evade localised 
therapies such as surgical resection and radiotherapy. Additionally, invasive GBM 
cells exhibit lower proliferation rate and higher apoptotic resistance, making them 
more resistant to chemotherapy [43]. Despite progress in the development of new 
molecular markers for GBM, the overall survival of responsive patients has only 
minimally improved in the past 20 years [44], and there is great need for an anti-
invasive therapy in GBM. In the present study, we introduce a novel 
pharmacological agent (fraction E), which is a potent blocker of GBM invasiveness 
in vitro. We also show that proposed AQP1 inhibitor, AqB050 [45], inhibits brain, 
colon, and breast cancer migration, invasion, and growth. 
 
From all the fractions of AqB051 tested, fraction E exhibited pharmacological 
characteristics most similar to those of AqB051. In all GBM cell lines, 75% block 
of invasiveness was observed for cells treated with fraction E (9 g/mL), and 94% 
block of invasiveness was observed for AqB051 (9 g/mL). Other fractions were 
ineffective (data not shown), so fraction E likely contained the anti-invasive 
compound from AqB051. AQP1-expressing cell lines MDA-231-MB, U87-MG, 
and U251-MG were sensitive to block of invasion by AqB050 (see figure 3.2, 
chapter 3) [46]. It is reasonable to propose that the AqB050-mediated component 
of block of invasiveness occurs at least in part via AQP1 inhibition [14]. 
Interestingly, fraction E was less potent than AqB051 in blocking invasion of U251-
MG and A172 cells. This might have been due to the presence of AqB050 in the 
AqB051 mixture, producing an additive block in these cell lines. 
 
GBM cell invasiveness was highly sensitive to AqB051 at doses that had a very low 
or no effect on GBM wound closure capacity. In all GBM cell lines and the DLD1 
cell line, 94% block of invasiveness was observed for AqB051 9 g/mL. This 
same dose had no effect on U251-MG and A172 wound closure, and only blocked 
U87-MG wound closure by 18.6  4.6%. This would suggest that the AqB051 
mixture is likely to be inhibiting GBM invasion in part via mechanisms that are not 
necessary for 2D wound closure such as chemotaxis and ECM degradation. The 
fluorometric MMP activity assay tested the effect of the pharmacological 
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compounds on ECM degrading proteases. AqB051 enhanced MMP activity 
compared to batimastat (positive control), but batimastat did not inhibit MMP 
activity compared to vehicle, suggesting a false negative result. The fluorometric 
reagent produced high background fluorescence (data not shown), which might 
have reduced precision of the measurement. This was a limitation of the study as 
the result was inconclusive. Nevertheless, we determined that the mechanism of 
action of the target compound in fraction E was unlikely to involve modulation of 
adhesion to, or degradation of adjacent ECM fibres, as glioblastoma invasiveness 
was still heavily constrained by AqB051 and fraction E in the absence of the ECM 
layer. Instead, the unknown target compound in fraction E might inhibit 
chemotactic machinery.  
 
AqB051 significantly inhibited endothelial tube formation in HUVECs. Many 
ligands that stimulate chemotaxis in cancer have also been linked with 
angiogenesis, including epidermal growth factor (EGF), vascular endothelial 
growth factor (VEGF), transforming growth factor alpha (TGF), transforming 
growth factor beta (TGF) and fibroblast growth factor (FGF) [40-42]. Therefore, 
future studies might involve testing the hypothesis that the target compound in 
AqB051 and fraction E reduces cancer invasiveness via block of one of the above 
dual chemotactic and angiogenic factors. The high potency of AqB051 in blocking 
invasion particularly in glioblastoma lines, not in HT29 colon and MDA-231-MB 
breast cancer lines, indicates other biologically active components in the AqB051 
mixture must influence invasion differentially across the diverse cell lines, and 
suggests potential targeted therapies could be possible.  
 
AqB051 and AqB050, but not fraction E, inhibited GBM proliferation. AQP1 
overexpression stimulates lung cancer cell proliferation [47], so the inhibition of 
AQP1 activity by AqB050 might explain the decrease in GBM proliferation 
observed following treatment with AqB050 in both serum-treated and serum-free 
conditions. Moreover, dose-dependent block of cell proliferation by AqB050 was 
also observed in malignant mesothelioma (MM) cells where ≥20% of the MM 
population expressed AQP1; AqB050 had no effect when ≤20% of the MM 
population expressed AQP1, suggesting AQP1 as a target for AqB050 [32]. 
186 
 
Fraction E has no effect on cell proliferation or cell viability, suggesting the anti-
invasive effects of fraction E are not a result of cytotoxicity or reduced cell growth. 
Considering fraction E does not inhibit GBM cell proliferation, the inhibition of 
proliferation by AqB051 observed in the serum free condition might be due to the 
AqB050 compound present in AqB051. The anti-proliferative effect of AqB051 is 
nullified in the presence of serum, likely due to the effect of constituent growth 
factors.  
 
In summary, prognoses for patients with GBM have improved only minimally in 
the past 20 years [44], largely due to the survival mechanisms of GBM cells that 
are in the invasive phenotype. We are identifying a novel pharmacological agent 
(in fraction E of AqB051), which appears to be a potent blocker of GBM 
invasiveness in vitro. We also show that AQP1 inhibitor, AqB050, blocks breast 
cancer invasiveness, and GBM proliferation. With further investigation, these 
pharmacological compounds with biological activity could lead to the discovery of 
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Chapter 6: Thesis General Discussion and Future Considerations 
6.1 Thesis main findings and innovative contributions  
Aquaporin-1 (AQP1) is an intrinsic protein well known as a pathway for water flux 
across cell membranes [1], and plays an important role in fluid absorption and 
secretion in some epithelia, including kidney tubules, choroid plexus and ciliary 
epithelium of the eye [2]. AQP1 also enhances cell migration and metastasis in a 
subset of aggressive cancers [3-6]. AQP1 knockdown impairs cancer cell migration 
in vitro [7-9], and increasing AQP1 levels by transfection into deficient lines 
accelerates cell migration in vitro and increases the probability of lung metastases 
in murine models [4]. AQP1 is also an ion channel [10-12], and the physiological 
role of AQP1 ion conductance is not yet fully understood. Like AQP1, AQP4 is a 
pathway for water flux but does not substitute for AQP1 in enabling cell migration, 
suggesting that the migration-enhancing property of AQP1 relies on more than 
membrane water permeability [13]. There is a gap in knowledge regarding the 
exclusive properties of AQP1 that enable its migration-enhancing effect, but both 
ion and water fluxes appear to be involved [14]. During cell movement, water and 
ion influxes establish local cell volume changes that enable process extension [14-
16]. A testable prediction is that AQP1-facilitated Na+ flux might contribute to the 
local osmotic gradient driving concurrent AQP1-mediated water influx at leading 
edges, leading to cell volume changes that enable process extension and cell 
migration [14, 17]. Therefore, part of the focus of this thesis was to test two 
hypotheses: (1) that AQP1 water and ion channels exhibit a coordinated role in 
AQP1-facilitated cancer cell motility; and (2) that the efficacy of AQP1 inhibitors 
depends on plasma membrane localisation of AQP1. To test these hypotheses we 
used a novel inhibitor of AQP1 ion conductance, AqB011 [18]; and the AQP1 water 
channel inhibitor bacopaside II [19] on AQP1-expressing human cancer cell lines.  
 
For the first time, work presented in this thesis showed that AqB011 inhibited 
migration and invasion in brain, colon, and breast cancer cells in vitro, and that dual 
pharmacological block of AQP1 water flux and ion conductance enhanced the 
magnitude of block of cell motility as compared to effects of AqB011 alone. This 
work suggested a novel role for the AQP1 ion conductance in enabling AQP1-
facilitated cell motility, supporting the first hypothesis. Cells expressing AQP1 on 
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the membrane were more sensitive to block by AQP1 inhibitors than cells with 
AQP1 localised intracellularly, which supported the second hypothesis. These 
findings revealed that AQP1 ion conductance is a putative pharmacological target 
for anti-invasive therapy. Pharmacologically targeting both AQP1 water and ion 
channels could yield potential for lower dosage requirements to produce an efficient 
block of cell migration; additionally, side effects might be reduced in cells that do 
not require both AQP1 water and ion channel properties to function normally. 
Therapeutically inhibiting AQP1 is unlikely to produce many debilitating side 
effects in vivo. Studies on AQP1-knockout mice, and humans lacking endogenous 
AQP1 have reported symptoms of defective urine-concentrating function exclusive 
of any other debilitating abnormalities [20, 21], and the clinical benefits would 
likely outweigh this side effect. Additionally, determining AQP1 cell membrane 
localization could be an important screening tool for identifying cancer subtypes 
likely to respond to AQP1 inhibitors.  
 
Work from this thesis also identified a novel pharmacological modulator of 
glioblastoma (GBM) invasiveness in vitro. AqB050 is a bumetanide derivative that 
has been described as an AQP1 inhibitor [22]. During the intended re-synthesis of 
AqB050, an error resulted in the formulation of a mixture of compounds (AqB051) 
including the target molecule (AqB050) and related derivatives. The AqB051 
mixture strongly blocked GBM transwell invasion at doses that had no effect on 
cell growth or viability. Therefore, the third hypothesis for this thesis was that (3) 
the biologically active component of the AqB051 mixture inhibits chemokine-
dependent GBM invasiveness, independently of interactions with local 
extracellular matrix. The AqB051 mixture was fractionated into eight constituent 
mixtures via thin layer chromatography and chemical components in each fraction 
were characterised using high resolution mass spectrometry (work done by Mass 
Spectrometry Facility, School of Chemistry, University of Sydney, NSW). Of the 
eight fractions, AqB050 constituted the majority of one of the lower MW fractions, 
and a higher MW fraction labelled “fraction E” demonstrated biological activity 
that was most similar to the effects of the AqB051 mixture. My analyses thus far 
have revealed that AqB050 reduced invasiveness in GBM and breast cancer cells, 
and reduced GBM cell proliferation, suggesting AQP1 as a potential target for 
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treating GBM invasiveness and growth. Moreover, a novel pharmacological 
compound present in fraction E strongly inhibited chemokine-dependent GBM 
invasion in multiple GBM cell lines in vitro, with and without ECM, in support of 
the third hypothesis. Current treatment for GBM is mainly focused on removal and 
destruction of the tumourous cells [23, 24]. Identifying the pharmacological 
compound with biological activity in fraction E might have potential to be an 
adjuvant anti-invasive treatment, improving effectiveness of current treatments for 
GBM.  
 
Finally, work here provided an innovative approach for measuring net 2D cell 
migration via the wound closure assay, using a circular wound instead of a straight 
line. This method demonstrated improved reproducibility, precision, and sampling 
objectivity for measurements of wound sizes as compared to classic scratch assays. 
Other benefits of the method include simplicity and low cost as compared with 
commercially available assays for generating circular wounds. 
 
6.2 Future considerations 
6.2.1 Role of AQP1 ion conductance in cancer invasion and metastasis 
AQP1 ion conductance has been previously reported to be important for fluid 
regulation in the choroid plexus [25]; and colon cancer cell migration [18]. Work 
from this thesis revealed a potential coordinated function for AQP1 water and ion 
conductance in cancer cell migration and invasion, involving synchronised water 
and ion influx to generate cellular processes on the leading edge of migrating cells. 
AqB011 inhibited AQP1 ion conductance in Xenopus oocytes [18] and also 
attenuated 2D wound closure and 3D transwell invasion in colon, breast, and brain 
cancer. Future work might include investigating pharmacological sensitivity to 
AqB011 in non-AQP1-expressing cell lines following wild-type AQP1 
transfection. The prediction would be that AQP1-trasfected cell lines would be 
more sensitive to block of migration by AqB011. It would also be intriguing to 
transfect AQP1-null cancer cell lines with AQP1 constructs that have been mutated 
so that AQP1 ion conductance is inactivated or activated without affecting water 
permeability. The structural conformation of cytoplasmic loop D is important for 
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AQP1 ion channel gating and does not affect water permeability. Site-directed 
mutagenesis could be carried out using primers designed to introduce selected 
mutations in the loop D domain that reduce AQP1 ion conductance, such as alanines 
substituted for two arginines (R159A+R160A); aspartic acid for proline (D158P); 
or threonine for proline (T157P) [26]. We predict that cancer cells expressing AQP1 
R159A+R160A,  D158P, or T157P mutants would migrate slower than control cells 
transfected with wild type AQP1, and would be insensitive to AqB011. 
Alternatively, mutagenesis could be carried out to introduce selected mutations in 
the loop D domain that enhance AQP1 ion conductance, such as glycine substituted 
for proline (G166P) [26]; we would predict that cancer cells expressing this mutant 
would migrate faster than control cells transfected with wild type AQP1, and would 
be more sensitive to AqB011.  
 
6.2.2 Targeting AQP1 channels in glioblastoma 
AQP1 is upregulated in GBM [27-29] and enhances GBM invasiveness; however 
pharmacologically targeting AQP1 channels to reduce growth and invasiveness in 
GBM has not been previously tested. In 9L gliosarcoma cells, simultaneous 
upregulation of AQP1, lactate dehydrogenase, and cathepsin B is stimulated by 
increased glucose metabolism at the tumour periphery [30]. It has been proposed 
that simultaneous upregulation of these proteins enhances invasiveness via 
acidification and enzymatic degradation of the extracellular matrix; AQP1 might 
enable this by shuttling water and CO2 into the extracellular environment, thus 
promoting a more acidic extracellular space. Work from this thesis showed that 
AQP1 blockers, bacopaside II and AqB05, inhibited 3D invasion through an ECM 
barrier in several GBM cell lines, which might be partly explained by inhibition of 
AQP1-facilitated acidification of the extracellular environment. However, there is 
still a gap in knowledge as to the mechanisms of action by bacopaside II and 
AqB050, as these compounds also inhibited cell migration in the absence of ECM. 
Moreover, AqB011 inhibited GBM cell migration and invasion, and the role of 
AQP1 ion conductance in GBM cell motility is yet to be determined. Notably, GBM 
cell migration requires the movement of water and ions at the leading edge [31-33]. 
Therefore, a testable prediction might be that AQP1 inhibitors work by attenuating 
the AQP1-facilitated water and ion fluxes at the leading edge of a migrating GBM 
194 
 
cell, which contribute to both extracellular acidification and cell volume changes 
that enable process extension and cell migration. Future investigation might test the 
effect of AQP1 inhibitors on acidification of the GBM extracellular environment 
with the lactate assay [30]. Additionally, a limitation of the work done for this thesis 
was that AQP1 knockdown studies were inconclusive in colorectal cancer cell line 
HT29. Further work might also involve performing AQP1 gene transfection or 
knockdown in GBM cells to determine whether presence or absence of AQP1 
affects sensitivity to AQP1 inhibitors.  
 
Interestingly, AqB050 and AqB011 also inhibited GBM cell proliferation, and 
reduced cell viability at higher doses; these effects might be connected to inhibition 
of AQP1-facilitated alkalisation of the GBM cell cytoplasm. GBM intracellular 
environment is more alkaline than normal brain cells [34], and Hayashi and 
colleagues (2007) proposed that AQP1 maintains 9L gliosarcoma cell viability by 
regulating intracellular pH levels [30]. As AQP1-facilitated CO2 efflux might be 
important for maintaining a favourable alkaline intracellular environment in GBM, 
it would be intriguing to investigate whether AqB011 or AqB050 also inhibit 
AQP1-enabled CO2 transport, which might explain why AqB050 and AqB011 
blocked GBM cell proliferation at low doses, and cell viability at higher doses. 
Transfection of AQP1 cDNA into NIH-3T3 lung cancer cells increased cell 
proliferation, as determined by the MTT assay [35]. Future work might include 
investigation into the role of AQP1 in regulating intracellular pH in lung cancer, 
and whether these cells would also be sensitive to reduced invasiveness and 
proliferation following treatment with AqB050 or AqB011. Finally, it would be 
useful to test these inhibitors in murine models of GBM to see if their anti-
proliferative and anti-invasive effects translate to beneficial outcomes in vivo.  
 
6.2.3 Identification of the biologically active compound in fraction E, and 
implications for glioblastoma treatment 
GBM cells with an invasive phenotype have low rates of proliferation and 
apoptosis, providing improved resistance to chemotherapy and radiotherapy [36]. 
An invasive phenotype allows GBM cells to evade surgical resection, making GBM 
difficult to treat. With the overall survival for patients with GBM improving only 
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minimally in the past 20 years [37], new anti-invasive therapies in GBM are needed. 
Refinement and chemical characterisation of the biologically active compound in 
fraction E could offer insight into a new class of compounds with potent anti-
invasive properties in GBM, if proven in animal models in vivo and eventually in 
clinical trials. The pharmacological characteristics and molecular targets of the 
biologically active compound(s) in AqB051 are not yet known. The AqB051 
mixture also strongly inhibited invasiveness in the DLD1 colorectal 
adenocarcinoma cell line, but not in HT29 colorectal or MDA-231-MB breast 
cancer cell lines (see Figure 5.2, chapter 5). The variable efficacy of the AqB051 
mixture across different cell lines might suggest specific molecular target(s) of the 
active compound in AqB051, as opposed to many targets likely to have non-specific 
or unfavourable side effects. Genomic and transcriptomic analyses comparing 
AqB051-sensitive and -insensitive cell lines could identify classes of molecular 
targets for further characterisation.  
 
Work in this thesis showed that fraction E and AqB051 more potently inhibited cell 
migration in the presence of a chemotactic gradient, as opposed to no gradient. This 
might suggest that fraction E and AqB051 inhibit chemotactic machinery. Although 
there are many mechanisms involved in the invasiveness of glioma cells [24, 38], 
chemotaxis plays an important role in enabling directional migration and invasion 
of the tumour cells into healthy brain tissue [39]. Chemotaxis is mediated by 
chemokines, chemotactic receptors, growth factors, and growth factor receptors 
[39]. There are many chemokines and growth factors that have been attributed to 
enabling GBM chemotaxis and invasiveness, including the stromal cell-derived 
factor 1, also known as C-X-C motif chemokine 12 [40]; epidermal growth factor 
[41, 42]; scatter factor, also known as hepatocyte growth factor [43]; transforming 
growth factor alpha [43]; and fibroblast growth factor 1 [43]. Future work might 
investigate the effect of down-regulating receptors for these chemotactic factors in 
GBM cells and testing whether AqB051 or fraction E are still able to inhibit 
invasiveness. If the inhibitors lose sensitivity in any of the knockdown conditions, 
it would suggest that the target receptor in that condition might be the 
pharmacological target for the inhibitor. It would also be interesting to evaluate the 
effects of AqB051 and fraction E in another assay that tests chemotaxis without 
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requiring the cells to undergo dynamic cell volume changes to pass through very 
narrow pores, such as the ibidi -Slide Chemotaxis assay (catalogue number 80326) 
[44]. If the inhibitors were less effective in the -Slide chemotaxis assay, it could 
mean that the enhanced potency of inhibitors in the transwell invasion assay was 
due to the requirement to traverse narrow very narrow pores, which is not necessary 
in the wound closure assay. Overall, continued research into the identification and 
pharmacological properties of the biologically active compound in AqB051 and 
fraction E is crucial to potentially uncovering new pharmacological therapies and 
molecular targets for GBM. 
 
6.2.4 Targeting AQP1 channels to regulate angiogenesis 
Angiogenesis occurs in cancer when tissue hypoxia stimulates the formation of new 
vasculature, enabling tumours to better obtain nutrients and metastasize to distant 
organs [45]. Endothelial cell proliferation, differentiation and migration are crucial 
for angiogenesis [46]. AQP1 is expressed in peripheral vascular endothelial cells 
and is upregulated in low oxygen conditions [47, 48]. AQP1 is thought to contribute 
to angiogenesis by enabling endothelial cell migration [9, 49, 50], so 
pharmacological inhibition of AQP1-enabled endothelial cell migration might 
impede angiogenesis in cancer, and consequently restrict cancer growth and 
metastasis. Acetazolamide inhibited tumour growth and metastasis in mice with 
Lewis lung carcinoma [51, 52], perhaps as a result of reduced AQP1 expression 
[53]. Alternatively, this agent is known to be a broad spectrum carbonic anhydrase 
(CA) inhibitor [54, 55] and might cause effects by inhibition of CA activity, since 
expression of CA IX has been associated with poor prognosis in nasopharyngeal 
carcinoma [56], oesophageal and gastric adenocarcinoma [57], breast cancer [58], 
and lung cancer [59]. Bacopaside II was shown to inhibit angiogenesis and 
endothelial cell migration in vitro [60], which might be due in part to AQP1 water 
channel inhibition, although bacopaside II is likely to have non-specific effects 
including induction of cell cycle arrest and apoptosis [61], inhibition of 
acetylcholinesterase activity, or reduction of intracellular oxidative stress [62]. 
Future studies might use AqB011 to investigate the effects of AQP1 ion 
conductance on endothelial cell migration and angiogenesis. If endothelial cells 
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express AQP1 on the membrane, a prediction would be that AqB011 inhibits 
angiogenesis by restricting endothelial cell migration.  
 
6.2.5 AQP1 pharmacological modulators for the treatment of non-neoplastic 
pathologies 
In addition to cancer invasion and metastasis, AQP1 has been implicated in several 
other pathologies. For example, AQP1 modulators might be useful for the treatment 
of elevated intracranial pressure (ICP). Elevated ICP is a potentially lethal condition 
that occurs following stroke or traumatic brain injury, and is largely due to fluid 
build-up within the brain, also known as cerebral oedema [63, 64]. AQP1-null mice 
exhibited significantly reduced ICP following acute brain trauma as compared to 
wild type mice. This was largely due to reduced central venous pressure (CVP), as 
AQP1-null mice are unable to concentrate their urine, so more fluid is excreted [20, 
65]. AQP1 is highly expressed in the choroid plexus epithelium [66, 67], and the 
reduction in ICP was also determined to be due to reduced secretion of 
cerebrospinal fluid from the choroid plexus in the AQP1-null mice, although to a 
lesser extent [65]. Thus, AQP1 inhibitors could be useful for the treatment of 
elevated ICP, although it is important to consider the blood brain barrier as an 
obstacle for drug bioavailability. Considering the significance of AQP1 ion 
conductance for fluid regulation in the choroid plexus [25], it would be intriguing 
to test AqB011 and other AQP1 inhibitors such as AqB050 and Bacopaside II in 
models that simulate choroid plexus fluid secretion in vitro, or models of acute brain 
injury in vivo.  
  
AQP1 inhibitors might also be a useful treatment for reducing non-cerebral oedema. 
Conditions such as nephrotic syndrome (NS), cirrhosis, and congestive heart failure 
(CHF) often lead to various forms of oedema that range from low severity such as 
swollen eyelids and limbs, to higher severity such as pulmonary oedema, increased 
body weight, and ascites [68-71]. One of the main therapeutic targets for treating 
these forms of oedema involve restriction of reabsorption of salts in the kidney, 
resulting in higher water content in the urine [68]. Common pharmacological 
therapies for oedema include thiazide diuretics, which block the sodium-chloride 
transporter in the distal convoluted tubules (DCTs) of the kidney, and loop diuretics 
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that inhibit the sodium-potassium-chloride cotransporter in the ascending limb of 
the loop of Henle [72]. These agents are generally effective in restricting 
reabsorption of water and salts in the kidney, however some patients with more 
advanced conditions are resistant to DCT diuretics or loop diuretics [73]. Thus, 
there is a need for a combination therapy that can be used with current diuretics. 
AQP1 is highly expressed in the kidney proximal tubule and descending loop of 
Henle [74], enabling water reabsorption into the blood. Renal water reabsorption in 
mice lacking AQP1 was significantly reduced [75] due to dysfunctional proximal 
tubule water resorption [76], and reduced water permeability in the descending loop 
of Henle [77]. Therefore, future work might involve testing AQP1 blockers 
AqB050 or bacopaside II in combination with loop or DCT diuretics in a mouse 
model to test effects on urinary concentration ability. A prediction would be that 
combined treatment with the AQP1 inhibitor would cause a stronger reduction in 
urinary concentration than treatment with a DCT or loop diuretic alone.  
 
Glaucoma is a pathology of the eye in which impaired outflow of aqueous humour 
leads to elevated intraocular pressure, and eventually blindness [78]. AQP1 is 
highly expressed in cells of the conventional outflow pathways for aqueous humour 
such as the trabecular meshwork (TM) and Schlemm’s canal endothelial cells [79-
81]. AQP1 improves TM cell viability during mechanical strain [82], and facilitates 
TM-mediated aqueous humour outflow [83]. Additionally, AQP1 is highly 
expressed in the ocular ciliary epithelium of the eye [80], where it enables secretion 
of aqueous humour [84]. AQP1 deletion in mice reduces aqueous humour secretion 
and intraocular pressure, so pharmacological inhibition of AQP1 might treat 
glaucoma by decreasing secretion of and outflow resistance to aqueous humour, 
thus reducing intraocular pressure.  
 
AQP1 is expressed in the plasma membrane of dorsal root ganglion (DRG) neurons 
and nociceptive C-fibres [85-87], contributing to the perception of inflammatory 
thermal pain and cold pain in part by interaction with Nav1.8 sodium channels [88]. 
AQP1 also enables DRG axonal growth and regeneration [89], which was proposed 
to be due to AQP1-facilitated plasma membrane extension of the DRG axons. Thus, 
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AQP1 might be a novel pharmacological target for treatment of inflammatory pain, 
or to accelerate neural regeneration.  
 
In addition to investigating the effects of AQP1 antagonists, there is also benefit in 
searching for agonists of AQP1 that enhance osmotic membrane water 
permeability. For example, AQP1 agonists might be able to enhance the efficacy of 
peritoneal dialysis (PD) for patients with end-stage renal disease. The ability for 
water to traverse the peritoneal membrane via osmosis is a crucial predictor of 
outcome for patients that require peritoneal dialysis [90]. AQP1 is expressed in the 
capillary and venule endothelium of the peritoneum [91], and is critical for 
ultrafiltration and osmotically driven water transport across the peritoneal 
membrane during PD [92, 93]. AQP1 agonist AqF026 directly and specifically 
enhanced AQP1-facilitated osmotically driven water transport across the peritoneal 
membrane in a mouse model [94], so it would be fascinating to investigate the effect 
of AqF026 in a clinical setting of peritoneal dialysis. 
 
6.3 Thesis Conclusion 
This thesis supported the hypotheses that AQP1 ion conductance plays a role in 
AQP1-facilitated cancer cell motility, that the efficacy of AQP1 inhibitors depends 
on plasma membrane localisation of AQP1, and that the biologically active 
component of AqB051 inhibits GBM invasiveness independently of interaction 
with extracellular matrix. Findings revealed new biological activities for previously 
described AQP1 inhibitors such as bacopaside II, AqB011, and AqB050, and 
potentially new pharmacological modulators that potently inhibit GBM invasion. 
Work here has paved the way for improving methods utilized for measuring cell 
migration, investigating the role of AQP1 ion conductance and subcellular 
localisation in cancer migration and growth, and testing the effects of AQP1 
modulators in treating glaucoma; cerebral oedema; oedema associated with CHF, 
cirrhosis, and nephrotic syndrome; pain perception and neuronal regeneration; and 
end-stage renal disease. Future investigations should utilise the findings produced 
from this thesis to further explore pharmacological modulators of AQP1 and novel 
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